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Abstract 
Chlamydia)trachomatis!infection!is!the!most!common!bacterial!sexually!
transmitted!disease!in!the!United!States.!!Irregular!screening!to!identify!infected!
individuals!and!a!lack!of!sterilizing!immunity!to!C.)trachomatis)has!led!to!a!dramatic!
increase!in!the!number!of!reported!C.)trachomatis)infections!over!the!last!twenty!
years.!!Repeated!infections!with!C.)trachomatis!lead!to!serious!sequelae!such!as!
pelvic!inflammatory!disease!and!ectopic!pregnancy,!which!can!result!in!infertility.!!!
It!is!unclear!why!the!adaptive!immune!system,!specifically!the!CD8+!T!cell!
response,!is!unable!to!protect!against!subsequent!C.)trachomatis)infections.!!In!this!
dissertation!I!first!describe!the!endogenous!CD8+!T!cell!response!in!the!genital!
mucosa!during!C.)trachomatis!infection.!!I!found!that!primary!C.)trachomatis!
infection!elicits!a!robust!CD8+!T!cell!response.!!However,!rechallenge!with!C.)
trachomatis)produces!a!secondary!CD8+!T!cell!response!that!is!numerically!weaker!
compared!to!the!primary!response.!!I!found!that!depletion!of!CD8+!T!cells!prior!to!
primary!or!secondary!infection!has!no!impact!on!the!host’s!ability!to!clear!C.)
trachomatis.))All!together!these!data!indicate!that!CD8+!T!cells!do!not!contribute!to!
protecting!the!host!against!C.)trachomatis)infection!of!the!genital!tract.!!
In!the!third!chapter!I!examined!the!expression!of!different!immunoI
inhibitory!molecules!in!the!genital!tract!of!C.)trachomatis.))I!focused!on!further!! iv!
characterizing!the!expression!of!the!immunoIinhibitory!ligand!PDIL1.!!I!found!that!
upon!infection!PDIL1!is!highly!expressed!on!epithelial!cells!of!the!genital!tract!and!
dendritic!cells!within!the!draining!lymph!nodes.!!Furthermore!I!show!that!the!
receptors!for!PDIL1,!PDI1!and!B7I1,!are!highly!expressed!on!CD8+!T!cells!after!
infection!has!resolved.!!In!the!final!part!of!this!dissertation!I!!demonstrate!that!the!
PDI1/PDIL1!pathway!contributes!to!the!defective!CD8+!T!cell!response!during!C.)
trachomatis)infection.!!Deletion!or!inhibition!of!PDIL1!or!PDI1!restores!the!CD8+!T!
cell!response!and!enhances!C.)trachomatis!clearance.!!!! v!
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Chapter One: Introduction ! 2!
Chlamydia trachomatis, Disease and Epidemiology 
 
Chlamydia trachomatis is the most highly reported cause of sexually transmitted 
bacterial infections in the United States (1).  In the last 20 years, the prevalence of C. 
trachomatis infection has more than doubled in the United States.  There are 16 defined 
serovars of C. trachomatis.  Infection of the ocular tissue by serovars A-C is the leading 
cause of preventable blindness worldwide (2).  Serovars D-K infect the urogenital tissue 
and are transmitted sexually.  Additionally, serovars L1, L2, L2a and L3 not only infect 
the urogenital tissue and are spread by sexual contact, but also cause an invasive disease 
of the lymph nodes (3).  Women who contract the sexually transmitted C. trachomatis 
can develop fallopian tube scarring, pelvic inflammatory disease, and ectopic pregnancy, 
all of which can have severe consequences for fertility (4).   Although C. trachomatis 
infections can be cleared with antibiotics, primary C. trachomatis infections remain 
subclinical or “silent” in about 70-80% of infected women and thus often go untreated (4, 
5).  In some untreated women (20-40%) infection ascends to the fallopian tubes where it 
can establish a persistent infection and cause pelvic inflammatory disease (6).  Persistent 
infections result in immune mediated tissue scarring and fibrosis, which lead to infertility 
(6).  In addition, even with antibiotic treatment there is evidence for recurrent or 
persistent infections; recurrent infections can lead to worse outcomes in terms of 
inflammation and damage of the female reproductive tract (7, 8).  The evidence of 
recurrent infections indicates that the immune system fails to develop an effective 
memory response that can prevent subsequent infections.   
The main challenge in controlling C. trachomatis disease is identifying infected 
individuals and treating them before permanent damage to the reproductive tract occurs.  ! 3!
Current efforts to implement widespread screening to detect infected individuals will 
likely reduce disease spread.  However, screening will not prevent the damage that occurs 
with multiple infections.  A vaccination program in girls before they are sexually active 
will likely be the most impactful approach in reducing C. trachomatis infections and 
limiting disease sequelae.  Because natural immunity to C. trachomatis is ineffective, it is 
necessary to develop a vaccine that could induce protection superior to that acquired from 
natural infection.  In order to develop a successful vaccine, it is essential to understand 
the life cycle of C. trachomatis within the host and how natural immunity fails to prevent 
recurrent C. trachomatis infections.  By understanding the failure of natural immunity to 
C. trachomatis we can hopefully develop ways to generate a productive immune response 
through vaccination.  The work of this dissertation is designed to better understand the 
failure of the adaptive immune system to respond to genital tract infection with C. 
trachomatis, specifically the CD8
+ T cell response and the specific mechanisms that play 
a role in inhibiting a productive CD8
+ T cell response. 
 
C. trachomatis Biology 
  C. trachomatis is an obligate intracellular bacterium that depends on the host cell 
for survival and propagation.  C. trachomatis transitions between two developmental 
forms during its biphasic life cycle.   The elementary body (EB) form of C. trachomatis is 
able to survive outside of the host cell but exhibits very little metabolic activity.  
Importantly, EBs are the infectious form of C. trachomatis.  Upon attaching to an 
epithelial cell, the EB induces its uptake into the host cell (9).  Within a membrane bound ! 4!
compartment termed the inclusion, the EB differentiates into the other developmental 
form: the metabolically active, but noninfectious, reticulate body (RB) (Figure 1-1).   
 
EB 
RB 
1. 
2. 
3. 
4. 
5. 
 
 
Figure 1-1 Developmental cycle of C. trachomatis.  C. trachomatis has a 
biphasic life cycle.  1. The metabolically inactive EB (purple) attaches to the host 
epithelial cell and induces its uptake.  2. The EB transitions into the metabolically 
active RB within the inclusion.  3. The RBs divide by binary fission within the 
inclusion.  4. At about 24-26 hours after invasion, RBs begin to differentiate back 
into elementary bodies.  5. 48-hours post-invasion, EBs are released from the cell 
and the infectious cycle is repeated.  
 
The membrane of the inclusion is made up of host lipids, mostly derived from the 
Golgi apparatus and endoplasmic reticulum.  In order to replicate, the RBs must scavenge 
nutrients from the host cell.  At the same time, C. trachomatis must prevent host cell 
processes that are meant to degrade foreign and pathogenic entities. Although the RB is 
secluded within the inclusion, it interacts extensively with the host cell.  C. trachomatis 
uses a type III secretion system to inject C. trachomatis effectors directly into the host ! 5!
cytosol.  There are about 125 known and predicted C. trachomatis type III secreted 
effectors and the majority of these effectors have no known function (10).  However, 
studies using small-molecule inhibitors of the C. trachomatis type III secretion system 
have indicated that this system is necessary for a productive infection (11, 12).  Within 
the inclusion, the RBs divide extensively by binary fission.  Between 24 and 48 hours 
post infection, through a yet-to-be defined trigger, the RBs differentiate back into EBs.  
EBs exit the host cell by lysis or extrusion, and can then infect neighboring cells.   
 
Innate Immune Reponses to C. trachomatis  
Because of Chlamydia’s unique biphasic lifecycle there are multiple ways in 
which the immune system can respond to and eliminate C. trachomatis from the host 
tissues.  The female genital tract can be subdivided into the lower genital tract including 
the vagina and cervix, and the upper genital tract including the uterus and fallopian tubes. 
Upon entering the host through the lower genital tract, C. trachomatis is immediately 
subjected to innate immune responses, which are the primary defenses against infection.  
Commensal bacteria that colonize the vaginal tissue provide a first line of defense against 
pathogens.  The commensal Lactobacilli species produce lactic acid, which keeps the pH 
of the vaginal tissue between 3.5 and 5 (13).  Studies on the effectiveness of topical 
microbicides have indicated that exposure of C. trachomatis EBs to a solution with a pH 
of 5.0 leads to reduced infectivity, indicating that C. trachomatis might be susceptible to 
the low pH of the vaginal tissue (14).  However, the fact that C. trachomatis is generally 
transmitted by coitus makes it likely that C. trachomatis can overcome this inhibition.   ! 6!
The cells that line the cervix produce thick mucus that provides a barrier to both 
sperm and pathogens.  Studies have shown that the mucus produced by the cervical 
epithelial cells also contains the antimicrobial molecules lysozyme and secretory 
leukocyte protease inhibitor (SLPI) (15, 16).  Although SLPI from cervical mucosal 
secretions has been shown to inhibit the pathogenesis of another bacterial sexually 
transmitted infection (STI), Neisseria gonorrhoeae, it does not seem to have an effect on 
C. trachomatis infectivity (17, 18).   
Within the host cell there are cell autonomous responses that limit bacterial 
replication.  In order to limit replication of a pathogen within a vacuole, such as C. 
trachomatis, the host must first recognize the existence of a pathogen-containing vacuole 
as a “non-self” entity.  In murine epithelial cells, interferon-γ (IFNγ) signaling induces 
the expression of a family of IFNγ-inducible p47 guanosine triphosphate phosphatases 
(GTPases) termed immunity-related GTPases (IRGs) (19).  The GTPases Irgm1 and 
Irgm3 recognize and decorate “self” vacuoles within the host cell, thus the absence of 
Irgm1 and Irgm3 from vacuoles is a signal to the host that the vacuole is pathogen-
containing (20).  Vacuoles that lack Irgm1/m3 become targets for other IRG proteins as 
well as Guanylate Binding Proteins (GBPs).  IRG proteins can directly disrupt pathogen-
containing vacuoles, releasing the contents of the vacuole into the cytosol where they can 
be targeted by autophagic processes (21).  GBPs recruit additional antimicrobial factors 
including the NADPH oxidase NOX2, which produces potent anti-microbial reactive 
oxygen species anions (22, 23).  Although Chlamydia muridarum, which has a specific 
tropism for mice, has evolved unknown mechanisms to evade restriction by the IRGs, C. 
trachomatis is extremely susceptible.  Irgm1 and Irgm3 are required for murine-cellular ! 7!
resistance to C. trachomatis, and mice lacking Irgm1/m3 exhibit delayed clearance of C. 
trachomatis (24).   
 Interestingly, humans lack the majority of the genes encoding the IRGs, and cell 
autonomous resistance to C. trachomatis in humans is mediated by a completely different 
mechanism (25).  IFNγ signaling in human cells induces the expression of indoleamine-
2,3-deoxygenase (IDO).  IDO catabolizes the amino acid tryptophan and deprives C. 
trachomatis of this essential nutrient.  Upon tryptophan starvation, C. trachomatis enters 
into a non-replicative persistent state (26).  However, C. trachomatis expresses a 
tryptophan synthase, which is an enzyme capable of synthesizing tryptophan from indole 
(27).  This persistent state is reversible if either tryptophan or indole becomes available 
(26, 27).  It is believed that C. trachomatis can overcome tryptophan starvation in the 
genital tract by using indole produced from the vaginal flora (19).  Interestingly, C. 
muridarum lacks a functional tryptophan synthase, suggesting that Chlamydia species 
have separately evolved host-specific immune evasion mechanisms.  
Although it is not completely clear how, C. trachomatis can bypass the innate 
barriers of the lower genital tract and ascend to and establish infection in the upper 
genital tract.  The epithelial cells that line the uterus produce an array of antimicrobial 
molecules and cytokines that are meant to create a pathogen-restrictive inflammatory 
environment.   The defensins, HD5 and HNP2 are upregulated during infection with C. 
trachomatis and HNP2 is able to inhibit C. trachomatis infectivity, likely by 
permeabilizing the EB membrane (28, 29).  It has also been shown that cultured cervical 
epithelial cells secrete the inflammatory cytokines interleukin-8 (IL-8), IL-6, tumor 
necrosis factor-α (TNFα), and granulocyte-macrophage colony-stimulating factor (GM-! 8!
CSF) during C. trachomatis infection (30, 31).  Additionally, it was shown that infected 
epithelial cells secrete IL-1α following lysis (30).   These cytokines likely have a role in 
recruiting the innate immune cells, including natural killer (NK) cells, macrophages, 
neutrophils and dendritic cells.  These innate immune cells can engulf and degrade 
extracellular EBs, as well as produce inflammatory cytokines such as IFNγ and TNFα, 
which restrict C. trachomatis growth in epithelial cells (32).  Even though there is an 
early influx of innate immune cells to the upper genital tract upon C. trachomatis 
invasion, the innate response is not sufficient to limit infection and thus perhaps the more 
important role of the innate immune cells is to recruit and activate the cells of the 
adaptive immune response. 
 
Adaptive Immune Responses to C. trachomatis 
The adaptive immune response is absolutely essential for limiting C. trachomatis 
infection and providing a level of protection against reinfection.  There are two main 
arms of the adaptive immune response: the humoral response mediated by B cells, and 
the cellular response mediated by CD4
+ and CD8
+ T cells.  The activation of the adaptive 
immune response is believed to occur mainly within the lymph nodes that drain the 
genital tract, but there is also evidence of immune inductive sites within the genital tract 
(33, 34).  In other mucosal tissues, such as the intestines, there are organized lymphoid 
structures in which immune cells reside and can be activated upon infection.  However, 
these organized structures do not exist in the genital tract and instead there are clusters of 
immune cells that form the immune inductive sites (35).  Dendritic cells actually provide 
the essential link between the innate and adaptive responses.   After engulfing ! 9!
extracellular EBs or infected epithelial cells, dendritic cells can present Chlamydia 
antigen to T cells either in the draining lymph nodes or immune inductive sites (35, 36).   
Once activated, CD4
+ helper T cells can present antigen and activate B cells.  The 
main role of B cells is to produce antibody to block pathogen entry into cells (37).  There 
was early evidence suggesting that B cells might be an important mediator in limiting C. 
trachomatis infection.  Epidemiological studies indicated an inverse correlation between 
the amount of C. trachomatis recovered from the cervix and the amount of C. 
trachomatis specific IgA antibody (38).  However, subsequent studies demonstrated that 
mice lacking B cells did not exhibit exacerbated C. trachomatis infections (39).   In fact 
there are current attempts to stimulate a protective B cell response.  The dominant C. 
trachomatis antigen, major outer membrane protein (MOMP) is the primary candidate for 
a subunit vaccine and the main target to induce a humoral response. However, studies 
thus far have shown that there is extreme heterogeneity in MOMP sequences between the 
16 Chlamydia serovars, which is impeding the development of a pan-serovar protective 
antibody (40).   
Although the role of B cells during C. trachomatis infection is still debated, the 
importance of CD4
+ T cells is well described.   Antigen presenting cells (APCs) that have 
engulfed extracellular C. trachomatis antigen can process this antigen and present the 
resulting peptides on major histocompatibility (MHC) class II molecules to stimulate 
naïve CD4
+ T cells.  Activated CD4
+ T cells migrate to the site of infection and restrict C. 
trachomatis growth primarily through the secretion of the cytokine IFNγ.  IFNγ induces 
the expression of IDO in humans, and IRGs in mice, to restrict C. trachomatis growth 
(described above).   CD4
+ T cells are necessary in controlling C. trachomatis infection, as ! 10!
mice that are depleted of CD4
+ T cells have higher bacterial levels and prolonged 
infections (41).  Additionally, C. trachomatis specific CD4
+ T cells that are transferred 
into naïve mice are sufficient to provide mice with protection against infection (24, 41).   
For many intracellular pathogens, CD8
+ T cells can be the main mediator of 
adaptive immunity.  Unlike CD4
+ T cells that recognize extracellularly derived antigen, 
CD8
+ T cells recognize antigen that has been derived intracellularly.  During C. 
trachomatis infection, dendritic cells can engulf EBs or infected epithelial cells and 
through a mechanism known as cross-presentation, present processed peptides on MHC 
class I molecules to activate CD8
+ T cells.  Activated CD8
+ T cells proliferate and 
migrate to the genital tract where they are exposed to infected epithelial cells.  During 
infection of epithelial cells, C. trachomatis uses the type III secretion system to inject 
proteins directly into the host cytosol. The MHC class I machinery can access and 
degrade the type III secreted effectors, as well as other proteins present on the inclusion 
membrane, and present the peptides to activated CD8
+ T cells.  CD8
+ T cells that 
recognize infected cells can directly kill these cells through the secretion of perforin, 
which disrupts the epithelial cell membrane, and TNFα, which causes epithelial cells to 
undergo apoptosis.  CD8
+ T cells can also secrete IFNγ to aid in restricting C. 
trachomatis infection.   
The C. trachomatis antigen, CrpA, is the dominant epitope recognized by CD8
+ T 
cells (42).  CrpA specific CD8
+ T cells have been shown to migrate to the uterus and 
proliferate in response to C. trachomatis infection (43).  Additionally, naïve mice that 
receive activated CrpA specific CD8
+ T cells, derived from mice engineered to express 
only the T cell receptor specific for CrpA, are protected against subsequent C. ! 11!
trachomatis infection (43).  In fact, mice immunized against CrpA either through prior 
infection with Vaccinia virus expressing CrpA (Vac-CrpA) or Listeria monocytogenes 
expressing CrpA (L.m.-CrpA) are protected against subsequent systemic challenge with 
C. trachomatis.  Although it is clear that CD8
+ T cells can protect against C. trachomatis 
infection, there is also evidence to suggest that the endogenous CD8
+ T cells provide 
little protection during natural infection.   Unlike the protection generated by Vac-CrpA 
or L.m.-CrpA, naïve mice that receive CD8
+ T cells from mice previously infected with 
C. trachomatis are not protected from infection (42).  Together these data indicate a 
perplexing role of CD8
+ T cells during infection. 
 
Immune Memory Development  
  The cornerstone of immunity is the development of immunological memory such 
that hosts can quickly limit disease and clear pathogens that have been previously 
encountered.  Epidemiological evidence indicates that people who have been previously 
infected with C trachomatis are still susceptible to subsequent C. trachomatis infection 
and disease sequelea, thus supporting the hypothesis that the immunological memory that 
develops during C. trachomatis infections is defective.    
  During primary C. trachomatis infection in the genital tract, CD4
+ T cells are 
primed in the draining lymph nodes (dLNs).  Priming is the initial stage of T cell 
activation and sets the course for memory development.  During CD4
+ T cell priming, the 
T Cell Receptor (TCR) on the CD4
+ T cell binds the antigen presented on MHC Class II 
by a professional antigen presenting cell (pAPC).  In addition, co-stimulatory signaling 
by the pAPC is necessary to enhance TCR signaling in the T cell.  Finally the third signal ! 12!
needed for efficient priming and activation comes from cytokines, most predominantly 
IL-2, secreted both from the CD4
+ T cells and the pAPCs (44).    Fully activated CD4
+ T 
cells migrate to peripheral tissues where they can be stimulated to express high levels of 
cytokines by APCs, despite no or low levels of costimulatory signals in those tissues.  In 
the context of C. trachomatis infection, CD4
+ T cells migrate to the genital tract and 
expand over 30 fold to produce populations of CD4
+ T cells that can restrict C. 
trachomatis replication through the production of IFNγ (45, 46).  The populations of 
CD4
+ T cells contract to form a stable pool of memory cells.  CD4
+ T cells can develop 
into several types of memory cells: Th1, Th2, Th17 and T regulatory cells.  The type of 
memory cell that develops is largely determined by the cytokines present in the milieu 
during priming.   During C. trachomatis infection the main cytokines present are IFNγ 
and IL-12 (47, 48).  These cytokines drive the CD4
+ T cells to develop into Th1 cells, 
which are potent producers of IFNγ.  Studies have shown that mice that receive 
Chlamydia-specific Th1 skewed CD4
+ T cells are protected from infection with C. 
trachomatis (45).  However mice that receive Chlamydia-specific Th2 cells, which 
predominantly produce the cytokine IL-4, actually have higher bacterial levels (45).    
  Memory CD4
+ T cells are defined by the retention of the Th1/Th2 cytokine 
profile, rapid production of cytokines, and the ability to be restimulated with lower 
antigen dose.  Ultimately it is these characteristics that allow rapid pathogen clearance 
upon re-exposure. The memory Th1 cells that develop after primary C. trachomatis 
infection have the ability to rapidly expand upon reinfection and are superior at 
producing multiple cytokines IL-2, IFNγ, and TNFα compared to CD4
+ T cells generated 
during primary infection (49).  In fact CD4
+ T cells are absolutely required for protection ! 13!
against secondary C. trachomatis infection, as depletion of memory CD4
+ T cells prior to 
secondary challenge in mice results in high bacterial levels (41).   Additionally, these 
memory CD4
+ T cells alone are sufficient to confer protection in naïve mice.  Mice that 
receive memory CD4
+ T cells from previously infected mice are subsequently protected 
against C. trachomatis infection (Georg Stary, unpublished).   Collectively these data 
support that a robust and efficient memory CD4
+ T cell response develops following C. 
trachomatis infection. 
  Like CD4
+ T cells, the development of memory CD8
+ T cells begins during 
priming.  During C. trachomatis infection CD8
+ T cells are primed in the dLNs by 
recognizing antigen presented on MHC class I of dendritic cells. In addition to antigen 
stimulation through the TCR, CD8
+ T cells require costimulatory signaling mediated by 
CD28 expressed on the CD8
+ T cell membrane and CD80 or CD86 expressed on 
dendritic cells.  Finally, CD8
+ T cells require a third signal of inflammatory cytokines, 
typically IFNγ and IL-12, to become fully activated.   Activated CD8
+ T cells, 
subsequently termed effector CD8
+ T cells, can expand in number and migrate to the site 
of infection.  Effector CD8
+ T cells recognize cognate antigen presented on infected cells 
and produce the lytic cytokines to kill those cells.  Similar to CD4
+ T cells, the CD8
+ T 
cell population contracts several days after initial expansion and about 90% of the 
activated CD8
+ T cells are eliminated.  What remains is a pool of memory CD8
+ T cells 
(Figure 1-2). ! 14!
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Figure 1-2 CD8
+ T cell response directed against pathogen challenge.  Upon 
primary challenge (first arrow) with a pathogen, the CD8
+ T cells expand in 
number.  After the peak of expansion, 90% of the CD8
+ T cells are deleted and 
the remaining population forms the memory pool.  When the same antigen is 
encountered again (second arrow), the CD8
+ T cells respond more quickly and 
expand to higher numbers compared to primary response.  The pathogen is 
quickly cleared, significantly limiting disease. 
 
After the peak of CD8
+ T cell expansion and subsequent contraction of this 
population, the remaining 10% of CD8
+ T cells are retained as a pool of memory cells.  
Like memory CD4
+ T cells, the purpose of memory CD8
+ T cells is to provide a 
population of cells that can quickly respond when a pathogen is re-encountered.  
Functional memory CD8
+ T cells have a lower threshold of activation and can more 
readily produce cytokines such as IFNγ and TNFα.  The quick response of memory CD8
+ 
T cells serves to limit pathogen replication in the host before it can cause disease.   As 
mentioned, the development of the memory CD8
+ T cells depends largely on factors that ! 15!
occurred during priming, as well as environmental cues.  The three signals described 
above, TCR signaling, costimulatory and inflammatory cytokines, are sufficient for 
driving a robust primary CD8
+ T cell response.  However, these signals are not sufficient 
for developing stable memory CD8
+ T cells.  CD4
+ T cells are also necessary during the 
priming of CD8
+ T cells to promote the development of stable CD8
+ memory T cells that 
can elicit robust secondary responses.  The primary function of “CD4 help” is to promote 
IL-2 signaling.  IL-2 inhibits the cell death signaling pathway that is induced in CD8
+ T 
cells that have been repeatedly stimulated and undergone extensive expansion (50, 51).  
Current data suggest that CD4
+ T cell help can be indirect.  CD40L expressed on CD4
+ T 
cells signals through CD40 on dendritic cells to activate these dendritic cells (52).  
Activated dendritic cells are then able to interact with CD8
+ T cells to prime the CD8
+ T 
cells to produce their own IL-2 (53).  Therefore, CD8
+ T cells must be able to produce 
and respond to IL-2 in order to develop into functional memory cells (53).   
CD8
+ T cells differentiate into subsets of memory cells, defined by several 
characteristics, which determine the type of secondary response produced.  The majority 
of memory CD8
+ T cells express the IL-7 receptor (IL-7R) and the IL-15 receptor (IL-
15R).  Both IL-7 and IL-15 are required for memory CD8
+ T cells to maintain a basal 
level of proliferation, also termed homeostatic turnover (54, 55).  Factors such as antigen 
load, inflammation, and cytokine signaling influence the type of memory CD8
+ T cell 
that develops.   A subset of CD8
+ memory cells maintains high expression levels of the 
surface molecule CD62L.  CD62L sustains T cell rolling in high endothelial venules 
(HEV), which supports reentry of T cells into lymphoid tissue (56).  Cells expressing ! 16!
high levels of CD62L are known as central memory CD8
+ T cells (Tcm).  Alternatively, 
effector memory CD8
+ T cells (Tem) shed surface CD62L (57).   
Effector and central memory CD8
+ T cells differ in their ability to expand, 
respond to antigen and migrate to the sites of infection.  Tcm cells are primarily found in 
secondary lymphoid organs, as well as the spleen and blood and have an enhanced ability 
to expand with a low threshold of antigen stimulation.  Thus, for systemic infections with 
pathogens such as Lymphocytic!Choriomeningitis!Virus!(LCMV) Armstrong, Influenza, 
or L. monocytogenes, the Tcm is the major protective population of CD8
+ T cells (57).   
Effector memory T cells on the other hand typically circulate between the blood and 
peripheral tissues, and thus are believed to have enhanced access to peripheral infection.  
It has also been demonstrated that Tem cells have a higher capacity to produce effector 
cytokines, such as IFNγ and TNFα, and can be stimulated by nonprofessional APCs, but 
have lower expansion compared to Tcm cells (58, 59).  During cutaneous infection with 
Herpes Simplex Virus (HSV), the Tem population is required for protection (60).  The Tem 
population is also required for protection against certain viruses that infect the lung, 
indicating that this population can be a protective, especially at mucosal surfaces, despite 
the low expansion capacity of these cells (61).   
Interestingly the development of Tcm versus Tem is still unclear.  It has been well 
documented that over time the Tcm population in mice increases substantially over the Tem 
population .  There is data that suggests a linear development in which Tem cells 
eventually develop into Tcm cells over time.  In this model, Tem cells represent a 
transitional phase of CD8
+ T cells that overtime re-express CD62L (58, 62, 63).  
However, another model suggests that Tcm and Tem cells are distinct populations, and the ! 17!
increase in Tcm cells over time is an indication of their enhanced expansion capability 
over Tem cells (64, 65).  There are also discrepancies in the literature on the exact 
definition of Tem cells.  Tem were traditionally defined as the “peripheral” memory CD8
+ 
T cells because they were the primary memory population found in peripheral tissue.  
However, evidence suggesting that Tem cells circulate between the periphery and blood 
has brought up questions of whether Tem populations reside in peripheral tissues or are 
transient visitors.  Thus, an additional subset of memory CD8
+ T cells, termed resident 
memory (Trm), were described as CD8
+ T cells that permanently reside in specific tissues 
and do not re-circulate (66).   
Trm cells were traditionally defined by the expression of the CD103 molecule.  
CD103 functions as a receptor for E-cadherin, an adhesion molecule specifically 
expressed by epithelial cells (67).  Trm cells have been described for the skin, intestinal 
mucosa, brain and the vaginal mucosa (68).   Vaginal infection with the Human 
Papillomavirus (HPV) stimulates the expansion and retention of CD103
+ CD8
+ T cells 
within the vaginal mucosa.  Upon vaginal rechallenge these CD8
+ T cell provide superior 
protection compared to systemic CD8
+ T cells (69).  Ultimately, it remains unclear which 
cellular CD8
+ population mediates protection for the upper genital tract.   
 
CD8
+ T cell dysfunction during infection 
  The CD8
+ T cell response is a critical component of the immune response to 
intracellular pathogens.  However, a CD8
+ T cell response that is too robust can cause 
severe damage to host tissue, thus there are host mechanisms in place to limit CD8
+ T 
cell expansion and cytokine production.  These inhibitory mechanisms are important for ! 18!
maintaining peripheral tolerance and protecting the host from autoimmunity and 
pathology.  During activation, CD8
+ T cells express a variety of costimulatory and 
inhibitory receptors and ligands.  This provides a combination of signaling patterns that 
influence the expression of cytokines and proliferative responses, determining the 
activation and effector state of the CD8
+ T cell.  During an interaction with a pAPC, the 
engagement of immune-inhibitory molecules can reduce the signaling that originates 
from the TCR and costimulatory receptors.   For example, the molecule PD-L1 expressed 
by a pAPC engages PD-1 expressed on a CD8
+ T cell (70, 71).  This interaction causes 
the dephosphorylation PI3K, disrupting this signaling pathway and subsequently limiting 
the expression of IFNγ, IL-2 and the cell-survival molecule Bcl-xL (72) (Figure 1-3). 
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Figure 1-3 PD-1 dampens TCR signaling.  During interaction with an APC, the 
T cell response is mediated by costimulatory (green signals) and inhibitory (red  
signals) molecules.  When PD-1 is engaged by PD-L1, the SHP-2 phosphatase is 
recruited and prevents signaling from the costimulatory molecule CD28.  Adapted 
from (73). 
 
  The engagement of immune-inhibitory molecules, such as PD-1, does not just 
affect that immediate CD8
+ T cell response.  PD-1 signaling during priming of the CD8
+ 
T cell can permanently alter the CD8
+ T cell.  CD8
+ T cells that express PD-1 and are 
engaged by PD-L1 become exhausted and this has long-term consequences.  Exhausted 
CD8
+ T cells progressively lose the ability to produce IFNγ, TNFα and IL-2.  Exhausted 
CD8
+ T cells also fail to acquire key memory properties such as homeostatic turnover and 
the ability to mount robust recall responses.  Eventually, exhausted CD8
+ T cells undergo ! 20!
apoptosis, and in the context of infection this can substantially reduce the antigen-specific 
CD8
+ T cell population (74).  
A number of pathogens have evolved mechanisms to exploit the PD-1/PD-L1 
pathway to evade the CD8
+ T cell response and subsequently cause persistent infection.  
For example, during Lymphocytic!Choriomeningitis!Virus!cloneA13!(LCMV-Cl13) 
infection, PD-1 expressing CD8
+ T cells become exhausted and are unable to clear the 
virus, thereby contributing to chronicity of the infection (75).  However, blockade of the 
PD-1/PD-L1 pathway through antibody treatment can reverse CD8
+ T cell dysfunction 
and restore viral clearance (76).   
Similar to LCVM-Cl13, Human Immunodeficiency Virus (HIV) infection results 
in the expression of PD-1 on HIV specific CD8
+ T cells and the subsequent exhaustion of 
these CD8
+ T cells.  Studies of PD-1 expressing HIV specific CD8
+ T cells from human 
patients found that PD-1 expression positively correlated with the expression of the 
transcription factor basic leucine zipper transcription factor ATF-like (BATF) (77).  
Additionally, the engagement of PD-1 with PD-L1 led to the increase in BATF 
expression.  Over-expression of BATF in CD8
+ T cells led to increased apoptosis and 
reduced IL-2 production (77).  These studies have provided mechanistic insight into how 
PD-1 results in CD8
+ T cell dysfunction.   
 
CD8
+ T cell impairment during C. trachomatis infection 
  Like many chronic infections, C. trachomatis infection produces a CD8
+ T cell 
response that is impaired.  During primary systemic infection with C. trachomatis there is 
actually a very robust CD8
+ T cell response.  However, as described previously, the ! 21!
hallmark of immune memory is the ability to respond more quickly to rechallenge.  Upon 
systemic rechallenge with C. trachomatis, there is an extremely blunted secondary CD8
+ 
T cell response (78).  For many chronic infections, sustained antigen exposure is what 
drives CD8
+ T cell impairment.  However, for C. trachomatis this does not seem to be the 
case as mice treated with doxycycline to ensure complete C. trachomatis clearance still 
exhibit a blunted recall response (78).   
  The mechanism behind the blunted CD8
+ T cell response during C. trachomatis 
reinfection remained unclear.  However, it appeared that C. trachomatis infection resulted 
in a global suppression of CD8
+ T cells.  This was demonstrated by co-infection with C. 
trachomatis and Listeria monocytogenes.  Mice that were infected previously or 
simultaneously with C. trachomatis exhibited a reduced CD8
+ T cell response to L. 
monocytogenes, compared to mice that were only infected with L. monocytogenes (78).    
These results confirmed that C. trachomatis infection can alter the CD8
+ T cell response 
to a heterologous antigen, suggesting that C. trachomatis infection elicits a broad 
inhibitory mechanism.  Additionally these studies provided the key evidence to 
understanding why natural immunity to C. trachomatis is ineffective at preventing 
subsequent infection.   
   
Vaccine development against C. trachomatis 
  Studies of humans and mice have indicated that natural immunity towards C. 
trachomatis is impaired and fails to protect the host against reinfection.  Thus, having a 
vaccine that can produce superior protection is of the upmost importance.  In general 
vaccines can be DNA, subunit or cellular based.  The majority of vaccine studies for C. ! 22!
trachomatis have focused on subunit based immunizations.  As described earlier, the C. 
trachomatis protein MOMP is a major B cell antigen.  MOMP contains four variable 
domains that are antigenically variable among the 16 serovars of C. trachomatis and have 
made it difficult to induce pan-serovar protection.  However, recent studies have shown 
that immunization with recombinant MOMP (rMOMP) elicits antibody and CD4
+ T cell 
responses specific for constant domains of MOMP (79).  Immunization with rMOMP 
resulted in protection against several other C. trachomatis serovars, demonstrating that it 
is possible to generate heterotypic immunity against MOMP.   
Another antigen at the forefront of vaccine studies is the chlamydial protease-like 
activity factor (CPAF).  CPAF is expressed in C. trachomatis RBs, secreted out of the 
inclusion and predominantly found in the host cytosol.  Mice immunized with 
recombinant CPAF produce a CD4
+ T cell response that is protective against vaginal 
challenge with C. muridarum (80).   
Interestingly, less attention has been paid to investigating a protective CD8
+ T cell 
response.  This is likely due to the abundance of data demonstrating that memory CD8
+ T 
cells are impaired and offer little protection in the context of a natural infection.   
However, as described earlier, immunization against the CD8
+ T cell antigen, CrpA, can 
protect mice against subsequent systemic infection.  In general, CD8
+ T cells are the 
sentinels against intracellular pathogens and it is CD8
+ T cells that can directly kill 
infected cells.  Presumably, creating a combinatorial vaccine that elicits an antibody and 
a protective CD4
+ and CD8
+ cellular response will be most effective.  
  Several important caveats exist with current Chlamydia vaccine studies.   First, 
there is variability in the species used during studies.  Identifying antigens that protect ! 23!
against the mouse pathogen, C. muridarum, cannot necessarily be extrapolated to the 
human pathogen C. trachomatis.  More important is the variability in the site of 
immunization and the site of challenge.  Studies have used different routes of 
immunization that produce phenotypically different cellular responses.  Ultimately, to 
produce a protective response it will be important to immunize by a route that generates 
immune cells that can quickly migrate to the genital tract.  Attention should be paid to the 
HSV literature.  Researchers have described a CD8
+ T cell population that resides in the 
genital skin and mucosa that provides protection against subsequent HSV challenge (81).  
Additional studies have identified a method termed “prime and pull” for generating local 
CD4
+ and CD8
+ T cell memory in the vaginal mucosa.  In the prime and pull method, 
mice were subcutaneously immunized (or primed) with an attenuated HSV strain.  
Subsequently, chemokines were topically applied to the vaginal cavity of immunized 
mice to “pull” the CD4
+ and CD8
+ T cells to the genital tract.  The CD4
+ and CD8
+ T 
cells remained in the vaginal mucosa long term and provided superior protection 
compared to mice that did not receive the “pull” (82).   Whether the prime and pull 
method will work for other genital pathogens has not been investigated. 
  The HSV literature provides promising avenues for generating a protective 
vaccine against C. trachomatis.  Understanding how to generate local immunity will be 
critical to designing an effective vaccine against C. trachomatis.  However, significant 
differences exist between the two pathogens.  Most significant, in terms of generating an 
immune response, is the fact that in humans C. trachomatis does not stay in the vaginal 
cavity but ascends to the upper genital tract.  The immune responses within the vaginal 
cavity and upper genital tract differ.  Recent studies have shown that mice intravaginally ! 24!
infected with C. trachomatis, do not produce a significant CD4
+ T cell response 
compared to mice that have been inoculated with C. trachomatis directly into the uterus 
(41).  It is likely that CD8
+ T cell responses differ as well, although this has not been 
investigated.  Again these data point to the caveats of vaccine studies against C. 
trachomatis and the need to be aware of the location of bacterial challenge.  Ideally, 
future vaccine studies will investigate responses to C. trachomatis within the upper 
genital tract.   
 
Focus of dissertation 
C. trachomatis should be highly susceptible to the CD8
+ T cell response.  
However, the natural CD8
+ T cell response that is elicited upon C. trachomatis infection 
appears to play an insignificant role in protecting the host.  Moreover, the CD8
+ T cell 
response is highly impaired and C. trachomatis can actually dampen the CD8
+ T cell 
response to other pathogens which has significant implications for hosts that may be 
coinfected with C. trachomatis and any other genital pathogen.  I began my studies to 
more fully understand the endogenous CD8
+ T cell response to C. trachomatis infection 
of the genital tract.   Although the C. trachomatis specific CD8
+ T cell response had 
previously been described, those studies were performed using systemic infection and it 
remained unclear how the mucosal CD8
+ T cell response functioned.  What I have 
learned studying the response in the genital tract complements what has been described 
for systemic infection.  Furthermore, my studies led me to investigate mechanisms that 
impair the CD8
+ T cell response in the genital tract during C. trachomatis infection.  I ! 25!
discovered that the PD-1/PD-L1 pathway alters the CD8
+ T cell response and contributes 
to limiting C. trachomatis clearance.   
!
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Chapter Two:  The CD8
+ T cell response to  
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Introduction 
 
Infection with Chlamydia trachomatis stimulates both the innate and adaptive 
immune responses (1).   A clear understanding of the adaptive immune response to C. 
trachomatis will be key in developing a protective vaccine.  Studies have demonstrated 
that CD4
+ T cells are both necessary and sufficient to protect mice against C. trachomatis 
in the genital tract of mice (2).  However, because of the obligate intracellular nature of 
C. trachomatis there is interest in understanding the role that the CD8
+ T cell response 
may play in clearance of C. trachomatis.   CD8
+ T cells are generally stimulated by 
cytosolic derived antigen presented on Major Histocompatibility Complex class I (MHC 
class I), although professional antigen presenting cells (pAPCs) can take up extracellular 
antigen and present it on MHC class I through a process known as cross-presentation.  In 
infected epithelial cells, C. trachomatis proteins that are inserted into the inclusion 
membrane or secreted outside of the inclusion are the most likely candidates to be 
processed and presented on MHC class I.    
Previous research has demonstrated that CD8
+ T cells are efficiently primed 
during C. trachomatis infection (3, 4).  To date, seven C. trachomatis CD8
+ T cell 
antigens have been identified that are stimulated upon C. trachomatis infection (5-7).  Of 
these seven, one antigen, CrpA, has been best described (3, 6).   It has been demonstrated 
that systemic infection with C. trachomatis stimulates a robust primary expansion of 
CrpA-specific CD8
+ T cells (8).  As described in the Introduction, with acute pathogens 
such as Influenza or Listeria monocytogenes, the secondary CD8
+ T cell expansion upon 
rechallenge would be expected to occur more quickly and with a higher magnitude !39!
!
compared to primary challenge (9, 10).  However, during systemic rechallenge with C. 
trachomatis, the secondary CrpA-specific CD8
+ T cell expansion occurs with the same 
kinetics as primary expansion, with the peak of both primary and secondary CD8
+ T cell 
responses occurring at day seven-post infection.  Furthermore, the peak of secondary is 
significantly reduced in number compared to the peak of the primary response (8).   It 
was hypothesized that C. trachomatis systemic infection impairs the CD8
+ T cell 
response, and this was supported by experiments demonstrating that primary co-infection 
of mice with C. trachomatis and L. monocytogenes produce fewer L. monocytogenes 
specific CD8
+ T cells compared to mice infected with the same dose of L. monocytogenes 
alone (8).   Thus not only does C. trachomatis infection impair the recall capacity of the 
CD8
+ T cell response, but these data suggest that C. trachomatis reduces the ability of the 
primary CD8
+ T cells to respond to heterologous challenge.  Yet, how C. trachomatis 
infection inhibits the CD8
+ T cell response remained unclear. 
Although the CD8
+ T cell recall response to C. trachomatis is impaired, it is 
possible to generate protective CD8
+ T cell responses against C. trachomatis.  Mice 
immunized with Vaccinia expressing CrpA are protected against subsequent challenge 
with C. trachomatis (6).  Additionally, mice that receive CD8
+ T cells that are engineered 
to specifically express the T Cell Receptor (TCR) for CrpA are protected against 
systemic infection with C. trachomatis compared to mice that receive no T cells (3).  
These experiments provide strong support to the hypothesis that CD8
+ T cells have the 
ability to be an important protective response against C. trachomatis.  
A significant caveat to the studies described above is that these experiments were 
performed using a systemic model of infection.  In humans, C. trachomatis infects !40!
!
mucosal surfaces, specifically ocular and uterine epithelial cells, which generate 
phenotypically distinct immune responses compared to the systemic site of infection.  For 
example, CD8
+ and CD4
+ T cells require a specific set of chemokines in order to migrate 
to the genital tract, that are not required for systemic infection (11, 12).   It has previously 
been difficult to track the endogenous C. trachomatis specific CD8
+ T cell responses in 
the genital tract.   However, retrogenic CD8
+ T cells specific for CrpA were shown to 
proliferate, produce IFNγ and migrate to the genital tract in response to intrauterine 
infection with C. trachomatis (3).  What still remained unclear from previous research 
was the nature of the endogenous CD8
+ T cell response to genital infection with C. 
trachomatis.  Specifically it was unknown whether the impaired CD8
+ T cell response 
observed during systemic infection also occurs in the genital tract of C. trachomatis 
infected mice.  This chapter describes the endogenous CD8
+ T cell response to C. 
trachomatis infection of the murine genital tract and demonstrates that C. trachomatis 
infection of the genital tract produces an impaired CD8
+ T cell response that does not 
contribute to bacterial clearance. !41!
!
Results 
 
Characterizing the C. trachomatis-specific CD8
+ T cell response in the genital tract 
Previous work has described the CD8
+ T cell response during a systemic C. 
trachomatis infection.  However, little is known regarding the endogenous CD8
+ T cell 
response to C. trachomatis infection in the genital tract.  To characterize the mucosal 
CD8
+ T cell response to C. trachomatis, I transcervically infected mice with 10
6 inclusion 
forming units (IFU) of C. trachomatis.  At specific time points following primary 
infection, during memory phase and after secondary infection, I measured the number of 
C. trachomatis specific CD8
+ T cells in the draining lymph nodes (dLNs) and the uterus.  
Using an ELISPOT assay, I measured the number of IFNγ producing CD8
+ T cells 
specific for the C. trachomatis immunodominant antigen, CrpA, in the dLNs.  Five days 
after infection, the number of IFNγ producing CrpA
+ T cell population had expanded 
1,700 fold compared to day zero (Figure 2-1).   
 !42!
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Figure 2-1 CrpA specific CD8
+ T cell response in the dLNs during 
transcervical C. trachomatis infection. Mice were transcervically infected with 
10
6 IFU of C. trachomatis on day 0 (marked by 1
st arrow).  At time points 
marked, dLNs were harvested and the number of CrpA specific IFNγ-producing 
CD8
+ T cells was measured by ELISPOT.  Mice were rechallenged at the second 
arrow.  Each time point is the mean of five mice per group, and bars represent 
SEM.  Statistical significance of *p<0.05 is indicated for day 0 and day 28.  
**p<0.01 is indicated for day 5 primary and day 5 secondary infections.  Statistics 
were determined by Mann-Whitney Test. 
 
By day twenty-eight following infection, the number of IFNγ producing CrpA
+ T 
cells was substantially reduced compared to the peak of primary at day five, however 
there remained a memory population of CrpA T cells that was significantly higher in 
number compared to day zero (Figure 2-1).   
Other work has demonstrated that the secondary CD8
+ T cell response to acute 
pathogens such as L. monocytogenes and LCMV should occur faster and with a higher 
magnitude compared to the primary CD8
+ T cell response to that same pathogen.  
Therefore I expected that mice rechallenged with C. trachomatis would produce a 
secondary CD8
+ T cell response that was more robust compared to the primary response 
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observed.  Thirty-five days after primary infection, I transcervically rechallenged mice 
with 10
6 IFU of C. trachomatis.  Compared to primary infection, there was not a robust 
expansion of the IFNγ producing CrpA
+ T cells.  In fact, the peak of the secondary CrpA 
T cell response five days following secondary challenge, which should include both 
newly primed and antigen-experienced CD8
+ T cells, was 21 fold lower than the peak of 
the primary response (Figure 2-1).  Thirty days after secondary challenge, the IFNγ
+ 
CrpA population had returned to a level similar to day zero.  These data suggest that 
further antigen challenge caused the C. trachomatis-specific CD8
+ T cell population to 
either die or become unresponsive.  All together these data demonstrate that C. 
trachomatis stimulates robust CD8
+ T cell expansion during primary infection, but is 
unable to elicit a comparable response during secondary infection.    
Although there was a substantial CD8
+ T cell population in the dLNs upon 
primary infection, I questioned whether this translated to a C. trachomatis-specific CD8
+ 
T cell migration to the site of infection in the uterus. Using a previously described 
tetramer specific for the immunodominant C. trachomatis antigen, CrpA, I measured the 
endogenous CD8
+ T cell response in the genital tract by flow cytometry during primary 
infection, memory response, and secondary infection.  The number of CrpA
+ CD8
+ T 
cells expanded over 1500 fold between days zero and seven in the genital tract (Figure 2-
2).  After the peak of expansion, which occurred seven days following infection, the 
CrpA
+ CD8
+ T cell population contracted.  By day twenty-seven post infection the 
number of CrpA
+ CD8
+ T cells found in the genital tract was similar to day zero (Figure 
2-2).    !44!
!
 
Figure 2-2 CrpA specific CD8
+ T cell response in the genital tract during 
transcervical C. trachomatis infection. Mice were transcervically infected with 
10
6 IFU of C. trachomatis on day 0 (marked by 1
st arrow).  At time points marked, 
genital tracts were harvested and the number of CD8
+ T cells positive for the 
CrpA tetramer was measured by flow cytometry.  Mice where rechallenged at the 
second arrow.  Each time point is the mean of five mice per group, and bars 
represent SEM.  Statistical significance of *p<0.05 is indicated for day 7 primary 
and day 7 secondary infections by Mann-Whitney Test. 
 
 
As shown in Figure 2-1, there were very few CrpA-specific CD8
+ T cells in the 
dLNs during secondary infection with C. trachomatis.  I hypothesized that the low 
number of CD8+ T cells in the dLNs may be an indication that the activation and 
expansion of the secondary T cell response might occur in the uterus, and therefore a 
robust secondary response should be observed in the uterus during secondary infection.  
To test this, following the resolution of infection and the formation of a C. trachomatis 
specific memory CD8
+ T cell population, I transcervically rechallenged mice thirty-five 
days after the primary infection.  The peak of the secondary CrpA
+ CD8
+ T cell response 
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in the genital tract was seven days following challenge, however the secondary response 
was substantially reduced compared to the primary infection with 3.5 fold fewer CrpA
+ T 
cells found at the peak of secondary infection compared to primary infection (Figure 2-
2).  Together these data demonstrate that there is a substantial expansion of the primary 
C. trachomatis-specific CD8
+ T cell population, however there is a severely blunted 
secondary response in both the dLNs and the uterus.   
 
CD8
+ T cells are dispensable during C. trachomatis infection 
The previous data suggests that there is an impaired secondary CD8
+ T cell 
response to C. trachomatis.  However I questioned whether this correlated with a 
decrease in the number of effector CD8
+ T cells present in the genital tract following 
secondary infection.  IFNγ is the main cytokine necessary to restrict to C. trachomatis 
replication in the uterus, therefore I measured the number of IFNγ-producing CD8
+ T 
cells present in the genital tracts by intracellular cytokine staining of mice after primary 
and secondary infections.   Six days after secondary infection, there was a six-fold 
decrease in the number IFNγ-producing CD8
+ T cells compared to primary infection 
(Figure 2-3a).  Upon examining the mean fluorescent intensity of the IFNγ-producing 
population, it was evident that the CD8
+ T cells from both primary and secondary 
infections produced similar amounts of IFNγ (Figure 2-3b).  I further analyzed the total 
CD8
+ T cell population present in the uterus to examine if the decrease in secondary 
IFNγ-producing CD8
+ T cells was associated with an overall decrease in the CD8
+ T cell 
population.  There was a two-fold decrease in the overall number of CD8
+ T cells in the 
uterus during secondary infection compared to primary (Figure 2-3c).  However, there !46!
!
was also a significant two-fold decrease in the percentage of uterine CD8
+ T cells 
producing IFNγ (Figure 2-3d).   These data demonstrate that the magnitude of the 
cytokine producing secondary CD8
+ T cell population is significantly reduced compared 
to the primary response to C. trachomatis infection.  This reduction can not be fully 
attributed to an overall decrease in the number of CD8
+ T cells and suggests that IFNγ 
producing CD8
+ T cells are specifically deleted or impaired during secondary C. 
trachomatis infection. 
 
 
 !47!
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Figure 2-3.  IFNγ response of uterine CD8
+ T cells 6 days post secondary 
infection is lower than primary infection.  Mice were challenged with 10
6 IFU 
of C. trachomatis. A. Six days post primary or post secondary challenge, 
lymphocytes from the genital tract were stimulated and the number of IFNγ 
producing CD8
+ T cells were measured by ICCS.  B. MFI was determined from 
IFNγ
+ CD8
+ T cell population.  C. Total numbers of CD8
+ T cell were measured 
in the uterus by flow cytometry.  D.  The percentage of CD8
+ T cells that produce 
IFNγ.  Bars indicate the mean of five mice per group and error bars represent 
SEM.  *p<0.05 was determined by Mann-Whitney Test. 
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While it is clear that the CD8
+ T cell response is blunted during secondary 
infection, it remained unclear if the CD8
+ T cell population, during primary or secondary 
infection, contributed to C. trachomatis clearance.  To investigate this, I treated mice 
with anti-CD8 depleting or isotype control antibody every day for three days prior to 
primary infection, and every other day after infection.  I confirmed at least a 100-fold 
depletion of CD8
+ T cells in the uterus (Figure 2-4a, left panel) and observed similar 
depletion in the dLNs and spleens (data not shown).  Five days post infection, which is 
the peak of C. trachomatis infection in the uterus, bacterial levels were measured by 
quantitative real-time polymerase chain reaction (qPCR).  Mice depleted of CD8
+ T cells 
had similar bacterial levels in the uterus compared to mice treated with control antibody 
(Figure 2-4a, right panel).   On day seven when infection is beginning to be cleared 
from the uterus, both groups of mice still exhibited equivalent bacterial levels (Figure 2-
4b).  
 !49!
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Figure 2-4 CD8
+ T cell depletion during C. trachomatis transcervical 
infection does not impact clearance.  A.  Mice were treated with anti-CD8 
depleting antibody or isotype control 3 days prior to and every other day after 
primary transcervical infection with C. trachomatis.  Five days post infection 
CD8
+ and CD4
+ T cell populations were measured in the uterus (left panel) and 
bacterial levels were measured by qPCR (right panel). B.  Mice were treated with 
anti-CD8 depleting antibody or isotype control 3 days prior to and every other day 
after primary transcervical infection with C. trachomatis.  Seven days post 
secondary infection CD8
+ and CD4
+ T cell populations were measured in the 
uterus (left panel), and bacterial levels were measured by qPCR (right panel).  
Bacterial levels were normalized to host GAPDH levels.  Bars represent the mean 
of 4-9 mice per group, and error bars indicate SEM. 
 
 
Although it appeared that CD8
+ T cells do not contribute to C. trachomatis 
clearance, it remained possible that the strong mouse-specific innate immune response 
anti-CD8
Isotype
10
100
1000
10000
p
g
 
C
t
 
1
6
s
/
 
u
g
 
H
o
s
t
 
G
A
P
D
H
NS
anti-CD8
Isotype
1
10
100
p
g
 
C
t
 
1
6
s
/
 
u
g
 
H
o
s
t
 
G
A
P
D
H
NS
A.
B.
%
 
o
f
 
L
y
m
p
h
o
c
y
t
e
s
anti-CD8
Isotype
0
2
4
6
CD8+ T cells
CD4+ T cells
Day 5 Post-Infection Day 5 Post-Infection
Day 7 Post-Infection Day 7 Post-Infection
%
 
o
f
 
L
y
m
p
h
o
c
y
t
e
s
anti-CD8
Isotype
0
2
4
6 CD8+ T cells
CD4+ T cells!50!
!
mediated by the Immunity Related GTPases (IRGs) masked a protective role for CD8
+ T 
cells (described in the Introduction).  Previous work demonstrated that mouse IRGs are 
upregulated in response to IFNγ and can restrict C. trachomatis replication (13).  
However IRGs are not present in humans and do not contribute to C. trachomatis 
restriction in humans, thus deletion of mouse IRGs is believed to more closely 
recapitulate a human C. trachomatis infection.   Mice deleted for the genes Irgm1 and 
Irgm3 (Irgm1/m3
(-/-)) show delayed but effective C. trachomatis clearance (14).  
However, Irgm1/m3
(-/-) mice show an enhanced dependence on the adaptive immune 
response, specifically CD4
+ T cells, as depletion of CD4
+ T cells in these mice leads to 
significantly higher C. trachomatis levels (14).  To test if the mouse innate immunity may 
mask a role for CD8
+ T cells, I treated Irgm1/m3
(-/-) mice with CD8
+ depleting antibody 
or control antibody prior to primary C. trachomatis transcervical infection.  Due to the 
delayed clearance defect of these mice I waited eleven days after infection to measure 
bacterial levels in the uterus.  Both groups of mice showed equivalent bacterial levels.  
Together these data indicate that the CD8
+ T cell response is not necessary to control 
primary C. trachomatis infection and has no measurable impact on the clearance of C. 
trachomatis (Figure 2-5). !51!
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Figure 2-5 CD8
+ T cell depletion does not alter C. trachomatis levels during 
transcervical infection of Irgm1/m3
(-/-) mice.  Irgm1/m3
(-/-) deficient mice were 
treated with anti-CD8 depleting antibody or isotype control three days prior to and 
every other day after primary transcervical infection with C. trachomatis. Eleven 
days post-infection, CD8
+ and CD4
+ T cell populations were measured in the 
uterus and shown as the percentage of CD90.2
+ lymphocytes (left graph).  
Bacterial levels were measured by qPCR and normalized to host GAPDH levels 
(right graph).  Bars represent the mean of 4-5 mice per group and error bars 
indicate SEM.   
 
 
 
It is clear that CD8
+ T cells do not contribute to clearance of primary C. 
trachomatis infection in the uterus.  However, it remained a possibility that the memory 
CD8
+ T cells that developed after primary infection contributed to control of secondary 
infection. To test this, mice that recovered from primary infection were treated with anti-
CD8 depleting antibody or isotype control.  Five days after transcervical rechallenge, C. 
trachomatis levels in the uterus were measured by qPCR.  Mice that were treated with 
anti-CD8 depleting antibody had bacterial levels similar to mice treated with isotype 
control (Figure 2-6).  These data confirm that the secondary CD8
+ T cells do not 
contribute to control of C. trachomatis replication.  
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Figure 2-6  CD8
+ T cell depletion during secondary challenge does not impact 
C. trachomatis burden.   Mice treated with anti-CD8 depleting antibody or 
isotype control 3 days prior to and 2 days after secondary transcervical infection 
with C. trachomatis.  Five days post secondary infection CD8
+ and CD4
+ 
populations were measured in the genital tract and are shown as the % of CD90.2 
lymphocytes (left graph).  Bacterial levels were measured by qPCR and 
normalized to host GAPDH levels (right graph).    Bars represent the mean of 5 
mice per group and error bars indicate SEM.    
 
 
 
Infection with C. trachomatis impairs the CD8
+ T cell response to Listeria 
monocytogenes 
 
The data presented have clearly demonstrated that the CD8
+ T cell response that 
develops during a C. trachomatis infection 1. Exhibits a reduced secondary response that 
is numerically smaller compared to the primary response and 2. Does not contribute to 
control of C. trachomatis.  I hypothesized that infection with C. trachomatis induces an 
immunosuppressive environment that results in mis-priming of the CD8
+ T cells and the 
impaired recall response.   If this were true, then infection with C. trachomatis should 
also impair the CD8
+ T cell response to a heterologous antigen.  Previous studies 
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demonstrated that systemic co-infection with C. trachomatis and L. monocytogenes 
resulted in a reduction in the number of Listeria specific CD8
+ T cells (8).  I 
consequently decided to continue this system in the genital tract.  Preliminary results 
demonstrated that a dose of 10
5 colony forming units (CFU) of L. monocytogenes 
deposited transcervically in mice produced a CD8
+ T cell response numerically 
comparable to 10
6 C. trachomatis, therefore this dose was continued for subsequent 
experiments.  To test the hypothesis that C. trachomatis infection would impair the 
Listeria specific CD8
+ T cell response, I transcervically co-infected mice with 10
6 C. 
trachomatis and 10
5 L. monocytogenes engineered to express the Ova antigen (L.m.-Ova).  
Mice were either infected with C. trachomatis three hours prior to L.m.-Ova infection, or 
at the same time as L.m.-Ova infection, or infected with L.m.-Ova only (all mice received 
the same dose of L.m.-Ova).  Five days after infection, I measured the numbers of Ova-
specific CD8
+ T cells in the dLNs by ELISPOT.  Mice that were co-infected with C. 
trachomatis, either three hours prior to or at the same time as L.m.-Ova infection, had 
significantly fewer Ova specific IFNγ producing CD8
+ T cells compared to mice infected 
with L.m.-Ova alone (Figure 2-7a).  This was not due to differences in L.m.-Ova 
bacterial levels, as all mice had equivalent levels of bacteria (Figure 2-7b). 
 !54!
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Figure 2-7  C. trachomatis infection reduces the Listeria specific CD8
+ T cell 
response in the dLNs during co-infection of the genital tract.  Mice were 
transcervically infected with 10
6 IFU of C. trachomatis three hours prior to 
transcervical infection with 10
5 CFU of L.m.-Ova (left bar), or simultaneously 
infected (middle bar) or infected with 10
5 CFU of L.m.-Ova alone (right bar).  A. 
Five days post infection the number of OVA specific IFNγ producing CD8
+ T 
cells were measured by ELISPOT.  B. CFUs were measured in the spleen.  
*p<0.05 was determined by Mann-Whitney Test. 
 
 
Additionally, I measured the number of activated CD8
+ T cells in the uterus by 
staining for CD44, a surface marker that is upregulated on activated T cells, and analyzed 
cells by flow cytometry.  Mice that were infected with C. trachomatis three hours prior to 
L.m.-Ova infection had over a 2-fold decrease in the number of activated CD8
+ T cells 
present in the uterus compared to mice infected with L.m.-Ova alone.  However, there 
were equivalent levels of activated CD4
+ T cells (Figure 2-8).   Mice that were 
simultaneously coinfected with C. trachomatis and L.m.-Ova had similar levels of 
activated CD8
+ T cells and CD4
+ T cells.  These data provide compelling evidence that 
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infection with C. trachomatis results in the general suppression of the CD8
+ T cell 
response in the genital tract.  
 
 
 
Figure 2-8 Infection with C. trachomatis impairs the CD8
+ T cells response to 
L. monocytogenes. Mice were transcervically infected with 10
6 IFU of C. 
trachomatis three hours prior to transcervical infection with 10
5 CFU of L.m.-Ova 
(left bar), or simultaneously infected (middle bar) or infected with 10
5 CFU of 
L.m.-Ova alone (right bar).  Five days post infection the number of CD44
+ 
activated CD8
+ T cells (left graph) and CD44
+ activated CD4
+ T cells (right 
graph) were measured in the genital tract.  *p<0.05 was determined by Mann-
Whitney Test. 
 
 
 
Characterizing the CD8
+ T cell response to Listeria monocytogenes infection of the 
genital tract 
There are organs within the host that are considered immune-privileged because 
inflammatory responses in these organs can have especially negative consequences on 
fitness.  Thus, in organs such as the brain and eye there are organ-driven mechanisms to 
restrain inflammatory responses (15, 16). It is possible that the upper genital tract, which 
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includes the uterus, may also be an immune-privileged site because excessive 
inflammation is likely to damage the reproductive tract and have negative impacts on 
fertility.  In fact previous evidence suggested that TNFα producing CD8
+ T cells 
stimulated during Chlamydia muridarum infection contributes to inflammation and 
pathology of the uterus (17).  However, the coinfection experiments presented above 
suggested that C. trachomatis specifically suppressed the CD8
+ T cell response.  
Therefore I wanted to test if the CD8
+ T cell response observed during transcervical C. 
trachomatis infection represented a general mechanism of the host to limit the CD8
+ T 
cell response in the genital tract.  To test this idea, I examined the CD8
+ T cell response 
to L. monocytogenes, an organism known to elicit a protective CD8
+ T cell response, 
which can also infect the genital tract (18).  In order to compare the CD8
+ T cell 
responses between L. monocytogenes and C. trachomatis I engineered a L. 
monocytogenes strain expressing the full length CrpA gene (L.m.-CrpA).  I 
transcervically infected mice with 10
5 CFU of L.m.-CrpA and at multiple time points 
following primary infection, during memory and after secondary infection, I measured 
the number of CrpA specific CD8
+ T cells in the dLNs by flow cytometry.  Similar to 
what was observed with the CD8
+ T cell response against C. trachomatis,  L.m.-CrpA 
elicited a strong primary CD8
+ T cell response in the dLNs.  By day seven post infection 
the CD8
+ T cell population had expanded over 3000 fold, and by day fourteen this 
population had returned to numbers similar to uninfected mice (Figure 2-9).  After 
secondary challenge with L.m.-CrpA , the CD8
+ T cell population had an extremely 
blunted response compared to the primary infection, with an approximate six fold !57!
!
decrease in the number of CrpA specific CD8
+ T cells five days following secondary 
infection compared to primary infection (Figure 2-9).   
 
 
Figure 2-9: CrpA specific CD8
+ T cell response in the dLNs during  L.m.-
CrpA infection of the genital tract. Mice were transcervically infected with 10
5 
CFU of L.m.-CrpA on day 0 (marked by 1
st arrow).  At time points marked, dLNs 
were harvested and the number of tetramer positive CrpA specific CD8
+ T cells 
were measured by flow cytometry.  Mice where rechallenged with 10
5 CFU of 
L.m.-CrpA at the second arrow.  Each time point is the mean of five mice per 
group, and error bars represent SEM. Statistical significance of *p<0.05 is 
indicated for day 5 primary and day 5 secondary infections by Mann-Whitney 
Test. 
 
 
I next measured the CD8
+ T cell response during L.m.-CrpA infection in the 
genital tract by flow cytometry.  By day seven post-primary infection the CrpA specific 
CD8
+ T cell population had expanded 5000 fold (Figure 2-10).  The population quickly 
contracted and formed a memory population by day twenty-five that was about 100-fold 
higher than uninfected mice.  Mice were rechallenged with L.m.-CrpA  and the CrpA 
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specific CD8
+ T cell population quickly increased in the genital tract.  By day five post-
secondary infection, the CrpA specific CD8
+ T cell population was 4000 fold higher than 
day zero, to a total number significantly higher than day five post-primary infection 
(Figure 2-10).  The secondary response was equally high on days five and seven post 
secondary infection, but contracted by day fourteen.  The number of CrpA specific CD8
+ 
T cells measured on day seven post-primary and day seven post-secondary infections 
were not significantly different.  These data show that the CD8
+ T cell secondary 
response to L.m.-CrpA infection of the genital tract occurs more quickly compared to the 
primary response.  All together these data suggest that the impaired CD8
+ T cell response 
observed in the genital tract upon C. trachomatis infection may be specific to C. 
trachomatis.   
 
 
Figure 2-10: CrpA specific CD8
+ T cell response in the genital tract during 
transcervical L.m.-CrpA infection. Mice were transcervically infected with 10
5 
CFU of L.m.-CrpA on day 0 (marked by 1
st arrow).  At time points marked, 
genital tracts were harvested and the number of tetramer positive CrpA specific  
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(Figure 2-10 Continued) 
 
CD8
+ T cells were measured by flow cytometry.  Mice where rechallenged with 
10
5 CFU of L.m.-CrpA at the second arrow.  Each time point is the mean of five  
mice per group, and error bars represent SEM. Statistical significance of *p<0.05 
is indicated for day 5 primary and day 5 secondary infections by Mann-Whitney 
Test. 
 
The CD8
+ T cell response in the dLNs was very similar between C. trachomatis 
and L. monocytogenes infection.  However, the secondary CD8
+ T cell response in the 
genital tract differed between the two pathogens.  Compared to C. trachomatis,  L.m.-
CrpA infection resulted in a larger memory population and elicited a faster and 
numerically higher secondary response.  I hypothesized that these differences in 
secondary responses between C. trachomatis and L. monocytogenes infections may be in 
the phenotype of the CD8
+ T cells that are present in the genital tract during infection.  
To test this hypothesis, I transcervically infected mice with 10
6 C. trachomatis, 10
5 L. 
monocytogenes, or coinfected with both C. trachomatis and L. monocytogenes.  Six days 
post infection, I analyzed the CD8
+ T cell responses by flow cytometry.  CD8
+ T cells 
quickly develop memory phenotypes and can be broadly separated into two subsets based 
on the expression of CD127 (the IL-7 receptor) and CD62L (a lymph node homing 
marker).  CD8
+ T cells that express high levels of CD127 and CD62L are known as 
central memory T cells (Tcm/n) and typically home to lymphoid organs, however, this 
population of cells may also contain naïve cells (Tn).  CD8
+ T cells that express high 
levels of CD127 but low levels of CD62L are known as effector memory T cells (Tem) 
and migrate through peripheral tissues.  Total numbers of Tcm/n and Tem were measured in 
the genital tracts of infected mice and compared.  Mice infected with C. trachomatis had 
a Tem/Tcm/n ratio that was no different from uninfected mice.  However, mice infected !60!
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with L. monocytogenes had a significantly higher ratio of Tem cells to Tcm/n cells 
compared to mice infected with C. trachomatis.  Simultaneous co-infection with C. 
trachomatis and L. monocytogenes led to a Tem to Tcm/n ratio similar to L. monocytogenes 
infection alone (Figure 2-11).  Together these results indicate that C. trachomatis and L. 
monocytogenes infections produce phenotypically distinct CD8
+ T cell populations.   
 
 
Figure 2-11 Transcervical infection with L.m-Ova produces a higher Tem to 
Tcm/n ratio in the genital tract.  Mice were either uninfected, transcervically 
infected with 10
6 IFU of C. trachomatis, simultaneously infected with 10
6 IFU of 
C. trachomatis and 10
5 CFU of L.m-Ova, or infected with 10
5 L.m-Ova alone.  Six 
days post primary infection the total numbers of Tem (CD127
+, CD62L-) and Tcm/n 
(CD127
+, CD62L
+) in the genital tracts were measured by flow cytometry.  Bars 
show the mean ratio of total Tem over Tcm/n of five mice per group, and error bars 
represent SEM.  Statistical significance is indicated by *p<0.05 and **p<0.01, 
determined by Mann-Whitney Test. 
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Previous experiments demonstrated that infection with C. trachomatis prior to 
infection with L.m.-Ova resulted in fewer activated CD8
+ T cells in the genital tract 
(Figure 2-8).  In order to understand if this reduction in the number of activated CD8
+ T 
cells correlated with differences in CD8
+ T cell phenotype, I transcervically infected mice 
with C. trachomatis three hours prior to L.m.Ova infection or simultaneously infected 
mice with both C. trachomatis and L.m.Ova .  Five days post infection I measured the 
ratio of Tem to Tcm/n in the genital tracts (Figure 2-12).   Mice that received C. 
trachomatis three hours prior to L.m.Ova had a significant decrease in the ratio of Tem to 
Tcm/n cells.   Mice that were simultaneously infected with C. trachomatis and L.m.-Ova 
exhibited a similar Tem to Tcm/n ratio compared to mice that received L.m.-Ova.  All 
together these data suggest that prior infection with C. trachomatis alters the overall 
CD8
+ T cell response in the genital tract.  Interestingly it is only mice that were infected 
with C. trachomatis three hours prior to L.m.-Ova that exhibited both a decrease in the 
number of activated CD8
+ T cells in the genital tract and a decrease in the Tem to Tcm/n 
ratio, suggesting that activation status and Tem/Tcm/n ratio could be connected.  
 !62!
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Figure 2-12 Prior infection with C. trachomatis alters the ratio of Tem to Tcm/n 
during L.m.-Ova infection. Mice were transcervically infected with 10
6 IFU of 
C. trachomatis 3 hours prior to infection with 10
5 CFU of L.m-Ova, 
simultaneously infected with 10
6 IFU of C. trachomatis and 10
5 CFU of L.m-Ova, 
or infected with 10
5 L.m-Ova.  Five days post primary infection the total numbers 
of Tem (CD127
+, CD62L-) and Tcm/n (CD127
+, CD62L
+) in the genital tracts were 
measured by flow cytometry.  Bars show the mean ratio of Tem over Tcm/n of five 
mice per group, and error bars represent SEM.  *p<0.05 was determined by 
Mann-Whitney Test. 
 
  Finally I wanted to test if the CD8
+ T cell response elicited by L. monocytogenes 
would be protective against rechallenge with C. trachomatis.  I transcervically infected 
mice with C. trachomatis,  L.m-CrpA, or L.m.-Ova.  Four weeks after primary infection, I 
rechallenged mice with C. trachomatis and measured C. trachomatis burden in the genital 
tract five days later.  As expected, mice that were previously infected with C. trachomatis 
showed significantly reduced bacterial levels compared to unimmunized mice (Figure 2-
13).  Interestingly, mice that received L.m.-CrpA or L.m.-Ova showed bacterial levels 
similar to mice that were previously infected with C. trachomatis.  These data indicate 
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that infection with L. monocytogenes does protect against C. trachomatis, however it may 
not be dependent on the CD8
+ T cell response.  
 
 
Figure 2-13 Immunization with L. monocytogenes protects mice against C. 
trachomatis.  Mice were transcervically infected with 10
6 IFU of C. trachomatis, 
10
5 CFU L.m.-CrpA, 10
5 CFU L.m.-Ova, or left uninfected.  Four weeks after 
primary infections, mice were challenged with 10
6 IFU of C. trachomatis; five days 
later bacterial levels were measured by qPCR and normalized to host GAPDH 
levels. Shown is the compilation of 2 separate experiments, and error bars represent 
SEM.  *p<0.05 and ***p<0.0005 were determined by Mann-Whitney Test. 
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Discussion 
 
   The hallmark of immune memory is the ability of the adaptive immune system to 
respond more quickly and vigorously to antigen to which it has been previously exposed.  
For C. trachomatis, there is ample evidence showing that patients can reacquire C. 
trachomatis infections, thus indicating a lack, or functional impairment, of immune 
memory to C. trachomatis.  Systemic studies in mice showed that the CD8
+ T cell 
secondary response is blunted compared to the primary response.  The studies in this 
chapter provide the first evidence indicating that the mucosal CD8
+ T cell response to C. 
trachomatis is also impaired.   
Studies with acute viral pathogens such as Lymphocytic Choriomeningitis Virus 
(LCMV) and Influenza have provided the model for CD8
+ T cell responses.  In these 
studies, primary infection with the viral pathogen produces a substantial CD8
+ T cell 
response.  The virus is cleared, a stable CD8
+ memory population develops, and upon 
secondary challenge these memory cells are able to expand to greater numbers compared 
to primary infection thus clearing the virus before disease symptoms are apparent (9, 19).  
The data in this chapter clearly demonstrates that the secondary CD8
+ T cell response to 
C. trachomatis is blunted compared to the primary response and therefore does not mimic 
the model T cell response for these acute viral infections.  In fact the CD8
+ T cell 
response to C. trachomatis infection does resemble that of chronic infections.  For 
example, the CD8
+ T cell response to Hepatitis C Virus (HCV) is also described as 
dysfunctional.  During HCV infection, antigen-specific CD8
+ T cells produce low levels 
of IFNγ.  Although HCV specific CD8
+ T cells are present in infected patients, the levels !65!
!
of CD8
+ T cells do not correlate with low viral titers, suggesting that CD8
+ T cells are 
unable to control HCV infection (20).   
C. trachomatis is not the only sexually transmitted infection that results in 
impaired CD8
+ T cell responses that do not contribute to controlling pathogen burden.  
The Human Immunodeficiency Virus (HIV) is a genital pathogen that results in CD8
+ T 
cells that are unable to control viral replication (21).  Human Papilloma Virus (HPV) also 
elicits CD8
+ T cells that have impaired cytokine production (22).   However, the data 
from HPV and HIV studies were taken from human studies, in which these pathogens 
produce chronic disease.  There are very few studies examining the CD8
+ T cell 
responses to C. trachomatis in humans.  Though, there is evidence that CD8
+ T cells from 
C. trachomatis infected patients are low in lytic cytokine production (23).   
The impaired CD8
+ T cell response to C. trachomatis infection is similar to that 
of chronic pathogens, however in mice C. trachomatis produces an acute infection.  Thus 
it was unclear if the observed CD8
+ T cell response was representative of a C. 
trachomatis specific effect or a typical CD8
+ T cell response to a genital infection.  
Therefore L. monocytogenes was chosen in order to do a comparative analysis.  Infection 
with L. monocytogenes produces a well-described protective CD8
+ T cell response (24, 
25).  It was hypothesized that if the genital tract was an immune-suppressive environment 
than the CD8
+ T cell response to L. monocytogenes would be similar to that of C. 
trachomatis.  Transcervical infection with L. monocytogenes produced a CD8
+ T cell 
response in the dLNs that was identical to that of C. trachomatis.  Interestingly, the CD8
+ 
T cell response in the genital tract differed between the two organisms.  Most striking 
was the enhanced CD8
+ T cell response in the genital tract during secondary L. !66!
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monocytogenes infection compared to primary infection, this is in comparison to the 
extremely blunted CD8
+ T cell response to secondary C. trachomatis infection.  These 
data provide several interesting hypotheses.  The fact that the secondary CD8
+ T cell 
responses in the dLNs to both C. trachomatis and L. monocytogenes were blunted 
suggests that the secondary expansion and T cell recruitment could occur outside of the 
dLNs, possibly in the genital tract.  This is supported by the fact that there is very little 
expansion or retention of the CD8
+ T cell population in the dLNs during secondary L. 
monocytogenes infection, yet there is a robust secondary population present in the genital 
tract.  Furthermore, during L. monocytogenes infection there is a larger memory CD8
+ T 
cell population that is maintained in the genital tract compared to C. trachomatis 
infection, even though both infections produced similar numbers of CrpA specific CD8
+ 
T cells during primary infections.  The increase in the memory CD8
+ T cell population 
during L. monocytogenes infection may account for the larger secondary response upon 
rechallenge.   However, future studies should test this hypothesis by directly measuring 
the expansion of L. monocytogenes specific memory CD8
+ T cells transferred into a naïve 
host.  All together these data support that the CD8
+ T cell response to C. trachomatis is 
specific to the pathogen and does not represent the response generated by another 
pathogen.   
The ultimate question that remains is why is there a larger memory CD8
+ T cell 
population and larger secondary CD8
+ T cell response during L. monocytogenes infection 
compared to C. trachomatis?  Understanding the answer to this question may allow 
researchers to manipulate a protective CD8
+ T cell response to C. trachomatis.  The 
studies in this chapter begin to describe the differences between L. monocytogenes and C. !67!
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trachomatis that could contribute to the different recall capacities.  During L. 
monocytogenes infection, the CD8
+ T cells are skewed to a more Tem phenotype, whereas 
C. trachomatis infection produces a CD8
+ T cell population that is skewed toward a Tcm/n 
phenotype.   The higher Tem ratio in L. monocytogenes infection may account for the 
larger memory population present in the genital tract.  By expressing lower levels of 
CD62L, Tem cells are more likely to reside in, or migrate through, the peripheral tissue.  
Previous studies have demonstrated that in mucosal tissues Tem cells require less 
stimulation and are more quickly able to differentiate into cytokine producing effector 
cells when compared to Tcm/n cells (26, 27).  Tcm/n on the other hand express high levels 
of CD62L, which allow these cells to circulate systemically, but therefore result in these 
cells being physically separated from the mucosal site of infection (26).  In fact, previous 
studies have demonstrated that HPV may evade the immune response by skewing the 
CD8
+ T cell response towards the Tcm phenotype, thus excluding them from the genital 
mucosa (22).  The data presented in this chapter suggest that C. trachomatis infection 
skews the CD8
+ T cells to a Tcm/n phenotype, and this may contribute to the impaired 
CD8
+ T cell recall response.  This may also explain why mice that are infected with C. 
trachomatis prior to L. monocytogenes infection produce fewer activated CD8
+ T cells in 
the genital tract, however when mice are simultaneously coinfected the CD8
+ T cell 
response is skewed toward a Tem phenotype and there are more activated CD8
+ T cells in 
the genital tract.  Although correlative, these data suggest that the levels of activated 
CD8
+ T cells may be related to the populations of Tem to Tcm/n present in the genital tract.  
Future experiments should use activation markers to distinguish naïve T cells from 
central memory CD8
+ T cells in the genital tract of mice infected with C. trachomatis !68!
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and/or L. monocytogenes.  It is possible that the Tcm/n population in C. trachomatis 
infected mice is primarily naïve cells, which would indicate that primary infection fails to 
properly prime the CD8
+ T cell response.   Finally, the Tem skewed CD8
+ T cell response 
elicited by L. monocytogenes may partially explain why infection with this organism, 
lacking a known C. trachomatis antigen, still confers protection against C. trachomatis.  
Previous studies have demonstrated that L. monocytogenes specific memory CD8
+ T cells 
expressing low levels of CD62L mediate rapid, non-antigen specific IFNγ responses (27, 
28).  This suggests that the L. monocytogenes specific memory CD8
+ T cells may non-
specifically secrete IFNγ that leads to protection against C. trachomatis, although future 
experiments will test this hypothesis.  Furthermore, it will be interesting for future studies 
to discern if Tcm and Tem cells generated by L. monocytogenes infection provide different 
levels of protection against C. trachomatis and exhibit differences in bystander activity.   
It will be important to understand if bystander activity from memory CD8
+ T cells 
contributes to the mucosal immune response and mediates early control of pathogen 
replication in the genital tract.   
The evidence presented here leads to the hypothesis that C. trachomatis infection 
impairs the recall capacity of CD8
+ T cells, yet how that occurs is not clearly understood.  
To fully investigate this question it will be necessary to distinguish the kinetics of the 
secondary response.  The recall response following C. trachomatis secondary infection 
could be due to a lack of expansion of the memory cells, an impairment of naïve cells that 
also contribute to the secondary response, a migration defect or increased cell death of 
memory cells.   In order to discern between these possibilities future studies should 
examine CD8
+ T cell expansion in the genital tract by directly measuring dilution of the !69!
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molecule Carboxyfluorescein succinimidyl ester (CFSE) of memory CD8
+ T cells 
transferred into naïve mice.  Furthermore, coupling this experiment with apoptosis 
markers will allow researchers to investigate if there is increased death of memory CD8
+ 
T cells.  Another possible explanation for the lack of recall response to C. trachomatis 
infection is that the secondary expansion is happening outside the genital tract.  The 
experiments here have excluded the genital tract and dLNs, but it is possible that 
secondary expansion occurs in another tissue such as the spleen.  Investigating the 
presence of C. trachomatis specific CD8
+ T cells in other tissues following secondary 
infection will provide insight into the possibility that memory CD8
+ T cells are defective 
in their ability to migrate to the genital tract.   
What these experiments, and those of others, have not yet demonstrated is the 
existence of resident memory CD8
+ T cells in the upper genital tract.  In other mucosal 
surfaces, such as the skin and intestines, there are memory CD8
+ T cells that permanently 
reside in these tissues.  During infection, resident memory CD8
+ T cells are poised to act 
quickly in order to control infection.  Whether the Tem populations elicited by C. 
trachomatis and L. monocytogenes are actually resident memory populations is unclear.  
Future experiments can explore this possibility by comparing the ability of Tem and Tcm 
CD8
+ T cell populations isolated from the genital tracts of C. trachomatis or L. 
monocytogenes infected mice to migrate to the genital tract and provide protection in 
naïve mice.  Alternatively, by using a parabiosis model it will be possible to distinguish 
what cellular populations from immune mice are able, or unable, to migrate to the naïve 
parabiosed partner.  Ultimately the experiments in this chapter lay the foundation for !70!
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future studies that will enable researchers to understand the factors that determine a 
protective CD8
+ T cell response in the genital tract.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 !71!
!
Methods 
 
Mice 
C57BL/6 mice were purchased from The Jackson Labs.  IrgM1/3 deficient mice 
have been described previously (14).  All animals were maintained and cared for within 
the Harvard Medical School Center for Animal Resources and Comparative Medicine 
(Boston, MA).  All mice were treated with 2.5 mg medroxyprogesterone subcutaneously 
7 days prior to infection to synchronize the murine estrous cycle.  All experiments were 
approved by the Institutional Animal Care and Use Committee. 
 
Growth, isolation, and detection of bacteria 
C. trachomatis serovar L2 (434/Bu) was propagated within McCoy cell 
monolayers grown in Eagle’s MEM (Invitrogen, Grand Island, NY) supplemented with 
10% FCS, 1.5 g/l sodium bicarbonate, 0.1M nonessential amino acids, and 1 mM sodium 
pyruvate. Infected monolayers were disassociated from plates, using sterile glass beads, 
and were sonicated to disrupt the inclusion. Elementary bodies were purified by density 
gradient centrifugation, as described previously (29).  Aliquots were stored at -80°C in 
medium containing 250 mM sucrose, 10 mM sodium phosphate, and 5 mM L-glutamic 
acid (SPG) and were thawed immediately prior to use.  To quantify the levels of C. 
trachomatis quantitative PCR with 16S primers specific for Chlamydia was performed as 
has been previously described (29).  Listeria monocytogenes 10403S, and L.m.-Ova were 
provided by Darren Higgins.  L. monocytogenes strains were grown in Brain Heart 
Infusion media (BHI) and passaged through mice.  Prior to infection frozen aliquots of L. !72!
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monocytogenes were incubated in 10ml of BHI at 37°C for 1 hour with shaking.  Based 
on the OD 600, dilutions of L. monocytogenes were made in SPG.   To quantify levels of 
L. monocytogenes after infection, uterine tissue was homogenized in 2 ml of HBSS and 
80µl aliquots were plated on BHI containing 100µg/ml of streptomycin.  
 
Listeria monocytogenes-CrpA strain creation 
The CrpA gene was amplified from C. trachomatis serovar L2 (434/Bu) by PCR 
using the following primers; Fwd: 5’-
GGGCGGCCGAAATGAGCACTGTACCCGTTGT-3’; Rev: 5’-
GGGCGGCCGTTTGGGTCTGATCCACCA-3’.  The amplification added EagI 
restriction sites to both the 5’ and 3’ ends.  The construct was then ligated into the pVEV 
vector, created from the pPL2 integration vector and generously provided by Darren 
Higgins (30, 31).  The pVEV vector contains the ActA promoter and signaling sequences.  
This created a construct in which the CrpA sequence is fused between the ActA signal 
sequence and the OVA SIINFEKL sequence.  The vector was then integrated into the L. 
monocytogenes chromosome by electroporation with the following settings: 1 KV, 400 
ohms, 25 mFD.  The resulting strain was maintained on BHI containing 7.5µg/ml of 
chloramphenicol and 100µg/ml of streptomycin.  Secretion of CrpA-OVA fusion was 
confirmed by CrpA-tetramer staining and OVA-pentamer staining of splenocytes isolated 
from mice three days post intraveneous infection.     
 
Flow cytometry !73!
!
Tissues were mechanically disaggregated and immediately stained for surface 
markers.  For ICCS, tissues were stimulated for 5 h with 50 ng/ml PMA (Alexis 
Biochemical) and 500 ng/ml ionomycin (Calbiochem) in the presence of brefeldin A 
(GolgiStop; BD Biosciences) for intracellular cytokine staining. Cells were preincubated 
with anti-FcRg (Bio X-Cell) before staining with αCrpA-APC,  αCD4 Q-Dot, αCD8-Pe-
Cy7,  and αCD3-Pe (Biolegend).  Cells were also incubated with αCD11b-PB, αCD11c-
PB, αCD19-PB and αB220-PB (Biolegend) as a negative gate. For activation marker 
analysis, cell were incubated with αCD62L-ApcCy7 (Biolegend), αCD127-PerCP-Cy5.5 
(BD Biosciences), and αCD44-FITC (Biolegend).  For intracellular staining αIFN-g PE 
(BD Biosciences) was used. Cells were permeabilized with the Cytofix/Cytoperm Plus 
Kit according to the manufacturer’s instructions (BD Biosciences). The absolute cell 
number in each sample was determined using AccuCheck Counting Beads (Invitrogen). 
Data were collected on an LSRII (BD Biosciences) and analyzed using FlowJo (Tree 
Star).  APC-CrpA tetramer was provided by the National Institute of Health Tetramer 
Core Facility.   
 
ELISPOT  assays 
  ELISPOT filter plates were incubated overnight with 10µg/ml of anti-IFNγ 
capture antibody (Biolegend).  Plates were blocked with RPMI media for 1 hour.  EL4 
cells were incubated for one hour with 10µM of CrpA or OVA peptide, the cells were 
then treated for one hour with 100µg/ml Mitomycin C.  EL4 cells were washed several 
times and then plated at 10
5 cells per well.  Lymphocytes were harvested from infected 
mice and plated in triplicate with 5x10
5 and 2.5x10
5 lymphocytes per well.  Twenty-four !74!
!
hours later, plates were washed and then incubated with 10µg/ml of biotin conjugated 
anti-IFNγ antibody overnight at 4°C.  Plates were then incubated with Streptavidin-HRP 
for 1 hour at room temperature.  Plates were developed by incubating with BCIP/NBT 
solution (25mg in 10ml of H2O).  Spots were counted using a dissecting microscope. 
 
T cell depletion 
For CD8
+ T cell depletion experiments, mice depleted prior to primary challenge 
were injected i.p. with 200µg of anti-CD8 (clone 2.43) or isotype control (clone LTF-2) 
from BioXCell.  For primary challenge, mice were treated with antibody every day 
starting 3 days prior to primary challenge and then every other day after challenge.  Mice 
were sacrificed 5 days after challenge.  For secondary challenge, mice were treated every 
day for 3 days prior to secondary challenge and then every other day after secondary 
challenge.  
 
Statistical analysis 
The data represent the mean ± SEM and were calculated using GraphPad Prism 
version 4.0. P values were determined using the nonparametric Mann-Whitney U test.  
Significant differences between groups are indicated as follows: *p<0.05, **p< 0.01, and 
***p<0.005. 
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Chapter Three: Expression of the immuno-inhibitory ligand, 
PD-L1, is upregulated in the genital tract during  
C. trachomatis infection. !
!
80!
 
PD#L1&limits&the&mucosal&CD8+&T&cell&response&to&Chlamydia)trachomatis 
Sarah Fankhauser and Michael Starnbach 
 
 
Portions of this chapter have been submitted as part of a manuscript to the Journal of 
Immunology.  The project was conceived by S. Fankhauser and M. Starnbach.  
Experiments and data analysis were performed by S. Fankhauser, and all text and figures 
were produced by S. Fankhauser.  !
!
81!
Introduction 
 
In mice, Chlamydia trachomatis infection stimulates CD8
+ T cells that expand 
over 100 fold, and subsequently contract to form a memory population (1, 2).   However, 
upon rechallenge with C. trachomatis, the secondary CD8
+ T cell response is 
significantly smaller in magnitude, with fewer cytokine producing CD8
+ T cells, 
compared to the primary CD8
+ T cell response (2).  This type of impaired secondary 
CD8
+ T cell response is reminiscent of chronic infections with viral pathogens such as 
Human Immunodeficiency Virus (HIV) and Lymphocytic!Choriomeningitis!Virus!
Clone!13!(LCMV-Cl13).    The memory CD8
+ T cells that develop after HIV and 
LCMV-Cl13 infections exhibit an exhausted phenotype defined by low cytokine 
production, low replicative potential, and increased expression of pro-apoptotic genes, all 
of which lead to extremely deficient secondary CD8
+ T cell responses that are unable to 
control pathogen replication (3-5).  
A significant cause of defective CD8
+ T cell responses in chronic viral infections, 
such as HIV and LCMV-Cl13, is the engagement of immunoinhibitory pathways (6-9).  
The engagement of immunoinhibitory pathways can directly inhibit T cell signaling 
produced by the costimulatory molecules, or affect signaling pathways downstream that 
can lead to apoptosis, reduced cytokine production, and altered memory responses (10, 
11).  A well-described immunoinhibitory pathway is made up of the receptor PD-1 and 
its ligand PD-L1.  PD-1 expression can be induced on T cells upon activation, and PD-L1 
is expressed on a wide variety of cells including professional antigen presenting cells 
(pAPC), epithelial and endothelial cells (12-14).  It is unclear if the PD-1/PD-L1 pathway !
!
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or any other known immunoinhibitory pathways are responsible for producing the 
impaired secondary CD8
+ T cell response during C. trachomatis infection.  I 
hypothesized that the blunted CD8
+ recall response, and lack of CD8
+ T cell contribution 
to infection control, is due to the engagement of one or more immunoinhbitory pathways.  
In this chapter, I determine which, if any, immunoinhibitory ligands and receptors are 
highly expressed during C. trachomatis infection.   Immunoinhibitory ligands or 
receptors that are highly expressed upon C. trachomatis infection are potential candidate 
pathways that may function to alter the CD8
+ T cell response to C. trachomatis.   !
!
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Results 
 
Identification of immunoinhibitory molecules upregulated during C. trachomatis 
infection 
It is clear that C. trachomatis is able to stimulate a CD8
+ T cell response 
(Chapter 2 Figures 2-1 and 2-2).  However, our data and that of others have shown that 
this CD8
+ T cell response is impaired during C. trachomatis infection.  Different studies 
have demonstrated that the activation of immunoinhibitory pathways can directly inhibit 
the CD8
+ T cell response against different pathogens (4, 5).   I hypothesized that an 
immunoinhibitory pathway is upregulated during C. trachomatis infection.  I took a 
candidate approach and selected to study the expression of ligands and receptors that 
have been previously well described as having a role in restricting CD8
+ T cell responses.  
I transcervically infected mice with 10
6 C. trachomatis and examined the expression of 
selected immunoinhibitory receptors and ligands by quantitative real time reverse 
transcriptase-PCR (qRT-PCR) in whole uterine tissue at the peak of bacterial burden, five 
days post-infection (Figure 3-1).  Several genes exhibited altered expression in infected 
mice compared to mock infected mice.  The expression of 2B4, CD160 and Lag3 was 
significantly upregulated in infected mice, and the expression of PD-L2 and PD-1 was 
down-regulated in infected mice.  Interestingly, the immunoinhibitory ligand PD-L1, 
which binds to PD-1, was expressed over 10 fold higher in the uteri of infected mice 
compared to mock infected mice (Figure 3-1).  I chose to examine PD-L1 expression 
further, and this will be the focus for the remaining chapter. !
!
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Figure 3-1 Inhibitory molecule expression during primary C. trachomatis 
infection.  Mice were transcervically infected with 10
6 IFU of C. trachomatis or 
mock infected.  Five days post infection RNA was extracted from uterine tissue, 
qRT-PCR was performed using primers specific for the indicated genes and 
expression levels were normalized to host GAPDH expression levels.  Bars 
represent the mean of four mice.  Error bars indicate SEM.  Statistical 
significance is indicated by *p<0.05 and **p<0.01 by Mann-Whitney Test. 
 
 
PD-L1 upregulation is dependent on infection with live C. trachomatis infection  
 Previous work has suggested that PD-L1 expression limits the inflammatory 
response to Chlamydia muridarum, therefore PD-L1 expression was investigated further 
(15).   I questioned whether PD-L1 expression was dependent on live C. trachomatis 
infection or just the result of a non-specific inflammatory response to bacterial antigen.  I 
transcervically infected mice with either live or UV-inactivated C.trachomatis and 
assessed PD-L1 expression in the uterus by qRT-PCR five days after infection.  PD-L1 
expression in mice infected with UV-inactivated C. trachomatis was similar to mock-
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infected mice, thus confirming that the increase in PD-L1 expression is dependent on live 
C. trachomatis infection (Figure 3-2).  
 
 
Figure 3-2 PD-L1 upregulation is dependent on live C. trachomatis infection.  
Mice were transcervically infected with 10
6 IFU of live C. trachomatis, 10
6 IFU 
of UV-inactivated C. trachomatis, or mock infected.  Five days post infection 
RNA was extracted from uterine tissue, qRT-PCR was performed using primers 
specific for PD-L1 and expression levels were normalized to host GAPDH levels.  
Bars represent the mean of five mice.  Error bars indicate SEM.  Statistical 
significance is indicated by *p<0.05 by Mann-Whitney Test. 
 
To test if infection alone, independent of host immune responses, was sufficient to 
cause PD-L1 upregulation, I infected a cultured thymic epithelial cell line with live C. 
trachomatis or UV-inactivated C. trachomatis.  Eighteen hours after infection I measured 
PD-L1 surface expression by flow cytometry and compared this to uninfected cells.  
Similar to the in vivo data, PD-L1 was highly expressed on cells infected with live C. 
trachomatis, but not on cells infected with UV-inactivated C. trachomatis or uninfected 
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cells (Figure 3-3).  These data provide strong evidence that C. trachomatis infection 
directly upregulates PD-L1 expression.  
 
 
Figure 3-3 PD-L1 surface expression is upregulated on cultured epithelial 
cells 18 hours post C. trachomatis infection.  Cultured 1308.1 cells were 
infected at an MOI of 1:1 with live or UV-inactivated C. trachomatis.  18 hours 
post infection PD-L1 surface expression, indicated as geometric mean fluorescent 
intensity (gMFI), was measured by flow cytometry.  Bars represent the mean of 
three different wells, and error bars indicate SEM.  Data are representative of two 
independent experiments.  Statistical significance is indicated by ****p<0.0001 
by a Two-Tailed Students T test. 
 
 
PD-L1 is expressed on multiple cell types upon C. trachomatis infection 
Next I wanted to determine which cell types were responsible for the observed 
PD-L1 upregulation during C. trachomatis infection.  PD-L1 can be expressed on a 
variety of cell types such as dendritic cells, CD4
+ T cells, endothelial cells and epithelial 
cells.  Different cell types lead to variation in PD-L1 signaling properties (12, 16, 17).  I 
therefore wanted to examine the expression of PD-L1 on different cellular populations 
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within the uterus and draining lymph nodes (dLNs).  I transcervically infected mice with 
C. trachomatis; at different time points after primary and secondary infection I harvested 
the uteri and dLNs and measured PD-L1 surface expression by flow cytometry.    Five 
days after both primary and secondary infection PD-L1 surface expression increased five 
fold on uterine epithelial cells from infected mice compared to uninfected mice (Figure 
3-4).  PD-L1 expression on DCs, CD4
+ T cells and CD8
+ T cells in the uterus was 
comparable between infected and uninfected mice.  PD-L1 surface expression was also 
significantly higher on DCs in the dLNs five days after primary and secondary infection 
(Figure 3-5).   However, twenty-seven days after primary infection, during the memory 
phase, there was no difference in PD-L1 expression compared to uninfected mice 
(Figures 3-4 and 3-5).  These data demonstrate that PD-L1 is highly expressed on 
uterine epithelial cells and dLN DCs during primary and secondary C. trachomatis 
infection, but this elevated expression is not maintained after infection is cleared. 
 
 !
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Figure 3-4 PD-L1 is highly expressed on uterine epithelial cells upon 
transcervical C. trachomatis infection.  Mice were infected with 10
6  IFU of C. 
trachomatis and at indicated time points post infection, uteri were examined for 
PD-L1 expression by flow cytometry.  Epithelial cells were gated on live CD326
+ 
populations, DCs were gated on live, CD45
+, CD4
-, CD11
+ lymphocytes.  Shown 
are representative histograms of PD-L1 expression.  Black line represents infected 
mice, gray shaded histrogram represents mock infected mice.  Bar graphs show 
the average gMFI of PD-L1 expression on uterine epithelial cells (left) and uterine 
DCs (right) from five mice per time point. Error bars represent SEM.  Data are 
representative of two independent experiments. Statistical significance is 
indicated by *p<0.05 by Mann-Whitney Test. 
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Figure 3-5 PD-L1 is highly expressed on dendritic cells of the dLNs upon 
transcervical C. trachomatis infection.  Mice were transcervically infected with 
10
6 IFU of C. trachomatis and at indicated time points post infection, dLNs were 
examined for PD-L1 expression by flow cytometry.  Dendritic cells were gated on 
live CD45.2
+, CD11c
+, CD4
- lymphocytes. Shown are representative histograms 
of PD-L1 expression.  Black line represents infected mice, gray shaded 
histrogram represents mock mice.  Bar graphs show the average gMFI of PD-L1 
expression on CD11c
+ DCs from five mice per time point. Error bars represent 
SEM.  Data are representative of two independent experiments. Statistical 
significance is indicated by *p<0.05 by Mann-Whitney Test. 
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Priming of the CD8
+ T cell response occurs very early during infection.  Although 
the kinetics of priming are not known for C. trachomatis, for the bacterial pathogen 
Listeria monocytogenes CD8
+ T cells are primed by pAPCs between 24 and 48 hours of 
infection (18).  I hypothesized that PD-L1 expression on dLN DCs could alter priming of 
the CD8
+ T cells during C. trachomatis infection.  If this were true then PD-L1 
upregulation must occur very quickly upon infection.  To test this, PD-L1 surface 
expression was measured 20 hours after primary infection.  At this early timepoint, PD-
L1 surface expression was upregulated on dLN dendritic cells and uterine epithelial cells 
when compared to uninfected mice (Figure 3-6).  The early expression of PD-L1 on dLN 
DCs suggests that this molecule could impact the priming and development of the CD8
+ 
T cell response. 
 
 
Figure 3-6 PD-L1 surface expression is upregulated 20 hours post 
transcervical C. trachomatis infection.  Mice were transcervically infected with 
10
6 IFU of C. trachomatis.  Twenty hours post infection, dLN DCs (left panel) 
and uterine epithelial cells (right panel) were examined for PD-L1 expression by 
flow cytometry.  Bar graphs show the average gMFI of PD-L1 from five mice per 
group.  Error bars represent SEM. Statistical significance is indicated by *p<0.05 
and **p<0.01 by Mann-Whitney Test. 
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Previous studies have reported that PD-L1 expression depends on IFNγ signaling 
(19, 20).  There are two main pieces of evidence to suggest that PD-L1 upregulation is 
independent of IFNγ during C. trachomatis infection.  First, PD-L1 surface expression is 
upregulated during C. trachomatis infection of tissue culture cells, which produce very 
low levels of IFNγ (data not shown).  Second, there is no increase in PD-L1 surface 
expression during infection with UV-inactivated C. trachomatis, which still produces a 
potent inflammatory response. To test this hypothesis, I transcervically infected WT and 
IFNγ-deficient mice with C. trachomatis.  Five days post-infection, PD-L1 surface 
expression was measured by flow cytometry.  Interestingly, there was a significant 
upregulation of PD-L1 expression on dLN DCs in infected IFNγ-deficient mice, 
compared to mock infected IFNγ-deficient mice (Figure 3-7).  Furthermore, the level of 
PD-L1 surface expression on uterine epithelial cells measured in infected IFNγ-deficient 
mice was similar to that of infected WT mice, and significantly higher than mock 
infected mice (Figure 3-7).  Together these data indicate that there is an IFNγ 
independent upregulation of PD-L1 expression during C. trachomatis infection. 
 !
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Figure 3-7 PD-L1 upregulation is independent of IFNγ. Mice were 
transcervically infected with 10
6 IFU of C. trachomatis.  Five days post infection, 
dLN DCs (left graph) and uterine epithelial cells (right graph) were examined for  
PD-L1 expression by flow cytometry.  Bar graphs show the average gMFI of PD-
L1 from five mice per group.  Error bars represent SEM. Statistical significance is 
indicated by *p<0.05 and **p<0.01 by Mann-Whitney Test. 
 
  
The receptors for PD-L1 are upregulated during the memory response 
PD-L1 has two described receptors: PD-1 and B7-1, both of which are expressed 
on T cells.  Engagement of PD-L1 with either receptor on CD8
+ T cells can negatively 
regulate T cell function, and upregulation of PD-1 or B7-1 in memory CD8
+ T cells may 
be an indication of T cell exhaustion (4, 21-23).  Although neither receptor was 
upregulated by qRT-PCR in C. trachomatis infected mice (Figure 3-1), it is possible that 
the qRT-PCR assay of the whole uterine tissue was not sensitive enough to detect subtle 
differences of PD-1 and B7-1 expression on specific cell subsets.   Therefore, I measured 
PD-1 and B7-1 surface expression by flow cytometry on different cell subsets at time 
points following primary infection, during memory phase, and after secondary infection.   
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Neither PD-1 nor B7-1 displayed differences in expression in primarily infected mice 
compared to uninfected mice in any tissue I examined (Figure 3-8).  However, during the 
memory response at 27 days following primary infection both PD-1 and B7-1 surface 
expression were significantly upregulated on CD8
+ T cells within the dLNs (Figure 3-8).  
B7-1 also displayed significant upregulation of surface expression on CD8
+ T cells in the 
dLNs after the secondary infection, whereas PD-1 expression returned to levels 
comparable to uninfected mice.  As the expression of PD-1 and B7-1 are markers of 
CD8
+ T cell exhaustion, the upregulation of these molecules during memory phase 
suggests that CD8
+ memory T cells become exhausted following primary C. trachomatis 
transcervical infection. 
 
 
Figure 3-8 Surface expression of PD-L1 receptors, PD-1 and B7-1, is 
upregulated after C. trachomatis infection resolution.  Mice were 
transcervically infected with 10
6 IFU of C. trachomatis.  PD-1 (left) and B7-1 
(right) expression was measured by flow cytometry on CD8
+ T cells in the dLNs 
five days post primary infection, 27 days post primary infection (memory), or five  
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(Figure 3-8 Continued) 
 
days post secondary infection.  Bar graphs show gMFI of PD-1 expression or B7-
1 expression on CD3
+ CD8
+ T cells; shown is the average of 5 mice per time  
point and error bars represent SEM.  Statistical significance is indicated by 
*p<0.05 and **p<0.01 by Mann-Whitney Test. 
 
 
Taken together, these data demonstrate that PD-L1 expression is highly 
upregulated on uterine epithelial cells and the dLN DCs upon C. trachomatis infection.  
Furthermore, the receptors for PD-L1 are also upregulated on CD8
+ T cells once infection 
has cleared.  This work provides evidence suggesting a role of PD-L1- mediated 
inhibition of the immune response during C. trachomatis infection of the uterus. !
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Discussion   
 
  During CD8
+ T cell activation, stimulatory and inhibitory molecules provide 
important signaling to the T cell that ultimately shapes the T cell response.  Importantly 
there must be a balance between stimulatory and inhibitory signaling to produce an 
effective response that limits pathological damage. It was hypothesized that C. 
trachomatis infection would tip that balance toward inhibitory signaling, which could 
significantly impair the CD8
+ T cell response. This work sought to identify potential 
inhibitory pathways that could contribute to CD8
+ T cell dysfunction during C. 
trachomatis infection.  I observed that PD-L1 expression was highly upregulated during 
C. trachomatis infection and that PD-L1 upregulation was specific to infection with 
productive C. trachomatis infection.   
  The role of PD-L1 in immune regulation has been well described during chronic 
viral infection.   During HIV infection, PD-L1 is highly expressed on pAPCs and PD-1 
expressing-CD8
+ T cells from HIV-infected patients have impaired proliferative and 
IFNγ production capacity (24, 25).  Furthermore, there is a positive correlation between 
PD-1 expression on CD8
+ T cells and HIV disease progression, indicating that the PD-
L1/PD-1 pathway may play an important role in limiting viral replication (24).   Blockade 
of the PD-L1/PD-1 pathway results in expansion of HIV specific, IFNγ-producing CD8
+ 
T cells and suggests that this is a pathway that could be a viable therapeutic target (26).   
The PD-1/PD-L1 pathway also impairs the CD8
+ T cell response to Hepatitis B 
Virus (HBV).    PD-L1 is expressed on almost all cell types within a HBV inflamed 
mouse liver, and PD-1 is upregulated on HBV specific CD8
+ T cells (27).  Similar to HIV !
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infection, blockade of the PD-1/PD-L1 pathway results in the expansion of IFNγ  
producing CD8
+ T cells (28).  Blockade of this pathway reduces HBV persistence in mice 
(27, 28).   
It is clear that PD-L1 expression impacts the immune response and pathogen 
clearance. However, how PD-L1 expression results in delayed viral clearance is not fully 
understood.  PD-L1 expression on APCs can affect the development of CD8
+ T cells 
during priming and result in memory CD8
+ T cells that lose cytotoxic function; 
ultimately these impaired CD8
+ T cells cannot efficiently clear the pathogen.  However, 
blockade of the PD-1/PD-L1 pathway after memory CD8
+ T cell development has 
already occurred can still improve viral clearance, indicating another mechanism by 
which the PD-1/PD-L1 pathway impairs immune function.  Interestingly, different cell 
types expressing PD-L1 can differentially impact the immune response.  For example, 
PD-L1 deficiency on hematopoietic cells results in improved expansion and cytokine 
production of CD8
+ T cells during LCMV-Cl13 infection, however this does not 
necessarily lead to enhanced viral clearance (13).  PD-L1 deficiency on non-
hematopoietic cells does lead to enhanced viral clearance as well as severe 
immunopathology (13).  These studies suggest that PD-L1 expression on pAPCs can alter 
CD8
+ T cell responses, but PD-L1 expression on infected cells may protect these cells 
from cytolytic activity of CD8
+ T cells.  It is interesting that during C. trachomatis 
infection, PD-L1 surface expression is upregulated on both dendritic cells and epithelial 
cells.  This suggests that PD-L1 might have multiple roles during C. trachomatis 
infection.  Chapter Four of this thesis will examine the possible roles of the PD-L1/PD-1 
pathway during C. trachomatis infection. !
!
97!
 Although the PD-L1/PD-1 pathway plays a significant role in impairing the 
immune response to chronic viral infections, the majority of the upregulation of PD-L1 is 
associated with persistent antigen presence and inflammation, and clearance of the 
antigen can result in a reduction of PD-L1 expression.  Although C. trachomatis produces 
chronic infections in human, C. trachomatis produces an acute infection in mice.  
Therefore it was surprising to see that PD-L1 was so highly expressed in the murine 
genital tract during C. trachomatis infection.  However, in this instance PD-L1 
expression is dependent on the presence of infection, as it returned to pre-infection levels 
once infection is cleared.  Additionally, unlike infections with certain viral pathogens, 
PD-L1 expression during C. trachomatis infection was independent of IFNγ expression. 
What remains entirely unclear in the PD-L1/PD-1 field is whether a pathogen can 
directly alter PD-L1 or PD-1 expression for benefit of the pathogen.  In many models it 
has been shown that PD-L1 upregulation is dependent on the expression of IFNγ (19, 29).  
In the case of C. trachomatis, the data suggest that C. trachomatis directly upregulates 
expression of PD-L1, rather than through innate IFNγ signaling.   C. trachomatis has over 
120 known and predicted type III secreted effectors, and future studies will aim to 
understand if one or more of these effectors could be involved in altering PD-L1 
expression. 
Like chronic viral infections, infection with C. trachomatis leads to the 
development of CD8
+ T cells that exhibit signs of exhaustion.  Specifically, PD-1 
expression on CD8
+ T cells is a widely used marker for T cell exhaustion.  The data here 
indicate that both PD-1 and B7-1 are highly expressed on memory CD8
+ T cells 
following C. trachomatis infection, suggesting that these CD8
+ T cells may be exhausted.  !
!
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Future studies will test if memory CD8
+ T cells from C. trachomatis infected mice are 
truly exhausted by measuring cytokine production and proliferation during in vitro 
stimulation.  If CD8
+ T cells exhibit an impaired ability to produce IFNγ and IL-2 or to 
proliferate, this would indicate that CD8
+ T cells become exhausted following C. 
trachomatis infection.  If CD8
+ T cells are in fact exhausted or impaired by interaction of 
PD-L1 with one or both of its receptors during C. trachomatis infection, it may explain 
the diminished CD8
+ T cell population during secondary C. trachomatis infection and the 
inability of CD8
+ T cells to contribute to controlling infection.  These questions will be 
addressed in the next chapter. !
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Methods   
 
Mice 
C57BL/6 and B6.129S7-IFNγtm1Agt (IFNγ-/-) mice were purchased from The 
Jackson Labs.  All animals were maintained and cared for within the Harvard Medical 
School Center for Animal Resources and Comparative Medicine (Boston, MA).  All mice 
were treated with 2.5 mg medroxyprogesterone subcutaneously 7 days prior to infection 
with C. trachomatis to synchronize the murine estrous cycle.  Mice were infected with 
10µl of infectious agent using a non-surgical embryo transfer device (ParaTechs).  All 
experiments were approved by the Institutional Animal Care and Use Committee. 
 
Growth, isolation, and detection of bacteria 
C. trachomatis serovar L2 (434/Bu) was propagated within McCoy cell 
monolayers grown in Eagle’s MEM (Invitrogen, Grand Island, NY) supplemented with 
10% FCS, 1.5 g/l sodium bicarbonate, 0.1M nonessential amino acids, and 1 mM sodium 
pyruvate. Infected monolayers were disassociated from plates using sterile glass beads 
and were sonicated to disrupt the inclusion. Elementary bodies were purified by density 
gradient centrifugation, as described previously (30, 31).  Aliquots were stored at -80°C 
in medium containing 250 mM sucrose, 10 mM sodium phosphate, and 5 mM L-glutamic 
acid and were thawed immediately prior to use.  To quantify the levels of C. trachomatis, 
quantitative PCR (qPCR) with 16S primers specific for C. trachomatis was performed as 
has been previously described (30). 
 !
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Flow cytometry 
Tissues were mechanically disaggregated and immediately stained for surface 
markers. Cells were preincubated with anti-FcRg (Bio X-Cell) before staining 
with αCrpA-APC (National Institute of Health Tetramer Core) or αPD-L1-APC,  αCD4 
Q-Dot, αCD8-APC-Cy7,  and αPD-1-PeCy7, αB7-1-PE, αCD90.2-PerCP (Biolegend).  
Cells were also incubated with αCD11b-PB and αCD11c-FITC.  When necessary, the 
absolute cell number in each sample was determined using AccuCheck Counting Beads 
(Invitrogen). Data were collected on an LSRII (BD Biosciences) and analyzed using 
FlowJo (Tree Star). 
 
Inhibitory gene transcript expression 
Mice were transcervically infected with 10
6 inclusion forming units (IFU) of C. 
trachomatis as previously described (32).  Five days after infection, tissues were 
mechanically disaggregated in 2 ml of PBS and aliquots immediately frozen at -20°C.  
RNA was extracted from 80µl aliquots by phenol-chloroform precipitation.  Quantitative 
reverse transcriptase PCR (qRT-PCR) was performed using 25ng of purified RNA and 
amplified using Taqman SYBR Green mastermix.  The following primers were used: 
CTLA4 Sense: 5′-GTTGGGGGCATTTTCACATA-3 CTLA4 Antisense: 5′-
TTTTACAGTTTCCTGGTCTC-3; Tim3 Sense: 5′-
GAACTGAAATTAGACATCAAAGCAGC-3′ Tim3 Antisense: 5′-
GGTTCTTGGAGAAGCTGTAGTAGAGTC-3′; Lag3 Sense: 5′-
TCCGCCTGCGCGTCG-3′, Lag3 Antisense: 5′-
GACCCAATCAGACAGCTTGAGGAC-3′; CD160 Sense: 5- !
!
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GGCCACTTTCTCTCCGTTCTAG, CD160 Antisense: 5-
GGTGTGACCTTTGTCTCTGTCTTATC-3; 2B4 Sense: 5′-
GTTGCCACAGCAGACTTTC 
2B4 Antisense: 3′-TTCCAACCTCCTCGTACACGGTAC; PD-1 Sense 5′: 
CCCTCAGTCAAGAGGAGCAT; PD-1 Antisense 5′-TCCCAGCTTGTGGTAAACCT; 
PD-L2 Sense 5′: GTACCGTTGCCTGGTCATCT 
PD-L2 Antisense 5′: GCC AGG ACA CTT CTG CTA GG-3′; B7-1 Sense 5′-
ATGGCTTGCAATTGTCAGTTGA-3′ 
B7-1 Antisense 5′-ATCAGGAGGGTCTTCTGGGGG T-3′; PD-L1 Sense 5′-TGG ACA 
AAC AGT GAC CAC CAA-3′, PD-L1 antisense 5′-CCC CTC TGT CCG GGA AGT-3′.  
GAPDH Sense 5′-GGTGCTGAGTATGTCGTGGA-3′; GAPDH antisense 5′-
CGGAGATGATGACCCTTTTG-3 
 
Statistical analysis 
The data represent the mean ± SEM and were calculated using GraphPad Prism 
version 4.0. P values were determined using the Mann-Whitney Test or Students T-test.  
Significant differences between groups are indicated as follows: *p<0.05, **p< 0.01, and 
***p<0.005. !
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Introduction 
 
Chlamydia trachomatis is an obligate intracellular bacterial pathogen that infects 
1.4 million people in the United States each year, and the incidence of infection has 
continued to rise since 2000 (1).  Adolescent girls and young women infected with C. 
trachomatis face reproductive tract damage and increased risk of ectopic pregnancy and 
infertility (2).   Importantly, long term immunity does not develop and the risk of 
reproductive damage increases with multiple C. trachomatis infections (3-6) 
The work in previous chapters of this thesis detailed the defective CD8
+ T cell 
response to C. trachomatis that could contribute to the lack of, or impaired, long-term 
immunity that develops during infection.  I hypothesized that a known immunoinhibitory 
pathway may be upregulated during infection and thus contribute to impairing the CD8
+ 
T cell response.  PD-L1 expression is highly upregulated during C. trachomatis infection 
and therefore is a prime candidate for further investigation.  Although PD-1 expression is 
typically associated with persistent antigen, it is not until C. trachomatis infection has 
cleared that PD-1 surface expression is upregulated on CD8
+ T cells.  The expression of 
the other PD-L1 receptor, B7-1, also exhibited increased expression on CD8
+ T cells 
during memory phase.  These data suggest that the CD8
+ T cells may become exhausted, 
and this may explain the blunted recall response of the CD8
+ T cell population after 
rechallenge with C. trachomatis.    
It is PD-1 expression on CD8
+ T cells that is highly associated with an apoptotic 
phenotyope, and its interaction with PD-L1 has been well described in the literature (7, 
8).  During chronic viral infection with LCMV-Cl13, PD-L1-expressing professional 109$
$
antigen presenting cells (pAPCs) engage PD-1 on CD8
+ T cells.  The engagement of the 
PD-L1/PD-1 pathway antagonizes the T cell signaling mediated by stimulatory 
molecules, as well as affects downstream signaling pathways that decreases cytokine 
production and reduces memory potential (9, 10).   The CD8
+ T cells that upregulate PD-
1 exhibit a hierarchal loss of function, eventually becoming nonresponsive to antigen. 
The other described receptor for PD-L1 is B7-1.  B7-1 expressed on pAPCs 
engages CD28 on T cells to produce costimulatory signaling, or CTLA-4 on T cells to 
produce inhibitory signaling.  B7-1 is also expressed on T cells and engages PD-L1 to 
produce inhibitory signaling.  The role of PD-L1/B7-1 signaling is not as clear as PD-
L1/PD-1 in pathogenic models but there is evidence that the PD-L1/B7-1 pathway 
partially restrains self-reactive CD4
+ and CD8
+ T cells in non-obese diabetic mice (11).   
The work in this chapter describes the role of PD-L1 in inhibiting the CD8
+ T cell 
response to C. trachomatis and the implications this has on bacterial clearance.  Here I 
show that the CD8
+ T cell response to genital infection with C. trachomatis, as with 
chronic viral infections, is negatively affected by the immunoinhibitory receptor PD-1 
and its ligand, PD-L1.  Deletion or inhibition of this pathway improves the CD8
+ T cell 
response and results in enhanced bacterial clearance.   110$
$
Results 
 
PD-L1 and PD-1 contribute to control of C. trachomatis burden in the uterus 
The significant upregulation of PD-L1 expression in the genital tract upon C. 
trachomatis infection led me to consider that PD-L1 may impact the clearance of C. 
trachomatis.  To test this, I examined bacterial burden by quantitative real time PCR 
(qPCR) in WT mice and PD-L1 deficient mice five days after primary transcervical 
infection.   PD-L1 deficient mice exhibited a ten-fold lower bacterial load compared to 
WT mice (Figure 4-1).   I also tested whether the loss of PD-L1 affected protection 
during secondary challenge.   WT and PD-L1 deficient mice were transcervically infected 
with C. trachomatis, allowed to recover for four weeks and then reinfected 
transcervically.  Bacterial burden was measured in the uterus five days following 
secondary infection.  WT and PD-L1 deficient mice exhibited similar bacterial levels 
(Figure 4-1).  These data demonstrate that loss of PD-L1 improves bacterial clearance 
during primary infection, but has no effect on the ability of the host to clear secondary 
infection. 
 111$
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Figure 4-1  PD-L1 expression limits bacterial clearance.   WT and PD-L1 
deficient mice were transcervically infected with 10
6 IFU of C. trachomatis.  Five 
days after primary and secondary infection, bacterial levels in the uterus were 
measured by qPCR and normalized to host GAPDH levels.  Similar results were 
obtained in three independent experiments.  Error bars represent SEM.  *p<0.05 
by the Mann-Whitney test.   
 
 
Since PD-L1 deficient mice clear primary infection more efficiently, I sought to 
determine if therapeutically blocking PD-L1 would also enhance bacterial clearance.  To 
test this, I transiently blocked PD-L1 by administering anti-PD-L1 antibody three days 
prior and two days after primary infection.   Five days after primary infection I measured 
bacterial burden in the genital tracts of mice and observed that mice treated with anti-PD-
L1 antibody showed over a two log reduction in bacterial burden compared to mice 
treated with isotype antibody (Figure 4-2).  Similar to results observed in PD-L1 
deficient mice, mice that were treated with anti-PD-L1 antibody prior to primary 
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infection and then subsequently reinfected four weeks later exhibited no difference in 
bacterial burden compared to mice treated with isotype antibody (Figure 4-2).  These 
data indicate that transient blockade of PD-L1 during primary infection is sufficient to 
improve bacterial clearance, and does not affect bacterial burden during secondary 
infection.  These data suggest that protection during secondary infection may be mediated 
by PD-L1-independent adaptive immune responses. 
 
 
Figure 4-2 Transient PD-L1 inhibition enhances C. trachomatis clearance. 
WT mice were treated with isotype control or anti-PD-L1 antibody 3 days prior to 
and 2 days after primary transcervical infection with 10
6 IFU.  Five days after 
primary or secondary infection bacterial levels were measured by qPCR and 
normalized to host GAPDH levels.  Similar results were obtained in two 
independent experiments.  Error bars represent SEM.  *p<0.05 by the Mann-
Whitney test. 
 
 
PD-L1 can signal through the receptors PD-1 and B7-1.  In order to test which 
receptor PD-L1 was acting through to limit efficient bacterial clearance, I compared 
bacterial levels in WT mice and PD-1 deficient mice five days after primary transcervical 
!"#$%&'
()$*+,-+.
.
./
.//
.///
&
0
1
2
$
1
.
3
"
4
1
5
0
1
6
#
"
$
1
7
8
9
:
6
A. B.
111111111111;<1
11111111111119:+.+4+1
/=/.
/=.
.
./
.//
&
0
1
2
$
1
.
3
"
4
1
5
0
1
6
#
"
$
1
7
8
9
:
6
>
C.
;<19?*@(?%
9:+A.+4+119?*@(?%
;<1B'C#)D(?%
9:+A.+4+1B'C#)D(?%
/=/.
/=.
.
./
.//
.///
&
0
1
2
$
1
.
3
"
4
1
5
0
1
6
#
"
$
1
7
8
9
:
6 >
>
!"#$%&'19?*@(?%
()$*+9:+A.19?*@(?%
!"#$%&'1B'C#)D(?%1
()$*+9:+A.1B'C#)D(?%
/=/.
/=.
.
./
.//
.///
.////
./////
&
0
1
2
$
1
.
3
"
4
1
5
0
1
6
#
"
$
1
7
8
9
:
6 >
>
NS NS
D.
Figure 3
NS113$
$
infection.  PD-1 deficient mice had significantly lower bacterial burden compared to WT 
(Figure 4-3).    To determine if PD-L1 may also act through the receptor B7-1, I treated 
mice three days before and two days after primary infection with an antibody to block 
B7-1, or isotype control.  Five days after transcervical infection I measured bacterial 
levels in the uterus and determined that there was no significant difference in bacterial 
burden in mice treated with anti-B7-1 antibody compared to mice treated with isotype 
control (Figure 4-4).  Together these data demonstrate that PD-L1 likely signals through 
PD-1 and not B7-1 to inhibit bacterial clearance.  Moreover blockade or deletion of the 
interaction between PD-L1 and the receptor PD-1 leads to enhanced bacterial clearance.   
 
 
Figure 4-3 PD-1 expression limits C. trachomatis clearance. WT and PD-1 
deficient mice were transcervically infected with 10
6 IFU.  Five days after 
primary infection bacterial levels in the uterus were measured by qPCR and 
normalized to host GAPDH levels.  Similar results were obtained in two different 
experiments.  Error bars represent SEM.  *p<0.05 by the Mann-Whitney test. 
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Figure 4-4 B7-1 does not contribute to C. trachomatis clearance. WT mice 
were treated with anti-B7-1 antibody or isotype control 3 days prior to and 2 days 
after transcervical infection with 10
6 IFU.  Five days after primary infection the 
bacterial levels in the uterus were measured by qPCR and normalized to host 
GAPDH levels. Error bars represent SEM. 
 
 
PD-L1 pathway contributes to the inhibition of the uterine CD8
+ T cell response 
following transcervical C. trachomatis infection  
The experiments described in Chapter Three show that PD-L1 is expressed early 
during infection on dendritic cells in the draining lymph nodes (dLN DCs).  DCs are the 
pAPCs that prime the CD8
+ T cells during C. trachomatis infection (12, 13).   I therefore 
postulated that PD-L1 expression alters the CD8
+ T cell response that results in the defect 
in bacterial clearance I observed.  To test this I assessed the phenotype of the CD8
+ T 
cells that developed during infection in WT and PD-L1 deficient mice.  Memory CD8
+ T 
cells can be broadly separated into two subsets: central memory T cells (Tcm) and effector 
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memory T cells (Tem) (14, 15).  These subsets are defined by the expression of the surface 
markers CD62L and CD127 (14-16).  The lymph node homing marker, CD62L, mediates 
CD8
+ T cells extravasation into the vasculature and entry into lymphoid organs and is 
highly expressed on Tcm cells and naïve CD8
+ T cells (Tn) (15).  Tem cells express low 
levels of CD62L which allows this population to stay in the periphery (15).  The IL-7 
receptor, CD127, is necessary for CD8
+ T cells to respond to IL-7 which promotes T cell 
development and persistence in the periphery.  CD127 is highly expressed on both Tcm/n 
and Tem cell subsets (14).  To test if PD-L1 expression affects the CD8
+ T cell phenotype 
during C. trachomatis infection, I transcervically infected WT and PD-L1 deficient mice 
and compared the Tem/Tcm/n ratio of the CD8
+ T cell response by flow cytometry 
following primary, during memory phase, and after secondary infection.  At all three time 
points I observed a significant decrease in the percentage of Tcm/n cells (CD62L 
high/CD127 high) in the genital tracts of PD-L1 deficient mice compared to WT mice 
(Figures 4-5 A and 4-5B, left panel).  Additionally there was a slight but significant 
increase in the percentage of Tem cells (CD62L low/CD127 high) in the uteri of PD-L1 
deficient mice (Figures 4-5A and 4-5B, left panel).   When I measured total numbers of 
Tem and Tcm/n cells in the genital tracts there was a significant three fold increase in the 
ratio of Tem to Tcm/n cells in PD-L1 deficient mice, compared to WT mice during primary 
infection (Figure 4-5C).  The three-fold increase in the ratio of Tem to Tcm/n cells was 
consistent when I compared PD-L1 deficient mice to WT mice during the memory phase  
(Figures 4-5A, 4-5B, and 4-5C middle panel).  Although there was an increase in the 
Tem to Tcm/n ratio following secondary infection, this difference was not significant 
(Figure 4-C left panel).  Notably, I was able to recapitulate the shift to a Tem phenotype 116$
$
at all time points in PD-1 deficient mice (Appendix B, Figure B-2).  These data indicate 
that PD-L1 expression skews the CD8
+ T cells towards a central memory phenotype 
during a primary C. trachomatis infection.  
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Figure 4-5 PD-L1 expression shifts the ratio of Tem and Tcm/n CD8
+ T cells 
during C. trachomatis infection.  (A) WT and PD-L1 deficient mice were 
transcervically infected with 10
6 IFU of C. trachomatis.  At indicated  
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(Figure 4-5 Continued) 
 
timepoints, uteri were harvested and stained for CD62L and CD127 expression.  
CD8
+ memory populations were gated on live, CD90.2
+, CD127
+, CD4
-, CD8
+ 
cells; histograms of CD62L expression of this population are shown. (B) 
Quantification of uterine Tem cells (CD127 high/CD62L low) and Tcm/n (CD127 
high/CD62L high) cells at time points indicated in WT and PD-L1 deficient mice.  
Bars represent mean of 4-5 mice per group. (C) Ratio of the absolute numbers of 
Tem to Tcm/n CD8
+ T cells found in genital tracts of WT and PD-L1 deficient mice.  
Bars represent mean ratios of 4-5 mice per group and error bars represent SEM.   
*p<0.05, **p<0.01 using the Mann-Whitney test.    
 
 
To test whether early PD-L1 expression skews the priming of CD8
+ T cells toward 
an effector memory CD8
+ T cell response, I treated mice with an anti-PD-L1 antibody 
three days prior to and two days after primary infection.  These mice were allowed to 
recover for 3 weeks before secondary infection in the absence of further antibody 
treatment.  Five days after secondary infection, mice treated with the anti-PD-L1 
antibody during primary infection had a significant increase in the ratio of Tem to Tcm/n 
cells found in the genital tract compared to mice treated with isotype control (Figure 4-
6).   This is consistent with the phenotype I observed in PD-L1 deficient mice and 
suggests that transient inhibition of the PD-1/PD-L1 pathway during primary expansion 
is sufficient to shift the balance between Tem and Tcm/n cells as they develop.  
Furthermore, this shift in T cell phenotype ratio is maintained through the recall response.   119$
$
 
Figure 4-6 Inhibition of PD-L1 during primary infection alters the CD8
+ T 
cell phenotype during recall.  Mice were treated with anti-PD-L1 blocking 
antibody or isotype antibody control three days prior and two days after primary 
transcervical infection with 10
6 IFU.  Mice were allowed to recover for four 
weeks, at which point they were rechallenged transcervically with 10
6 IFU of C. 
trachomatis.  Five days after rechallenge, the number of effector and central 
memory CD8
+ T cells were determined in the genital tract.  Indicated is the ratio 
of effector to central memory CD8
+ T cells.  ***p<0.005 by the Mann-Whitney 
test 
 
Next I tested whether the shift towards the CD8
+ T cell effector memory 
phenotype in PD-L1 deficient mice would affect functions such as antigen-specificT cell 
abundance or IFNγ production.  First I assessed whether the absence PD-L1 would 
restore the magnitude of the secondary CD8
+ T cell response that is lacking in WT C. 
trachomatis infected mice.  Five days after secondary infection, I observed a significant 
1.5 fold increase in the number of C. trachomatis-specific CD8
+ T cells found in the 
genital tract of PD-L1 deficient mice compared to WT mice (Figure 4-7).   Moreover, I 
observed that the number of C. trachomatis-specific CD8
+ T cells in PD-L1 deficient 
mice was significantly higher in secondary infection compared to primary infection of 
PD-L1 deficient mice (Figure 4-7).  These data suggest that the absence of PD-L1 
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signaling results in CD8
+ T cells that have enhanced recruitment to the genital tract, or 
are able to expand to greater numbers, upon reinfection.  
 
 
Figure 4-7 C. trachomatis specific CD8
+ T cell response is enhanced in PD-L1 
deficient mice.  Five days after primary or secondary transcervical challenge, the 
number of Chlamydia-specific CD8
+ T cells using a tetramer specific for the 
Chlamydia antigen CrpA were quantified in the genital tracts of WT and PD-L1 
deficient mice.  Similar results were obtained in two independent experiments.  
Bars represent the mean of 4-5 mice per group with SEM. *p<0.05 by the Mann-
Whitney test. 
 
The second functional consequence of PD-L1 deficiency I assessed was the 
expression of IFNγ, a cytokine critical in restricting C. trachomatis growth.    I compared 
the ability of endogenous uterine CD8
+ T cells to produce IFNγ in WT and PD-L1 
deficient mice.  In comparison to WT mice I observed that PD-L1 deficient animals had a 
significant increase in the number of IFNγ-producing CD8
+ T cells by flow cytometry 
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during both primary and secondary responses (Figure 4-8).  This suggests that PD-L1 
deficiency leads to the expansion or retention of a larger population of CD8
+ T cells 
capable of producing IFNγ during both primary and secondary infection. 
 
 
 
Figure 4-8 The CD8
+ IFNγ response is enhanced during C. trahomatis 
infection in PD-L1 deficient mice. Five days after primary or secondary 
transcervical challenge, the number of IFNγ
+ CD8
+ T cells in the uterus was 
measured by ICCS. Bars indicate the mean of five mice per group and error bars 
represent SEM. *p<0.05 by the Mann-Whitney test. 
 
PD-L1 deficiency leads to a Tem skewed CD8
+ T cell population and an increased 
number of IFNγ producing CD8
+ T cells.  However, it was unclear if this phenotype was 
the result of a decrease in cell death or an expansion of the Tem population.  Previous 
reports indicated that PD-L1 expression led to the increased expression of the pro-
apoptotic marker, Bim, which subsequently limited the number of CD8
+ T cells in the 
memory pool (17). To test if PD-L1 expression differentially effected Bim expression in 
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CD8
+ T cell populations, I examined the expression of Bim during primary C. 
trachomatis infection of mice treated with anti-PD-L1 or control antibody.  Five days 
after primary infection I examined Bim expression by flow cytometry in different T cell 
populations.  Bim expression was similar in CD4
+ T cells from mice treated with control 
and anti-PD-L1 antibodies, however Bim expression was significantly lower in CD8
+ T 
cells from mice treated with anti-PD-L1 antibody (Figure 4-9 A and B).   When I 
separated CD8
+ T cells into Tcm/n and Tem populations I observed that Bim expression did 
not significantly differ in Tcm/n cells from mice treated with control antibody or anti-PD-
L1 antibody (Figure 4-9 C).  However, Bim expression was significantly lower in Tem 
cells of mice treated with anti-PD-L1 antibody, compared to mice treated with control 
antibody (Figure 4-9 D).  These results suggest that PD-L1 selectively increases Bim 
expression in Tem cells, likely contributing to the decrease in this population.  Although 
Bim-mediated apoptosis of Tem cells may be one mechanism that PD-L1 expression 
limits this population, it does not exclude the possibilities that PD-L1 may also limit 
expansion potential or recruitment of specific populations to the uterus.   123$
$
 
Figure 4-9 Bim expression is lower upon PD-L1 blockade.  Mice were treated 
with isotype control or anti-PD-L1 blocking antibody three days prior and two 
days after primary transcervical infection with 10
6 IFU.  Five days after infection, 
Bim expression was measured in CD4
+ T cells (A), CD8
+ T cells (B), Tcm/n CD8
+ 
T cells (C) and Tem CD8
+ T cells (D) from the genital tracts.  Shown is the 
average geometric mean fluorescent intensity (gMFI) of 4-5 mice per group.  
*p<0.05 by the Mann-Whitney test. 
 
 
 
In the absence of PD-L1 CD8
+ T cells contribute to protection against C. 
trachomatis. 
The shift to an effector memory CD8
+ T cell response in PD-L1 deficient mice led 
me to question whether the CD8
+ T cell population was now able to contribute to limiting 
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bacterial burden.  To test this, I administered anti-CD8
+ antibody or isotype antibody to 
PD-L1 deficient and WT mice three days before and two days after primary infection.  I 
confirmed by flow cytometry a 10-100-fold decrease in CD8
+ T cells in the uterus, dLNs, 
and spleen of mice treated with the anti-CD8 antibody (Appendix B, Figure B-6).  Five 
days after infection I measured bacterial levels.   CD8
+ T cell depletion in WT mice did 
not exacerbate bacterial burden compared to WT mice treated with control antibody 
(Figure 4-10).  As expected, PD-L1 deficient mice treated with control antibody showed 
significantly lower bacterial burden compared to WT mice treated with control antibody 
(Figure 4-10).  However, PD-L1 deficient mice treated with anti-CD8 antibody no longer 
exhibited the lower bacterial levels observed in PD-L1 deficient mice treated with control 
antibody (Figure 4-10).   Although CD8
+ T cells appear to be dispensable in WT mice, 
PD-L1 deficient mice require CD8
+ T cells to confer total enhanced bacterial clearance.   
These data therefore support that the enhanced bacterial clearance seen in PD-L1 
deficient mice is in part mediated by the altered CD8
+ T cell response.   
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Figure 4-10 CD8
+ T cells contribute to bacterial clearance in PD-L1 deficient 
mice.  WT and PD-L1 deficient mice were treated with anti-CD8 depleting 
antibody or isotype control antibody 3 days prior to and 2 days after primary 
infection.  Mice were infected with 10
6 IFU of C. trachomatis, and five days post 
infection bacterial burden was measured in the uterus by qPCR and normalized to 
host GAPDH levels. Similar results were obtained in 2 independent experiments. 
*p<0.05 by the Mann-Whitney test 
 
Although the CD8
+ T cell recall response we observed (Figures 4-6 and 4-7) 
could potentially contribute to bacterial clearance, PD-L1 deficiency did not lead to 
enhanced bacterial clearance during secondary infection. I reasoned that it was possible 
that any secondary protection afforded by the enhanced CD8
+ T cell response in PD-L1 
deficient mice would be masked by the even more efficient CD4
+ T cell response.    To 
decouple secondary protection mediated by CD4
+ T cells from protection via CD8
+ T 
cells, I depleted CD4
+ T cells prior to secondary challenge in WT and PD-L1 deficient 
mice.   Mice were transcervically infected and examined for bacterial burden and T cell 
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counts five days later.  CD4
+ T cell depletion was confirmed by flow cytometry 
(Appendix B, Figure B-7).  As expected, depletion of the CD4
+ T cells in WT mice led 
to significant exacerbated bacterial burden (Figure 4-11).  However, CD4
+ T cell 
depletion in PD-L1 deficient mice did not lead to increased bacterial burden as in WT 
mice, and in fact there were significantly lower bacterial levels in PD-L1 deficient mice 
treated with anti-CD4 depleting antibody compared to WT mice treated with anti-CD4 
depleting antibody (Figure 4-11).  Thus, CD4
+ T cells are not necessary for protection 
against secondary challenge in PD-L1 deficient mice.  
 
 
 
Figure 4-11 CD4
+ T cells are not required for protection in PD-L1 deficient 
mice.  WT and PD-L1 deficient mice were treated with isotype control antibody 
or anti-CD4 antibody 3 days prior to and 2 days after secondary infection.  Five 
days after secondary infection, bacterial levels were measured in the uterus by 
qPCR and normalized to host GAPDH levels.  Shown in the compilation of 2 
separate experiments *p<0.05 by the Mann-Whitney test 
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These data suggest that CD8
+ T cells can compensate for the lack of CD4
+ T cells 
during secondary infection.  I next hypothesized that the altered phenotype of CD8
+ T 
cells, and not simply an increase in C. trachomatis specific CD8
+ T cells, secures 
protection in PD-L1 deficient mice.  In order to determine whether CD8
+ T cells from 
WT and PD-1 deficient mice were different in their ability to protect mice against 
infection, I collected CD8
+ T cells from the spleen, lymph nodes and genital tracts of 
naïve WT and PD-1 deficient mice (Figure 4-12 left panel).  I then transferred equal 
numbers of purified CD8
+ T cells into groups of naïve congenic IFNγ knockout mice, so 
that the only source of IFNγ was from the transferred CD8
+ T cells. One day after CD8
+ 
T cell transfer, I transcervically infected recipient mice with C. trachomatis (Figure 4-
12).   Five days after infection I measured the quantity of CD8
+ T cells in the dLNs and 
uteri.  Both WT and PD-1 deficient CD8
+ T cells were able to migrate to the uterus; 
furthermore there were equal numbers of CrpA specific CD8
+ T cells in recipient mice 
(Figure 4-13 a and b).  However, CD8
+ T cells from WT or PD-1 deficient mice were 
unable to confer protection compared to mice that received no T cells (Figure 4-14).   
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Figure 4-12 Experimental design of the T cell transfer experiment.  CD8
+ T 
cells were isolated from naïve (left side) or previously C. trachomatis infected 
(right side) WT and PD-1 deficient mice.  Isolated CD8
+ T cells were then 
transferred to naïve IFNγ knockout mice.  One day after T cell transfer, recipient 
mice were transcervically infected with 10
6 IFU of C. trachomatis.  Five days 
post infection, bacterial burden and T cell recruitment were measured. 
 
   Primary Infection                 
PD-1-/- WT
Harvest uteri,
draining lymph nodes.
Measure bacterial burden
Memory T cells
Day 1
Harvest lymph nodes
and spleen.
Transfer puri ed
CD8+ T cells to naive
IFNg-/-  mice
Day 27
Day 28
Infect
Day 33
PD-1-/- WT
Harvest uteri,
draining lymph nodes.
Measure bacterial burden
Naive T cells
*
C.
* *
CD8+  
* Previously
Infected Mice129$
$
 
Figure 4-13 CD8
+ T cells are recruited to the genital tracts of naïve IFNγ 
recipient mice.  A. Transferred CD8
+ T cell recruitment was measured in the 
genital tracts of recipient mice five days after transcervical infection; “naïve” and 
“memory” labels refer to origin of CD8
+ T cells.  B. The total number of C. 
trachomatis-specific CD8
+ T cells were measured in the genital tract using 
tetramer specific for CrpA. Bars represent the mean of 6-8 mice per group and 
error bars indicate SEM. ***p<0.005 by the Mann-Whitney test. 
 
 
Naïve WT and PD-1 deficient CD8
+ T cells start off equal in their abilities to limit 
C. trachomatis infection.   I was curious if memory WT and PD-1 deficient CD8
+ T cells, 
primed during C . trachomatis infection differed in their capacity to limit C. trachomatis 
infection.  To test this, I infected WT and PD-1 deficient mice and allowed these mice to 
recover for 4 weeks (Figure 4-12, right side).  I then isolated CD8
+ T cells from these 
mice and transferred equal numbers of purified CD8
+ T cells to naïve IFNγ knockout 
hosts.   One day later I infected recipient mice and five days after infection I measured 
the CD8
+ T cell response as well as bacterial burden in the uterus.   I recovered almost 
equal numbers of WT and PD-1 deficient CD8
+ T cells in the uterus and draining lymph 
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nodes of recipient mice (Figure 4-13a).   I also recovered similar numbers of C. 
trachomatis specific CrpA CD8
+ T cells in the uterus (Figure 4-13b.) When I measured 
bacterial levels in the genital tract of infected recipient mice I found that mice that 
received CD8
+ T cells from previously infected WT mice had bacterial levels similar to 
mice that received no T cells.  However, mice that received CD8
+ T cells from previously 
infected PD-1 deficient mice had significantly lower bacterial levels compared to mice 
that received WT CD8
+ T cells (Figure 4-14).  Taken together this data provide 
significant evidence that C. trachomatis infection severely impairs the CD8
+ T cell 
response via the PD-1/PD-L1 immunoinhibitory pathway, and disruption of the PD-
1/PD-L1 pathway restores the protective capacity of these T cells. 
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Figure 4-14 PD-1 deficient antigen-experienced CD8
+ T cells confer 
protection against C. trachomatis infection.  Recipient IFNγ knockout mice 
were infected with 10
6 IFU of C. trachomatis.  “Naïve” and “Memory” labels 
refer to origin of CD8
+ T cells.  Five days after infection bacterial levels were 
measured in the uterus by qPCR and normalized to host GAPDH levels.  Shown 
is the mean of 6-8 mice per group and error bars indicate SEM.  Similar results 
were obtained in two independent experiments.   *p<0.05 by the Mann-Whitney 
test. 
 
 
PD-L1 is required on hematopoietic and non-hematopoietic cells to inhibit 
protection against C. trachomatis.  
PD-L1 can be expressed on a variety of cell types, including DCs, T cells, 
endothelial cells and epithelial cells (18-20).  I sought to determine which cellular 
population expressing PD-L1 influenced the shift in the CD8
+ T cell response to a more 
central memory response.  It seemed likely that that PD-L1 expression on APCs would be 
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priming in WT mice.  To test this, I created reciprocal bone-marrow chimeras from WT 
and PD-L1 deficient mice.  After ensuring successful chimerism of at least 96%, I 
infected mice transcervically and analyzed the CD8
+ T cell response five days later.  As 
expected, PD-L1 deficient mice that received PD-L1 deficient bone marrow had a 
significantly higher ratio of Tem to Tcm/n cells found in the uterus, compared to WT mice 
that received WT bone marrow (Figure 4-15).   WT mice that received PD-L1 deficient 
bone marrow also had a significantly higher ratio of Tem to Tcm/n cells compared to WT 
mice that received WT bone marrow.  However, the shift towards an effector memory 
phenotype was still significantly lower than that observed in PD-L1 deficient mice that 
received PD-L1 deficient bone marrow (Figure 4-15).  PD-L1 deficient mice that 
received WT bone marrow had a similar ratio of Tem to Tcm/n cells in the uterus compared 
to WT mice that received WT bone marrow (Figure 4-15).  Overall these data indicate 
that PD-L1 expression on hematopoietic cells largely influences the CD8
+ T cell response 
and drives CD8
+ T cells to a more central memory phenotype during C. trachomatis 
infection.  However, the absence of PD-L1 is required on both hematopoietic and non-
hematopoietic cells to fully recapitulate the CD8
+ T cell response observed in PD-L1 
deficient mice.  
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Figure 4-15 PD-L1 expression on hematopoietic and non-hematopoietic cells 
contributes to PD-L1 deficiency phenotype.  WT and PD-L1 deficient 
reciprocal chimeric mice were transcervically infected with 10
6 IFU of C. 
trachomatis.  The uteri were harvested five days after infection.  The memory 
CD8
+ population was gated on live, CD90
+, CD4
- CD127
+, CD8
+ T cells.  Shown  
above is the histogram of CD62L expression of that population. Below is the ratio 
of Tem to Tcm/n cells found in the uteri of chimera mice.  Bars indicate the mean of 
4-5 mice per group and error bars represent SEM.  *p<0.05 by the Mann-Whitney 
test. 
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The absence of PD-L1 expression on hematopoietic cells alone was able to 
promote a CD8
+ T cell response that closely resembled that of PD-L1 deficient mice, 
however it was unclear if it was sufficient to decrease bacterial burden.  Therefore I 
measured bacterial burden in the chimeric mice 5 days after infection.  As shown in 
Figure 4-16, the absence of PD-L1 on either hematopoietic or non-hematopoietic cells 
alone was not enough to confer protection against C. trachomatis.  These data therefore 
suggest that the expression of PD-L1 on both hematopoietic and non-hematopoietic cells 
contributes to limiting C. trachomatis clearance.   
 
 
 
 
Figure 4-16 PD-L1 expression on hematopoietic and non-hematopoietic cells 
contributes to limiting C. trachomatis clearance. WT and PD-L1 deficient 
reciprocal chimeric mice were transcervically infected with 10
6 IFU of C. 
trachomatis.  Five days after infection bacterial levels were measured in the 
uterus by qPCR and normalized to host GAPDH levels. Error bars represent SEM. 
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Discussion 
 
Here I sought to identify mechanisms that contribute to the defective CD8
+ T cell 
response to C. trachomatis.  I hypothesized that one or more inhibitory mechanisms may 
be upregulated during infection that would affect the quality of the CD8
+ T cell response.  
In the previous chapter I demonstrated that PD-L1 is strongly upregulated during C. 
trachomatis infection.  Because PD-L1 has a well-known role in T cell exhaustion, I 
tested whether PD-L1 affects the CD8
+ T cell response during C. trachomatis infection.  
The data here demonstrate that PD-L1 expression alters the CD8
+ T cell memory 
phenotype, impairs the effector function of CD8
+ T cells and limits efficient C. 
trachomatis clearance. 
The PD-1/PD-L1 pathway is a critical T cell regulatory pathway that is important 
in maintaining the balance between immune tolerance and effector function.  In some 
pathogen models, engaging PD-1 on T cells has detrimental effects on pathogen 
elimination.  For example, infection with the lower respiratory viruses Influenza A virus 
(IAV) or metapneumovirus induces PD-L1 expression on lung epithelial cells which 
leads to CD8
+ T cell impairment (21).  Blockade of PD-L1 reverses CD8
+ T cell 
impairment, improves IFNγ production, and enhances viral clearance (21).  In cancer 
models, contact of CD8
+ T cells with PD-L1
+ tumor cells results in a reduction of the 
cytolytic activity of the CD8
+ T cells and an impaired ability to clear the tumor cells (22).  
For bacterial pathogens, the role of PD-1/PD-1 is less clear.  PD-L1 blockade in mice 
infected with Listeria monocytogenes impairs the CD8
+ T cell response and leads to 
exacerbated bacterial burden, indicating that PD-L1 acts as a stimulatory signal in this 136$
$
context (23, 24).   However, blockade of PD-L1 on monocytes infected with 
Staphylococcus aureus improves IL-2 production by CD8
+ T cells (25).  Interestingly, my 
data indicate that blockade of PD-L1 improves the IFNγ response of CD8
+ T cells during 
C. trachomatis infection, leading to the enhanced bacterial clearance that is observed 
during primary infection.  !
A major source of variability in previous studies has been the anatomical site of 
infection, which may give rise to the diversity of effects attributed to the PD-1/PD-L1 
pathway.  Some anatomic sites need protection from host immune responses, and 
inhibitory mechanisms may be necessary to limit inflammation damaging to the host.  In 
the respiratory tract for example, inhibitory PD-L1 signaling properly restricts T cells to 
avoid inflammation that could damage the lungs (26).   The upper genital tract is also a 
privileged immune site since excessive inflammation could reduce fertility.  During C. 
trachomatis infection, PD-L1 expression may allow the host to avoid an exaggerated and 
damaging CD8
+ T cell response.  In fact, evidence suggests that CD8
+ T cells contribute 
to the uterine pathology that results from C. trachomatis infection (27, 28).  One recent 
study demonstrates that blockade of PD-L1 in combination with the inhibitory receptor, 
Tim3, led to enhances uterine pathology of mice infected with Chlamydia muridarum 
(29).  Although, it was unclear from that study what factors mediate the enhanced 
pathology, it provides evidence that immune-inhibitory pathways are important for 
limiting inflammation and pathology in the genital tract.  Additional in-depth pathology 
studies will be required to understand if the lack of PD-L1 alone leads to enhanced 
pathology in the genital tract during C. trachomatis infection.  It is possible that multiple 
inhibitory pathways are engaged during C. trachomatis infection in order to avoid 137$
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inflammation in the host, and deleting one of these pathways may not be sufficient to 
observe changes in gross pathology.  We did observe upregulated expression of other 
inhibitory molecules, Lag3, 2B4 and CD160 in infected mice, and it will be interesting to 
investigate if these molecules also contribute to pathology and immune impairment 
during C. trachomatis infection. 
While upregulation of the PD-1/PD-L1 pathway may be important in limiting 
damage to the host, there is no doubt that impairing the CD8
+ T cell response would also 
be beneficial to the invading pathogen.   Although CD4
+ T cells are the main mechanism 
of C. trachomatis clearance during natural infection, it has been shown that C. 
trachomatis can be susceptible to the CD8
+ T cell response when these T cells are 
stimulated by vaccination or passively transferred (30).  C. trachomatis may therefore 
benefit from mechanisms to subvert the CD8
+ T cells.  Future experiments will be needed 
to determine whether C. trachomatis is capable of directly upregulating PD-L1 on 
infected cells.  However, there is no evidence to suggest that PD-1/PD-L1 deficiency 
alone provides an optimal CD8
+ T cell response, and there may be other inhibitory 
mechanisms that contribute to the impaired CD8
+ T cell response during C. trachomatis 
infection, . 
When Tem  and Tcm cells were first described in the literature, data indicated that 
the Tcm cells were the more effective subset in terms of expansion and clearance 
capabilities (31).  However, further studies demonstrated that the contribution of Tcm and 
Tem cells to pathogen control depends on the particular pathogen and the site of infection 
(32).   For pathogens that replicate in lymphoid organs, Tcm cells are required for 
controlling pathogen burden.  For example, Tcm cells are more efficient than Tem 138$
$
memory CD8
+ T cells at lysing LCMV-infected cells (33).   However, for mucosal 
infections, Tcm CD8
+ T cells are less effective since they are more confined to lymphoid 
organs and slow to respond to peripheral challenge.  Tem cells, on the other hand, migrate 
through or reside in peripheral tissues and thus are closer to the site of the pathogen upon 
reinfection and can immediately engage the pathogen and limit its replication (34-36).  
The data presented here suggest that C. trachomatis impairs the CD8
+ T cell response by 
skewing it to a Tcm/n phenotype.  During the primary response to C. trachomatis, it is clear 
that PD-L1 expression results in an increased Tcm/n CD8
+ T cell population while limiting 
the number of IFNγ producing CD8
+ T cells present in the uterus.  Future experiments 
should compare the Tcm/n populations in WT and PD-L1 deficient mice to determine if 
PD-L1 expression results in a higher proportion of naïve CD8
+ T cells.  One possible 
explanation for the impaired CD8
+ T cell response may be that PD-L1 expression limits 
CD8
+ T cell priming and activation and results in a higher proportion of naïve CD8
+ T 
cells. 
 C. trachomatis is highly susceptible to IFNγ, and the increased percentage of 
IFNγ producing CD8
+ T cells, within the total T cell population may explain the 
enhanced clearance I observe during primary infection in PD-L1 deficient mice.  
However, how PD-L1 deficiency leads to an increased number of IFNγ CD8
+ T cells is 
still unclear.  Evidence looking at the pro-apoptotic molecule, Bim, expression would 
suggest that PD-L1 leads to a disproportionate increase of Bim expression in Tem cells.  
This may be one mechanism to limit the expansion of Tem cells, thus decreasing the 
population that would readily produce IFNγ.  Additionally, Tem cells are the population of 
CD8
+ T cells likely to be retained in the uterus, and this could explain the increased 139$
$
population of C. trachomatis specific CD8
+ T cells in PD-L1 deficient mice following 
secondary infection.  To test these hypotheses, future studies should perform detailed 
comparison of apoptotic markers, as well as markers of expansion, in T cells from PD-L1 
deficient and WT mice.   
Importantly these data show that memory cells generated in the absence of PD-
1/PD-L1 signaling during C. trachomatis infection are able to provide superior protection 
compared to memory cells from WT mice.   Although the major difference between Tcm 
and Tem cells may be in their capacity to migrate to peripheral tissues, our data indicate 
that there is a functional difference as well, and that this difference is mediated by the 
PD-1/PD-L1 interaction.  Additionally these data provide insight into peripheral CD8
+ T 
cell responses in general.  Unlike systemic infections, an effective secondary CD8
+ T cell 
responses in the periphery may be defined by the effector phenotype of the CD8
+ T cell 
population, and not by their capacity to greatly expand.   Here I provide evidence that the 
PD-1/PD-L1 pathway is an important factor in regulating peripheral CD8
+ T cell 
responses by skewing the CD8
+ T cells to a more central memory phenotype, ultimately 
impairing the ability of these CD8
+ T cells to respond upon rechallenge.  Little is known 
about the development of Tcm and Tem cells in the genital tract.  I show that the Tem cell 
subset can be an important memory population in the genital tract during C. trachomatis 
infection.  Mechanisms to promote the expansion and retention of effector memory CD8
+ 
T cells, whether by inhibiting PD-L1 or by other means, will be an important concept in 
the design of Chlamydia vaccines.  An effective C. trachomatis vaccine may have to 
overcome inhibition mediated by PD-L1 to improve the CD8
+ T cell response without 
causing immunopathologies in the genital tract.140$
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Materials and Methods 
 
Mice 
C57BL/6, B6.PL-Thy1a (CD90.1 congenic), and B6.129S7-IFNγtm1Agt 
(IFNγ-/-) mice were purchased from The Jackson Labs.  PD-L1 and PD-1 deficient mice 
have been described previously and were generously provided by Arlene Sharpe.  αPD-
L1 blocking antibody (clone 10F.9G2) was generously provided by Gordon Freeman; 
αB7-1 blocking antibody (clone 1G10),  IgG2a and IgG2b control antibodies were 
purchased from BioXCell.  For transient inhibition experiments, mice were treated with 
200µg αPD-L1 or αB7-1 each day for three days prior to infection and then every other 
day after infection.  All animals were maintained and cared for within the Harvard 
Medical School Center for Animal Resources and Comparative Medicine (Boston, MA) 
(37, 38).  All mice were treated with 2.5 mg medroxyprogesterone subcutaneously 7 days 
prior to infection with C. trachomatis to synchronize the murine estrous cycle.  All 
experiments were approved by the Institutional Animal Care and Use Committee. 
 
Growth, isolation, and detection of bacteria 
C. trachomatis serovar L2 (434/Bu) was propagated within McCoy cell 
monolayers grown in Eagle’s MEM (Invitrogen, Grand Island, NY) supplemented with 
10% FCS, 1.5 g/l sodium bicarbonate, 0.1M nonessential amino acids, and 1 mM sodium 
pyruvate. Infected monolayers were disassociated from plates using sterile glass beads 
and were sonicated to disrupt the inclusion. Elementary bodies were purified by density 
gradient centrifugation, as described previously (39) .  Aliquots were stored at -80°C in 141$
$
medium containing 250 mM sucrose, 10 mM sodium phosphate, and 5 mM L-glutamic 
acid and were thawed immediately prior to use.  To quantify the levels of C. trachomatis, 
quantitative PCR (qPCR) with 16S primers specific for C. trachomatis was performed as 
has been previously described (39). 
 
Flow cytometry 
Tissues were mechanically disaggregated and immediately stained for surface 
markers or stimulated for 5 h with 50 ng/ml PMA (Alexis Biochemical) and 500 ng/ml 
ionomycin (Calbiochem) in the presence of brefeldin A (GolgiStop; BD Biosciences) for 
intracellular cytokine staining. Cells were preincubated with anti-FcRg (Bio X-Cell) 
before staining with αCrpA-APC (National Institute of Health Tetramer Core) or αPD-
L1-APC,  αCD4 Q-Dot, αCD8-APC-Cy7,  and αCD90.2-PeCy7 (Biolegend).  Cells were 
also incubated with αCD11b-PB, αCD11c-PB, αCD19-PB and αB220-PB to exclude 
these populations. For activation marker analysis, I examined αCD62L-FITC and 
αCD127-PerCP (BD Biosciences).  Bim staining was performed with primary rabbit 
αBim followed by secondary αRabbit-PE (Cell Signaling). For intracellular cytokine 
staining αIFNγ PE (BD Biosciences) was used and cells were permeabilized with the 
Cytofix/Cytoperm Plus Kit according to the manufacturer’s instructions (BD 
Biosciences). The absolute cell number in each sample was determined using AccuCheck 
Counting Beads (Invitrogen). Data were collected on an LSRII (BD Biosciences) and 
analyzed using FlowJo (Tree Star). 
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T cell depletion and transfer 
For CD8
+ and CD4
+ T cell depletion experiments, mice were injected i.p. with 
200 µg of anti-CD8
+ (clone 2.43), or 200 µg of anti-CD4
+ (clone GK1.5) or isotype 
control (clone LTF-2).  Mice were treated with antibody every day starting 3 days prior to 
primary challenge and then every other day after challenge.  Mice were sacrificed 5 days 
after challenge.  For secondary challenge, mice were treated every day 3 days prior to 
secondary challenge and then every other day after secondary challenge.  
For CD8
+ T cell transfer experiments, lymphoid organs and uteri were collected 
from naïve WT (Thy1.1) and PD-1 deficient (Thy1.1) mice.  CD8
+ T cells were isolated 
using Dynal negative selection CD8
+ T cell kit (Invitrogen) and 5x10
6 purified CD8
+ T 
cells were transferred i.v. into naïve Thy1.2 IFNγ deficient mice.   
 
Generation of bone marrow chimeras 
Bone marrow was obtained from femurs of WT and PD-L1 deficient mice.  10
7 
WT and PD-L1 deficient bone marrow cells were injected i.v. into groups of PD-L1 
deficient and WT mice irradated with 800 rads.  Cells from these chimeras were analyzed 
after 6 weeks. 
 
Statistical analysis 
The data represent the mean ± SEM and were calculated using GraphPad Prism 
version 4.0. P values were determined using the nonparametric Mann-Whitney T test.  
Significant differences between groups are indicated as follows: *p<0.05, **p< 0.01, and 
***p<0.005. 143$
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Chapter Five: Discussion ! 149!
The increase in Chlamydia infections over the last 20 years is a major concern for 
medical personnel, epidemiologists, researchers, and the millions of people infected.  It 
has remained unclear what mechanisms prevent the development of sterilizing immunity 
during C. trachomatis infection.  Without understanding the limitations of natural 
immunity, it will be difficult to design a vaccine that can circumvent or manipulate these 
limitations.  Previous examination using the mouse model has demonstrated that both 
CD4
+ and CD8
+ T cells respond to infection, however an in depth analysis of the 
endogenous CD8
+ T cell response in the genital tract had not been performed.  This thesis 
focused on understanding the kinetics of the endogenous CD8
+ T cell response to C. 
trachomatis and the mechanisms that act to limit that response. 
 
C. trachomatis infection suppresses the mucosal CD8
+ T cell response. 
The upper reproductive tract requires a tightly regulated immune response.  To 
overcome infection, the host must elicit protective immunity while limiting pathological 
responses that could cause permanent damage and negatively impact fertility.  However, 
this goal is not achieved during infection with C. trachomatis.  Rather, genital C. 
trachomatis infection results in severe immunopathology and very little protective 
immunity.  Particularly interesting is that CD8
+ T cells derived from a natural C. 
trachomatis infection are not protective, while CD8
+ T cells derived outside a natural C. 
trachomatis infection are protective (1).  Why are these potentially protective responses 
specifically impaired during C. trachomatis infection?  This incongruence led me to more 
thoroughly investigate the natural CD8
+ T cell response during C. trachomatis infection 
of the genital tract.   ! 150!
In Chapter Two I showed that C. trachomatis-specific CD8
+ T cells responded 
upon primary infection, but that the secondary response was significantly impaired in 
both the dLNs and the genital tract.  In comparison, transcervical infection with L. 
monocytogenes produced a much more robust secondary CD8
+ T cell response in the 
genital tract.   It is unlikely that the limited secondary expansion in the dLNs contributed 
to the robust population observed in the genital tract during L. monocytogenes infection, 
as the numbers of CD8
+ T cells present in the genital tract were significantly greater than 
the CD8
+ T cells found in the dLNs at every time point (Figures 2-9 and 2-10).  This 
evidence suggests that upon rechallenge in the genital tract, secondary CD8
+ T cell 
expansion may not occur in the dLNs.  During L. monocytogenes secondary CD8
+ T cell 
expansion may occur in the genital tract.  However, this hypothesis will be rigorously 
tested in the future by directly measuring and comparing CD8
+ T cell expansion in 
multiple tissues, including the dLNs, genital tract, spleen and liver during the course of C. 
trachomatis and L. monocytogenes infections.  These studies will test the hypothesis that 
CD8
+ T cells are specifically impaired in their recall capacity during C. trachomatis 
infection by failing to expand or be recruited to the genital tract. 
 
C. trachomatis alters the CD8
+ T cell response through the PD-1/PD-L1 pathway. 
  In Chapter Four I describe how PD-L1 expression alters the CD8
+ T cell response 
to C. trachomatis.  PD-L1 deficient mice that are infected with C. trachomatis exhibit 
lower primary bacterial burden compared to WT mice.  I expected that this decrease in 
burden would correlate with an increase in the number of C. trachomatis-specific CD8
+ T 
cells present in the uterus during primary infection.  I did not observe an increase in the ! 151!
number of CrpA specific CD8
+ T cells, however I cannot rule out that other antigen-
specific CD8
+ T cells may have increased in number (Figure 4-6).  The most striking 
difference between WT and PD-L1 deficient mice, however, was the alteration in the 
phenotype of the CD8
+ T cells.  PD-L1 deficient mice exhibited a significant increase in 
the ratio of effector memory (Tem) cells to naïve and central memory (Tcm/n) cells, and 
this correlated with an increase in the number of IFNγ producing CD8
+ T cells present in 
the genital tract.  While depletion of CD8
+ T cells in PD-L1 deficient mice did not 
completely restore bacterial levels to that of WT, the altered CD8
+ T cells in PD-L1 
deficient mice mediated the majority of protection observed (Figure 4-10). 
  I observed that PD-L1 deficiency restores the protective capacity of memory 
CD8
+ T cells.  Memory CD8
+ T cells from PD-L1 deficient mice also exhibited an 
increase Tem/Tcm/n ratio, and this likely resulted in an increase in the number of IFNγ- 
producing CD8
+ T cells that could quickly be activated upon secondary infection.  An 
appropriate future direction for this work would be to test whether Tem cells are truly able 
to confer better protection compared to Tcm cells.  To address this, one could transfer 
sorted Tem or Tcm cells from previously infected mice and compare C. trachomatis burden 
in infected recipient mice.  It will be interesting to test not only which population confers 
protection in the absence of PD-L1/PD-1 signaling, but also to see if one population from 
WT mice is able to confer more or less protection.  If Tem cells from WT mice are able to 
confer protection then this would provide support to the hypothesis that PD-L1 mediates 
its effects during C. trachomatis by limiting the Tem/Tcm/n ratio.   If Tem cells from WT are 
unable to confer protection, it would suggest that PD-L1 may act through a mechanism ! 152!
other than or in addition to altering the Tem/Tcm/n ratio in order to limit C. trachomatis 
clearance.   
  A final question that still remains is the mechanism by which PD-1/PD-L1 
signaling alters the Tem/Tcm/n ratio.  When investigating the numbers of each population 
present in the uterus, it is clear that there is a slight increase in the number of Tem cells 
and a slight decrease in the number of Tcm/n cells.  However, there is no difference in the 
total number of memory cells present in the genital tract.  These data suggest that PD-L1 
does not limit the expansion of CD8
+ T cells, but alters the developmental pathway of 
CD8
+ T cells as they acquire memory phenotype.  Since I did not distinguish between Tcm 
and Tn cells in my experiments, it is possible that the PD-1/PD-L1 pathway inhibited 
priming and activation of the CD8
+ T cells.  To test this, it will be necessary to compare 
proportions of Tn and Tcm in WT and PD-L1 deficient mice.  Alternatively it is possible 
that PD-L1 expression specifically drives CD8
+ T cells to become Tcm. Other studies 
have shown that PD-L1 expression limits the conversion of Tcm cells to Tem, however it is 
unclear how PD-L1 limits the conversion (2).  In general CD8
+ T cells that experience 
enhanced TCR signals and longer duration of signal develop into Tem cells that do not 
progress to Tcm cells or take a longer amount of time to progress to Tcm cells (3).  This 
would indicate that the Tem/Tcm ratio is established during priming, and would concur 
with my data indicating that PD-L1 blockade during priming alters the CD8
+ T cell 
response during secondary infection (Figure 4-6).  By inhibiting downstream TCR 
signaling in CD8
+ T cells, it is likely that the PD-L1/PD-1 signaling drives the CD8
+ T 
cell down a Tcm developmental pathway. Alternatively, it may be that PD-L1 signaling 
does not necessarily promote conversion of Tem cells to Tcm cells but actually results in ! 153!
increased apoptosis of Tem cells specifically.  In support of this hypothesis I have found 
that expression of the pro-apoptotic gene Bim is significantly lower in Tem cells of PD-L1 
deficient mice compared to WT mice. Future studies should investigate the expression of 
other apoptosis markers to better understand if PD-1/PD-L1 signaling differentially 
affects apoptotic potential in Tcm and Tem cells.   
In the interest of developing therapeutics, future studies should also investigate 
how the timing of PD-L1 expression alters the Tem/Tcm ratio.  If the Tem/Tcm ratio is 
established during priming as I hypothesize, is it possible to alter the ratio after the 
memory CD8
+ T cell population has been established?  To investigate this question, one 
should treat previously infected mice with anti-PD-L1 antibody.  Memory cells should be 
collected and transferred to congenic naïve mice; after recipient mice are infected the 
Tem/Tcm ratio should be measured in the transferred memory CD8
+ T cells.   This 
approach will allow researchers to test how anti-PD-L1 treatment specifically affects 
already established memory T cell populations.  If anti-PD-L1 treatment alters the 
Tem/Tcm ratio after memory formation then anti-PD-L1 antibody might be a valuable 
treatment option to improve the immune response in C. trachomatis-infected patients.   
 
Model for how PD-L1 limits C. trachomatis clearance 
  The section above describes how the PD-1/PD-L1 pathway drives the CD8
+ T cell 
response towards a Tcm/n phenotype.  The data presented in this thesis provide an 
interesting model that could explain how PD-L1 deficiency alters the CD8
+ T cell 
response to improve bacterial clearance.  During primary infection, PD-L1 expression on 
epithelial cells may directly protect these cells from cytolytic killing by CD8
+ T cells by ! 154!
disengaging the CD8
+ T cell.  Alternatively,  when CD8
+ T cells are engaged by PD-L1 it 
may cause transcriptional changes in the CD8
+ T cell that lead to the Tcm/n phenotype and 
a dampening of the cytolytic response.  The interaction with PD-L1 expressing epithelial 
cells leads to inefficient bacterial clearance during primary infection, which can be 
reversed by PD-L1 deficiency or blockade.  In the absence of PD-L1, CD8
+ T cells have 
an enhanced ability to recognize and engage infected cells or have an improved cytolytic 
capacity that contributes to bacterial clearance.  Future experiments should test the 
cytolytic response of CD8
+ T cells to infected cells in vitro with and without PD-L1 
blockade to investigate if CD8
+ T cell cytokine production is reduced in the presence of 
PD-L1.  
Once engaged by PD-L1, the CD8
+ T cell may be headed down a transcriptional 
course that results in the increased expression of PD-1 and the development of the Tcm/n 
phenotype.  PD-1 expression indicates that CD8
+ T cells may be exhausted as infection is 
cleared and memory is established, thus T cells are more prone to apoptosis and have a 
decreased ability to produce cytokines.  Furthermore, the PD-L1/PD-1 interaction drives 
CD8
+ T cells to a Tcm/n phenotype, which further disables the secondary response by 
sequestering antigen-experienced CD8
+ T cells from the genital tract.  Upon reinfection 
the secondary CD8
+ T cells that are able to migrate to the genital tract have lost the 
capacity to produce IFNγ and other inflammatory cytokines, thus these CD8
+ T cells do 
not contribute to secondary bacterial control.  In the absence of PD-L1, adaptive immune 
responses other than CD8
+ T cells are able to quickly control infection.  However, in the 
absence of PD-L1, CD8
+ T cells become sufficient for controlling infection.  Future 
studies should investigate the transcriptional changes that occur in CD8
+ T cells ! 155!
following C. trachomatis infection in the presence and absence of PD-L1.  It will be 
interesting to test if the transcriptional profile of memory CD8
+ T cells from C. 
trachomatis is similar to what has been described for exhausted CD8
+ T cells in other 
models (4).   
 
Effector memory and Central memory T cell responses in the genital tract 
Mucosal surfaces require CD8
+ T cells that can easily and quickly access infected 
epithelial cells.  Tem cells are specialized for mucosal responses.  Tem cells shed surface 
expression of the lymph node homing molecule, CD62L, after activation and can 
therefore reside at length in mucosal tissues and be activated by infected epithelial cells.  
In contrast, Tcm and naïve cells maintain high levels of CD62L, migrate through the 
vasculature, and require pAPCs to become activated.  During transcervical infection with 
L. monocytogenes, I observed a higher ratio of Tem to Tcm/n cells present in the genital 
tract compared to infection with C. trachomatis.  Yet, I still observed a significant Tcm/n 
population present in the genital tract, indicating that these cells may be circulating 
through the genital tract as well.  The presence of Tcm/n cells also indicates that Tem cells 
must compete with this population for antigen.  A high Tem to Tcm/n ratio would favor 
expansion of the Tem population.  Thus the increased presence of Tem cells in the genital 
tract, which can be activated by infected epithelial cells, likely contributes to the robust 
secondary response observed with L. monocytogenes infection.  During C. trachomatis 
infection, however, the low Tem to Tcm/n ratio indicates that Tem cells are outcompeted for 
antigen by Tcm cells.  Tcm cells require pAPCs for activation and subsequent expansion.  
However, I’ve shown that the DC population in the uterus is much lower than that of the ! 156!
epithelial population, and additional evidence from our lab has shown that the DC 
population may be functionally impaired during C. trachomatis infection (X. Zhang, 
unpublished).  Therefore, the Tcm population would have an abrogated ability to become 
activated and expand upon secondary infection.  Ultimately, a detailed comparison of the 
Tem and Tcm responses in the genital tract during primary and secondary C. trachomatis 
infections will need to be performed using proliferation makers to fully understand these 
differences in expansion. 
The different cytotoxic capacities of Tem and Tcm/n cells predict that these cells 
differentially contribute to protection against viral, bacterial and host driven assaults.  
Transcervical immunization with L.m.-CrpA, which resulted in a high Tem/Tcm/n ratio, 
protected mice against subsequent C. trachomatis infection.  It is likely that the enhanced 
capacity of Tem cells to produce IFNγ contributed to protection against C. trachomatis 
infection.   Interestingly, immunization with L.m.-Ova, which shares no known antigen 
with C. trachomatis, also resulted in a level of protection against C. trachomatis 
infection.  These results suggest that Tem cells have a more potent bystander effect, 
meaning they can be non-specifically activated, compared to Tcm/n cells that contributes 
to C. trachomatis clearance.  In order to test this hypothesis in the future, it will be 
necessary to deplete mice of CD8
+ T cells after L.m.-OVA infection to determine if this 
population indeed contributes bystander protection against C. trachomatis.   
 
Immuno-inhibitory pathways involved in the immune response to  
C. trachomatis ! 157!
  C. trachomatis is a pathogen that is highly adapted to live within its human host. 
As such, C. trachomatis has evolved mechanisms to inhibit host immunity to further its 
persistence and enhance its transmission.  The work in this dissertation describes one 
mechanism that C. trachomatis uses to limit the CD8
+ T cell response and enhance its 
own survival in the host.  I hypothesized that C. trachomatis, like other chronic 
pathogens, may cause the upregulation of immuno-inhibitory pathways to suppress the 
host immune response.  I found that in fact several immuno-inhibitory pathways are 
upregulated during transcervical infection with C. trachomatis.  My data focused on the 
biological consequences of PD-L1 expression, however I also observed an upregulation 
of the inhibitory molecules Lag3, CD160 and 2B4 was also significantly upregulated 
during C. trachomatis infection.   
  Lag3 is expressed on a variety of lymphocytes, including NK cells, B cells and T 
cells (5, 6).  Lag3 expressed by tolerized T cells is thought to have a role in limiting T 
cell responses to self-antigen (7).  However, Lag3 expression following infection can also 
indiscriminately limit pathogenic responses by T cells.  Expression of Lag3 on regulatory 
T cells (Tregs) causes these cells to directly suppress effector functions of other T cells 
(7).  In my studies I did not explore the role of Lag3 or Tregs in regulating immunity 
towards C. trachomatis, however it is reasonable to hypothesize that Lag3 expression 
could contribute to the suppression of CD8
+ T cell responses during C. trachomatis 
infection.  Interestingly CD160 has dual roles of stimulation and inhibition of T cell 
responses (8).  CD160 binding to MHC I enhances cytolytic activity and cytokine 
production of CD8
+ T cells (9).  However, CD160 binding to the Herpesvirus Entry 
Mediator (HVEM) on CD4
+ T cells inhibits CD4
+ T cell activation (10).  It will be ! 158!
interesting to investigate if CD160 plays a role in the CD8
+ and/or the CD4
+ T cell 
responses to C. trachomatis.  The expression of 2B4 also exhibits dual functions.  The 
expression of 2B4 on CD8
+ T cells during chronic viral infections limits secondary T cell 
expansion (11).  However, 2B4 expressing natural killer (NK) cells engage CD48 on 
target cells which leads to enhanced cytotoxicity and IFNγ production (12).   
  Ultimately there may be several mechanisms that contribute to suppressing the 
immune response against C. trachomatis.  Other studies have found that immuno-
inhibitory molecules such as the PD-1 and Lag3 act cooperatively to inhibit CD8
+ T cell 
responses, and combinatorial blockade of these molecules further enhances CD8
+ T cell 
mediated immunity compared to either single blockade (13, 14).  Future studies should 
not only examine the biological roles of each of these molecules alone during C. 
trachomatis infection, but also explore how combinations of these molecules might 
synergistically act to alter the immune response to C. trachomatis.   
 
Host mediated versus C. trachomatis mediated immune-inhibition 
The question remains whether the upregulation of these immuno-inhibitory 
pathways is mediated directly by C. trachomatis or mediated by the host to limit 
damaging pathology.  It is possible that C. trachomatis expresses a factor, e.g. type three 
secreted effector, which directly alters expression of one or more of these immuno-
inhibitory pathways.  Although direct manipulation of immuno-inhibitory molecules by a 
pathogen has not been yet described, alteration of host transcription by pathogens is well 
documented (15-17).  Since C. trachomatis has a type III secretion system (T3SS), any 
one of these secreted effectors or proteins present in the inclusion membrane, would have ! 159!
access to the host cytosol and could potentially alter expression of a number of genes, 
including immuno-inhibitory genes.  To investigate whether a C. trachomatis T3SS 
effector can directly modulate the expression of an immuno-inhibitory molecule, one 
should singly express the secreted effectors of C. trachomatis in tissue culture cells and 
observe if any one of these can recapitulate the increased expression of PD-L1 and/or 
other immuno-inhibitory molecules.   
In order to understand if these immuno-inhibitory pathways contribute to limiting 
pathology of the host, a thorough histopathology analysis will need to be performed in 
mice that are either deficient in these molecules or treated with blocking antibodies.  
Although my own studies did not uncover consistent differences in pathology between 
WT and PD-L1 deficient mice, it’s possible that multiple pathways are involved with 
limiting inflammation and subsequent pathology.  Furthermore, it would be interesting to 
investigate if there is a connection between expression of immuno-inhibitory molecules 
within the genital tracts of patients that have or have had C. trachomatis infections and 
either fully recover or develop inflammatory sequelae such as endometritis or pelvic 
inflammatory disease (PID).  Currently the reported rate at which women develop PID 
following C. trachomatis infection ranges from 3% to 30% (18).  It will be useful for 
clinicians to understand if immuno-inhibitory molecules contribute to the risk of 
developing an inflammatory condition.  
Identification of the mechanisms that alter both CD4
+ and CD8
+ T cell responses 
will allow researchers to manipulate these mechanisms and ultimately contribute to more 
effective treatment and vaccine design.   Combining antibiotic treatment with blockade of 
immuno-inhibitory molecules might prove to be a promising therapeutic that could ! 160!
enhance the host’s natural immune response against C. trachomatis infection.  However 
the delicate balance between enhancing the immune response and limiting damaging 
pathology should obviously be considered.   
 
Other C. trachomatis mediated diseases 
Importantly it will be of interest to know if PD-L1 expression also limits C. 
trachomatis clearance and promotes disease in other tissues. In addition to the genital 
mucosa, C. trachomatis is a pathogen of the ocular tissue.  PD-L1 expression on retinal 
epithelial cells has been shown to inhibit cytotoxic function of CD8
+ T cells to maintain 
an immunosuppressive environment (19).  As an immune privileged site, it will be 
important to understand if the role that PD-L1 plays in the genital mucosal also extends 
to the ocular mucosa during C. trachomatis infection.   
Interestingly, C. trachomatis is the most common bacterial trigger of reactive 
arthritis (ReA) (20).  C. trachomatis induced ReA occurs when C. trachomatis infected 
macrophages or monocytes migrate into the synovial tissue (21).  C. trachomatis can 
enter into a persistent, non-replicative, state in which immune cells and IFNγ become 
much less effective, thus allowing C. trachomatis to persist in the tissue.  Occasionally 
patients with ReA exhibit acute inflammation, and this is probably due to C. trachomatis 
transitioning from persistence to a metabolically active form.  While the exact immune 
mechanisms that mediate C. trachomatis ReA are unclear, patients who exhibit chronic 
ReA also exhibit much lower levels of IFNγ compared to patients that resolve ReA  (22).  
Although counterintuitive, these data suggest that an increase in the cellular populations 
that secrete inflammatory IFNγ may help resolve ReA.  PD-L1 deficiency contributes to ! 161!
T cell hyperactivity, which would promote the inflammation characteristic of arthritis, 
however in the context of C. trachomatis-induced ReA effector T cells may be necessary 
to resolve infection.  It will be interesting to investigate whether PD-L1 plays a role in 
limiting or promoting the symptoms of ReA.   
 
C. trachomatis suppresses the CD8
+ T cell response to other pathogens 
C. trachomatis infections are highly associated with the occurrence of other 
sexually transmitted infections (STI).  There are obvious lifestyle factors that contribute 
to this association.  In addition, the evidence I present in Chapter Two indicates that 
infection with C. trachomatis may suppress the immune response to other pathogens.  By 
broadly suppressing the CD8
+ T cell response, C. trachomatis may limit the host’s ability 
to clear other infections of the genital tract.  The data presented in Chapter Two 
demonstrate that prior C. trachomatis infection reduced the number of activated CD8
+ T 
cells in the uterus following infection with L. monocytogenes.  Prior infection with C. 
trachomatis skewed the Tem/Tcm/n ratio towards more Tcm/n cells, and this could not be 
overcome by subsequent infection with L. monocytogenes.  It is the shift reducing the 
Tem/Tcm/n ratio that may contribute to suppressing the CD8
+ T cell response in the genital 
tract.  Whether C trachomatis infection is altering the phenotype of L. monocytogenes-
specific CD8
+ T cells in the genital tract is unclear.  However, if the data from the dLNs, 
showing that co-infection with C. trachomatis results is a significant decrease in the 
number of IFNγ producing L. monocytogenes-specific CD8
+ T cells, is an indication then 
it is likely that C. trachomatis infection does alter the L. monocytogenes specific CD8
+ T 
cell response in the genital tract.  In order to test this hypothesis, tetramer staining of a ! 162!
dominant L. monocytogenes antigen-specific CD8
+ T cell population would have to be 
performed with and without C. trachomatis co-infection.   Furthermore, these C. 
trachomatis-induced T cell changes did not affect clearance of L. monocytogenes at the 
particular time point tested, although future studies should investigate if L. 
monocytogenes exhibits delayed clearance at later time points.    
C. trachomatis infection must occur prior to infection with L. monocytogenes to 
alter the CD8
+ T cell response, no effect is observed when coinfection occurs 
simultaneously.  This suggests that the mechanism, which alters the CD8
+ T cell 
response, is occurring extremely early during C. trachomatis infection that ultimately 
affects the general priming of CD8
+ T cells.  Based on the evidence presented in Chapter 
Three, the upregulation of an inhibitory pathway may contribute to this suppression, 
although future studies will confirm this.  What will be interesting for future 
investigations is whether prior C. trachomatis infection, that has been cleared, also 
suppresses the CD8
+ T cell response to a subsequent infection by a different pathogen.   
If CD8
+ T cell suppression is long term, this would suggest that people who have had 
previous C. trachomatis infections have an increased risk for contracting another STI.   
Furthermore, it will be necessary to understand if genital infection with C. trachomatis is 
able to suppress the CD8
+ T cell response in other mucosal organs.   
   
Developing a vaccine against C. trachomatis 
  As the most highly reported communicable disease in the United States, 
developing an effective vaccine to limit contraction and spread of C. trachomatis is of 
vital importance.  Previous efforts for designing a C. trachomatis vaccine have focused ! 163!
on identifying protective antibody responses.  In particular, researchers have focused on 
antibody responses to the major outer membrane protein (MOMP) of C. trachomatis.  
The data examining the protective effects of immunization against MOMP have revealed 
varying results.  Several studies have shown that it is possible to immunize against 
MOMP, using various vehicles, to elicit partial protection to C. trachomatis challenge 
(23, 24).  However, other studies have indicated that immunization against MOMP 
produces limited or no measurable protection compared to non-immunized animals (25, 
26).  Additionally, it has proved difficult to elicit a pan-serovar response that is protective 
against the multiple serovars of C. trachomatis.  The discrepancies in the many 
Chlamydia vaccine studies may arise due to the route of immunization, different 
adjuvants used, and strain of Chlamydia studied.  Future work should aim to optimize the 
vaccine delivery and adjuvants used such that cross-strain protection is achieved.   
  While studying protective antibody responses should prove fruitful, researchers 
should also investigate protective T cell responses that could be apart of a multisubunit 
vaccine.  Because CD8
+ T cells are able to identify and lyse infected cells, this population 
should be an integral part of the immune response to C. trachomatis.  Furthermore, the 
work in this thesis and that of others has shown that it is possible to generate a protective 
CD8
+ T cell response against C. trachomatis (1).  To date there has not been an effective 
T cell vaccine against a microbial pathogen.  However, advances in our knowledge of the 
heterogeneity of CD8
+ T memory cells have informed researchers as to the particular 
CD8
+ T cell types that can be protective against different challenges, and the ways to 
manipulate specific responses.  This has led to recent clinical trials testing the efficacy of 
a CD8
+ T cell vaccines against different types of cancers (27-30).  Furthermore, ! 164!
researchers are now studying how to improve CD4
+ and CD8
+ T cell responses against 
HIV through vaccination (31).  The work in this thesis has provided the hypothesis that 
generating a Tem specific response against C. trachomatis will provide long-term 
immunity in the genital tract.  Future work should aim to understand if Tem cells have 
superior protection against C. trachomatis as well as other genital pathogens, such as 
HIV and Gonorrhea neisseria.  Furthermore, it will be important to investigate how to 
elicit protective T cell responses in the genital tract through vaccination in combination 
with different adjuvants or blockade of inhibitory pathways. 
  The work of this thesis demonstrated that the PD-1/PD-L1 pathway alters the 
Tem/Tcm/n ratio, which may ultimately lead to less protection against C. trachomatis.  The 
PD-1/PD-L1 pathway negatively regulates the immune response to many viral pathogens 
and in many cancer models.  There is great interest in understanding how to manipulate 
the PD-1/PD-L1 pathway to improve the immune response in combination with 
vaccination, particularly in cancer models.  Evidence in mice shows that antibody 
blockade of PD-1 improves effector T cell responses and inhibits tumor cell 
dissemination (32-34).  Furthermore, several recent clinical trials have demonstrated that 
patients treated with anti-PD-1 or anti-PD-L1 antibody have slower tumor progression 
(35-37).   These trials show the promising potential of PD-1/PD-L1 blockade as an anti-
cancer therapy, and provide support that PD-1/PD-L1 blockade may be a beneficial 
treatment for other diseases as well.  
 
Concluding remarks 
 ! 165!
  The immune response to a chronic infection such as C. trachomatis involves the 
delicate balance of limiting host pathology while mounting an effector response capable 
of restricting bacterial replication.   By impairing elements of the adaptive immune 
response, C. trachomatis is able to tip the balance to favor its own replication.  This 
dissertation has identified the PD-1/PD-L1 pathway as one mechanism that inhibits the 
CD8
+ T cell response to C. trachomatis and prevents efficient clearance.   The findings 
presented here, and future studies aimed at understanding the role of other immuno-
inhibitory molecules in altering adaptive immunity, will aid the development of potential 
therapeutics and vaccines against C. trachomatis.   
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Appendix A: Characterizing the CD8
+ T cell response to the 
 C. trachomatis antigen PmpI ! 172!
  The data presented in Chapter 2 thoroughly describes the CD8
+ T cell response to 
the C. trachomatis antigen CrpA.  I wanted to understand if the response observed for 
CrpA was specific to that antigen or representative of the CD8
+ T cell response to other 
C. trachomatis antigens.  At the time of these studies the only other known CD8
+ T cell 
antigen identified in C57/BL6 mice was Polymorphic membrane protein I (PmpI) (1).  
PmpI is part of a family of proteins found in the outer membrane of C. trachomatis.  I 
decided to first compare the systemic responses to CrpA and PmpI to ensure that I could 
appropriately monitor the PmpI specific response.  I intravenously infected mice with C. 
trachomatis and measured the CrpA and PmpI specific responses by staining with 
tetramer specific for each antigen.  The number of PmpI specific CD8
+ T cells in the 
spleen was about 10 fold lower than the number of CrpA specific CD8
+ T cells (Figure 
A-1).   
 ! 173!
 
 
Figure A-1 Comparison of the PmpI and CrpA specific CD8
+ T cell responses 
during systemic infection.  Mice were intravenously infected with 10
7 IFU of C. 
trachomatis.  At indicated time points during primary and secondary infection 
spleens were harvested and tetramer
+ CD8
+ T cells were measured by flow 
cytometry.  Each time point is the mean of 5 mice per group and error bars 
represent SEM.   
 
 
  Although the number of PmpI specific CD8
+ T cells was low compared to the 
number of CrpA specific CD8
+ T cells during systemic infection I decided to investigate 
the PmpI specific response during transcervical infection.  I infected mice with 10
6 IFU 
of C. trachomatis; seven days following infection I measured the number of PmpI and 
CrpA specific CD8
+ T cells in the genital tract by flow cytometry.  I was unable to detect 
any significant difference in the PmpI population in infected mice compared to 
uninfected mice  (Figure A-2). ! 174!
 
Figure A-2 PmpI specific CD8
+ T cells are undetectable in the genital tract 
during transcervical C. trachomatis infection. Mice were transcervically 
infected with 10
6 IFU of C. trachomatis.  Seven days post infection genital tracts 
were harvested and tetramer
+ cells measured by flow cytometry.  Shown are 
representative flow plots of infected and uninfected mice for CrpA tetramer (top) 
and PmpI tetramer (bottom).  Cells were first gated on CD90.2
+, CD4
-, CD8
+ 
lymphocyte populations.  Tetramer
+ CD8
+ T cells are present in the top right 
quadrant of each plot.    
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Since I was unable to detect PmpI specific CD8
+ T cells in the uterus, I 
questioned whether this was due to a low abundance of PmpI specific CD8
+ T cells or 
possibly an issue with the tetramer.  To test this, I transcervically infected mice with C. 
trachomatis and measured the PmpI specific CD8
+ T cells present in the dLNs by 
ELISPOT assay over a time course of infection.  I was able to detect an expansion of 
PmpI-specific CD8
+ T cells in dLNs during primary infection; with the peak of the 
response occurring five days post infection (Figure A-3).  By seven days post infection, 
the number of PmpI specific CD8
+ T cells had returned to levels similar to mice at day 
zero.  After mice were rechallenged with C. trachomatis I observed a slight increase in 
the number of PmpI specific CD8
+ T cells, however the peak of secondary response was 
significantly lower than the peak of primary (Figure A-3).  All together these data 
demonstrate that PmpI specific CD8
+ T cells appear to be at a lower abundance compared 
to CrpA specific CD8
+ T cells.  By ELISPOT, at each time point the number of PmpI 
specific CD8
+ T cells detected was about 10 fold less than the number of CrpA specific 
CD8
+ T cells detected by ELISPOT (Figure 2-1).  However, the PmpI response was still 
similar to the CrpA response in that the secondary response was significantly lower than 
the primary response.  Thus these data indicate that the CrpA specific CD8
+ T cell 
response characterized in Chapter Two is representative of other C. trachomatis antigens. ! 176!
 
Figure A-3 PmpI specific CD8
+ T cells are stimulated during transcervical C. 
trachomatis infection.  Mice were transcervically infected with 10
6 IFU of C. 
trachomatis on day 0 (marked by 1
st arrow).  At timepoints marked, dLNs were 
harvested and the number of PmpI specific IFNγ producing CD8
+ T cells were 
measured by ELISPOT.  Mice were rechallenged at the second arrow.  Each 
timepoint is the mean of five mice per group, and bars represent SEM.  Statistical 
significance of **p<0.01 is indicated for day 5 primary and day 5 secondary 
infections.  Statistics were determined by Mann-Whitney Test. 
 
 
The low abundance of PmpI specific CD8
+ T cells led me to hypothesize that 
PmpI is expressed at extremely low levels during infection, or is unable to access the host 
cytosol, and thus is unavailable to be presented on MHC class I machinery and stimulate 
a CD8
+ T cell response.   However, transcriptional evidence from the Caldwell lab 
suggested that PmpI is actually expressed at higher levels compared to CrpA, and both 
PmpI and CrpA are expressed during the mid to late cycle of infection (2).  With this 
information I hypothesized that PmpI is actually a weaker antigen compared to CrpA.  To 
test these hypotheses I engineered a L. monocytogenes strain expressing PmpI fused to 
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the Ova SIINFEKL sequence (L.m.-PmpI).  If PmpI expression or access to the host 
cytosol are limiting factors in stimulating a robust CD8
+ T cell response during C. 
trachomatis infection, then infection with L.m.-PmpI should be able to produce a CD8
+ T 
cell response that is comparable to L.m.-CrpA.  If, however, PmpI is truly a weaker 
antigen compared to CrpA, then the CD8
+ T cell response to PmpI should be low 
regardless of the vector delivering the PmpI antigen.  I intravenously infected mice with 
either L.m.-CrpA or L.m.-PmpI.  Seven days post infection I measured the number of 
CrpA and PmpI specific CD8
+ T cells.  Because CrpA and PmpI were both fused to the 
Ova antigen I could also measure the number of Ova specific CD8
+ T cells using an Ova 
specific pentamer.  Infection with L.m.-PmpI produced significantly fewer PmpI-specific 
CD8
+ T cells compared to the number of CrpA specific CD8
+ T cells produced by L.m.-
CrpA (Figure A-4).  However, both L.m.-PmpI and L.m.-CrpA produced similar 
percentages of Ova specific CD8
+ T cells (Figure A-4).  These data confirm that the low 
percentage of PmpI specific CD8
+ T cells is not due to limited access to the cytosol or 
low expression levels during C. trachomatis infection. 
 ! 178!
 
Figure A-4. Infection with L.m.-PmpI produces few PmpI CD8
+ T cells.  Mice 
were intravenously infected with 10
5 CFU of Lm-CrpA or L.m.-PmpI. Seven days 
post infection spleens were harvested and tetramer specific CD8
+ T cells 
measured by flow cytometry.  Spleenocytes were stained with CrpA or PmpI 
tetramer (left graph) or Ova Pentamer (right graph).  Shown is the mean of 5 mice 
per group and error bars represent SEM.  Statistical significance is indicated by 
**p<0.01, determined by the Mann-Whitney Test. 
 
 
The data presented above provides compelling evidence that PmpI is in fact a 
weaker antigen compared to CrpA.  However, I had yet to rule out the possibility that the 
differences in CD8
+ T cell abundance were due to tetramer staining.  To test this 
possibility, I transcervically infected mice with either L.m.-CrpA or L.m.-PmpI.  Seven 
days post infection I measured the number of CrpA , PmpI, and Ova specific IFNγ 
producing CD8
+ T cells by ELISPOT assay.  Similar to the tetramer data, infection with 
L.m.-PmpI produced far fewer PmpI specific CD8
+ T cells compared to the CrpA specific 
response elicited by L.m.-CrpA (Figure A-5).  L.m.-PmpI and L.m.-CrpA produced 
similar numbers of Ova specific CD8
+ T cells (Figure A-5).  These data confirm that 
PmpI is a weaker antigen than CrpA.  Additionally these data suggest that the low 
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antigenicity of PmpI would make it difficult to study the endogenous PmpI response 
during transcervical infection.   
 
 
Figure A-5 PmpI elicits a weaker CD8
+ T cell response compared to CrpA.  
Mice were intravenously infected with 10
5 CFU of Lm-CrpA or L.m.-PmpI. Seven 
days post infection spleens were harvested and CrpA, PmpI and Ova specific 
IFNγ-producing CD8
+ T cells measured by ELISPOT assay.  Black bars represent 
CrpA and PmpI specific responses to L.m-CrpA and L.m.-PmpI infections 
respectively.  White bars represent the Ova specific response.  All bars represent 
the mean of 5 mice per group and error bars represent SEM.  Statistical 
significance is indicated by *p<0.05, determined by the Mann-Whitney Test. 
 
 
 
 
  Although PmpI is a weaker antigen compared to CrpA, I was curious if this 
antigen could still confer protection against C. trachomatis infection.  To test this, I 
intravenously immunized mice with L.m. strains expressing CrpA, PmpI or Ova, or 
immunized mice with C. trachomatis.  Twenty-eight days after immunization I 
challenged mice with 10
6 IFU of C. trachomatis.  Three days post infection I measured C. 
trachomatis burden in the spleen.  Mice immunized with L.m.-CrpA showed bacterial 
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levels equivalent to mice immunized with C. trachomatis, and significantly lower C. 
trachomatis levels compared to unimmunized mice and mice immunized with L.m.-Ova 
(Figure A-6).  Mice immunized with L.m.-PmpI showed C. trachomatis levels 
comparable to unimmunized mice.  These data confirm that mice immunized against 
PmpI are not protected against subsequent challenge with C. trachomatis. 
 
 
 
Figure A-6 Immunization with L.m.CrpA, but not L.m.-PmpI, protects 
against C. trachomatis challenge.  Mice were intravenously immunized with 10
5 
CFU of Lm-CrpA , L.m.-PmpI, L.m.-Ova, or 10
7 IFU of C. trachomatis,  
or left unimmunized. Twenty-eight days post infection mice were rechallenged 
intravenously with 10
7 IFU of C. trachomatis.  Three days after rechallenge 
bacterial levels in the spleen were measured by qPCR. in spleens.  Shown is the 
mean of 5 mice per group and error bars represent SEM.  Statistical significance 
is indicated by: *p<0.05 and **p<0.01, determined by the Mann-Whitney Test. 
 
 
  All together these data indicate that PmpI elicits a poor CD8
+ T cell response that 
is not protective against C. trachomatis.  Furthermore, the paucity of the CD8
+ T cell 
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response suggests that it is not a suitable antigen for further study during transcervical C. 
trachomatis infection.  Since these studies were conducted, four more C. trachomatis 
CD8
+ T cell antigens have been identified (3).  It will be interesting to investigate the 
CD8
+ T cell responses to these antigens and to understand if immunizations against such 
antigens produce protective CD8
+ T cell responses similar to CrpA. ! 182!
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Appendix B: Supplemental data of Chapter Four ! 184!
PD-1 deficiency recapitulates the phenotype of PD-L1 deficiency   
As described in Chapter 4, PD-L1 deficiency led to lower C. trachomatis levels 
after primary transcervical infection but did not alter C. trachomatis levels during 
secondary infection.  PD-1 deficient mice also showed lower C. trachomatis  levels after 
primary transcervical infection.  I sought to determine if PD-1 deficiency altered 
secondary bacterial clearance. I transcervically infected mice, allowed the mice to 
recover for four weeks before transcervically reinfecting these mice.  Five days post 
secondary infection I measured bacterial levels in the uterus using qPCR (Figure B-1).  
Similar to my observation with PD-L1 deficient mice, there was no difference in bacterial 
levels during secondary infection of WT and PD-1 deficient mice.  
 
 
Figure B-1 Bacterial burden during secondary infection of PD-1 deficient 
mice.  WT and PD-1 deficient mice were transcervically infected with 10
6 IFU of 
C. trachomatis and allowed to recover for 4 weeks.  Five days after secondary 
infection, bacterial levels in the uterus were measured by qPCR and normalized to 
host GAPDH levels.  Error bars represent SEM.   
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  I hypothesized that PD-L1 engages PD-1 to shift the CD8
+ T cells to a Tcm/n 
phenotype and impair C. trachomatis clearance.  In order to test this hypothesis I wanted 
to determine if PD-1 deficiency recapitulated the CD8
+ T cell phenotype observed in PD-
L1 deficient mice.  I therefore examined the CD8
+ T cell phenotype in the genital tracts 
of WT and PD-1 deficient mice during primary infection, memory, and secondary 
infection.   Similar to observations in PD-L1 deficient mice, the CD8
+ T cell response in 
PD-1 deficient mice was shifted toward the Tem phenotype at all time points tested 
(Figure B-2). 
 
 
   
Figure B-2 PD-1 deficiency increases the ratio of Tem to Tcm/n CD8
+ T cells 
during C. trachomatis infection.  WT and PD-1 deficient mice were 
transcervically infected with 10
6 IFU of C. trachomatis.  At indicated timepoints, 
uteri were harvested and stained for CD62L and CD127 expression.  CD8
+ 
memory populations were gated on live, CD90.2
+, CD127
+, CD4-, CD8
+ cells and 
either CD62L
+ (Tcm/n) or CD62L
- (Tem).  The percentage of Tem and Tcm/n cells of 
the total CD8
+ T cell population in the uterus was measured.  Bars represent mean 
ratios of percentage of Tem/Tcm/n of 4-5 mice per group and error bars represent 
SEM.   *p<0.05, **p<0.01 using Mann- Whitney Test.    
 
 
 
PD-L1 deficiency shifts the CD8
+, but not the CD4
+, Tem to Tcm/n ratio   
PD-L1 deficiency leads to a significant increase in the ratio of Tem to Tcm/n cells.  
However, I wanted to determine if this was due to a total increase in the number of 
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memory CD8
+ T cells present in PD-L1 deficient mice.  At the indicated time points I 
measured the total number of memory CD8
+ T cells found in the uteri of WT and PD-L1 
deficient mice.  The total number of CD127
+ memory CD8
+ T cell cells is comparable 
between WT and PD-L1 deficient mice (Figure B-3).   
 
 
Figure B-3 PD-L1 expression does not alter the total number of memory 
CD8
+ T cells found in the uterus. WT and PD-1 deficient mice were 
transcervically infected with 10
6 IFU of C. trachomatis.  At indicated timepoints, 
uteri were harvested and stained for memory marker CD127.  CD8
+ memory 
populations were gated on live, CD90.2
+, CD127
+, CD4
-, CD8
+ cells. Bars 
represent mean of total number of memory CD8
+ T cells from 4-5 mice per group 
and error bars represent SEM.    
 
 
 
When I examined the total numbers of Tem and Tcm/n cells in WT and PD-L1 
deficient mice I consistently observe increases in the total numbers of Tem cells in PD-L1 
deficient mice, although these increases are not statistically significant (Figure B-4).  
Together these data support that PD-L1 deficiency does not alter the number of memory 
CD8
+ T cell present in the uterus, but in a given host shifts the ratio of memory CD8
+ T 
cells by increasing the number of Tem cells and decreasing the number of Tcm/n cells.    
 
 
 
Day 27 Memory
T
o
t
a
l
 
C
D
1
2
7
+
 
C
D
8
+
 
T
 
c
e
l
l
s
WT
PD-L1-/-
0
5000
10000
15000
Day 5 Secondary
T
o
t
a
l
 
C
D
1
2
7
+
 
C
D
8
+
 
T
 
c
e
l
l
s
WT
PD-L1-/-
0
5000
10000
15000
20000
25000
Day 5 Primary
T
o
t
a
l
 
C
D
1
2
7
+
 
C
D
8
+
 
T
 
c
e
l
l
s
WT
PD-L1-/-
0
20000
40000
60000
80000 NS NS! 187!
 
 
 
Figure B-4 Total numbers of Tcm/n and Tem cells in WT and PD-L1 deficient 
mice. WT and PD-1 deficient mice were transcervically infected with 10
6 IFU of 
C. trachomatis.  At indicated timepoints, uteri were harvested and stained for 
CD62L and CD127 expression.  CD8
+ memory populations were gated on live, 
CD90.2
+, CD127
+, CD4
-, CD8
+ cells and either CD62L
+ (Tcm/n) or CD62L- (Tem).  
Bars represent mean totals Tcm/n and Tem of 4-5 mice per group and error bars 
represent SEM.   *p<0.05 using Mann-Whitney Test.    
 
 
 
It is clear that PD-L1 deficiency shifts the CD8
+ T cells towards a Tcm/n 
phenotype.  However, I wanted to understand if this shift in phenotype was specific for 
CD8
+ T cells or if it also occurred in the CD4
+ T cell population.  I therefore examined 
the ratio of CD4
+ Tem to Tcm/n cells in the genital tracts of infected mice.  At all time 
points tested there was no difference in the ratio of CD4
+ Tem to Tcm/n cells between WT 
and PD-L1 deficient mice (Figure B-5).  These data indicate that PD-L1 expression 
specifically affects the CD8
+ T cell population during C. trachomatis infection. 
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Figure B-5 PD-L1 expression does not shift the ratio of Tem to Tcm/n CD4
+ T 
cells during C. trachomatis infection.  WT and PD-L1 deficient mice were 
transcervically infected with 10
6 IFU of C. trachomatis.  At indicated timepoints, 
uteri were harvested and stained for CD62L and CD127 expression.  CD4
+ 
memory populations were gated on live, CD90.2
+, CD127
+, CD4
+, CD8
- cells and 
either CD62L
+ (Tcm/n) or CD62L- (Tem).  The percentage of Tem and Tcm/n cells of 
the total CD4
+ T cell population in the uterus was measured.  Bars represent mean 
ratios of percentage of Tem/Tcm/n of 4-5 mice per group and error bars represent 
SEM.   
 
 
PD-1 expression on CD8
+ T cells 
 
  In Chapter Three I demonstrated that PD-1 expression was upregulated on CD8+ 
T cells in the dLNs following resolution of C. trachomatis infection.  PD-1 expression 
was extremely low and although there was a significant increase in PD-1 expression on 
antigen-experienced CD8+ T cells, it was still low.  The representative histograms 
demonstrate the increase in PD-1 expression on CD8+ T cells following C. trachomatis 
infection (Figure B-6) 
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Figure B-6 PD-1 expression is upregulated on CD8
+ T cells in the dLNs 
following C. trachomatis infection. Mice were transcervically infected with 10
6 
IFU of C. trachomatis.  PD-1 expression was measured by flow cytometry on 
CD8
+ T cells in the dLNs five days post primary infection, 27 days post primary 
infection (memory), or five days post secondary infection.  Shown are 2 
representative histograms of PD-1 expression CD3
+ CD8
+ T cells of the dLNs. 
 
 
  Chapter Four demonstrated that PD-1 expression limits C. trachomatis clearance 
in the genital tract.  However, bacterial levels measured in PD-1, on the Thy1.1 
background, and Thy1.1 (WT) mice were lower than typically measured in PD-L1, 
Thy1.2 background, and Thy1.2 (WT) mice.  Interestingly, PD-1 expression is 
significantly lower on CD8
+ T cells from Thy1.1 mice and this may partially explain the 
lower bacterial levels measured during infection (Figure B-7).   
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Figure B-7 PD-1 expression is lower on CD8
+ T cells in Thy1.1 mice 
compared to Thy1.2 mice following C. trachomatis infection. Mice were 
transcervically infected with 10
6 IFU of C. trachomatis.  PD-1 expression was 
measured by flow cytometry on CD8
+ T cells in the spleen five days post primary 
infection. Bar graphs show gMFI of PD-1 expression on CD3
+ CD8
+ T cells in the 
spleen; shown is the average of 5 mice per time point and error bars represent 
SEM.  Statistical significance is indicated by *p<0.05 and **p<0.01 by Mann-
Whitney Test. 
 
 
 
 
T cell depletion in WT and PD-L1 deficient mice 
 
  In Chapter Four I demonstrated that CD8
+ T cell depletion in PD-L1 deficient 
mice abrogated protection against primary transcervical C. trachomatis infection.  To 
confirm depletion, I examined the CD8
+ T cell population in the uterus, dLNs and spleen 
(Figure B-8).  I also examined the CD4
+ T cell population to ensure that antibody 
depletion did not significantly affect the CD4
+ T cell population (Figure B-8).  Antibody 
treatment with the anti-CD8 antibody reduced the CD8
+ T cell population between 10 
and 100 fold in all organs tested in both WT and PD-L1 deficient mice.  Additionally, the 
CD4
+ T cell population was not significantly impacted.  These data confirm that CD8
+ T 
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cell depletion in PD-L1 deficient mice abrogates protection against C. trachomatis 
infection. 
 
 
 
Figure B-8 CD8
+ T cells are depleted upon antibody treatment.  WT and PD-
L1 deficient mice were treated with anti-CD8 depleting antibody or isotype 
control antibody 3 days prior to and 2 days after primary infection.  Mice were 
infected with 10
6 IFU of C. trachomatis, and five days post infection CD8
+ and 
CD4
+ T cells were examined in the uterus, dLNs, and spleen.   
 
 
 
  In Chapter Four I demonstrated that in PD-L1 deficient mice the CD8
+ T cell 
population was able to compensate for the lack of CD4
+ T cells and confer protection 
against secondary transcervical C. trachomatis  challenge (Chapter 4 Figure 4-11).  To 
confirm depletion of CD4
+ T cells I measured the CD4
+ T cell population in the uterus, 
dLNs and spleen of WT and PD-L1 deficient mice.  The CD4
+ T cell population was 
reduced 10 to 100 fold in all organs tested of mice treated with anti-CD4 antibody 
(Figure B-9).  Additionally the CD8
+ T cell population was not negatively impacted by 
antibody treatment.  These data confirm that CD4
+ T cell depletion was successful and 
that protection observed in CD4-depleted PD-L1 deficient mice is not due to the presence 
of CD4
+ T cells.  
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Figure B-9 CD4
+ T cells are depleted upon antibody treatment.  WT and PD-
L1 deficient mice were treated with anti-CD4 depleting antibody or isotype 
control antibody 3 days prior to and 2 days after secondary infection.  Mice were 
infected with 10
6 IFU of C. trachomatis, and five days post infection CD8
+ and 
CD4
+ T cells were measured in the uterus, dLNs, and spleen.   
 
   
Taken together the data from this chapter support the conclusions presented in 
Chapter Four.  Importantly the data indicating that PD-1 deficiency recapitulates the 
phenotype of PD-L1 deficiency provides additional evidence that the PD-1/PD-L1 
interaction specifically shifts the memory CD8
+ T cell population to the Tem phenotype.  
In addition, the successful CD8
+ and CD4
+ T cell depletions supports the data indicating 
that CD8
+ T cells are an important protective population in PD-L1 deficient mice during 
transcervical C. trachomatis infection.   
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